Current insurance and contractholder liabilities

5,710

5,388

Pharmacy and other service costs payable

30,333

28,465

Accounts payable

10,659

9,294

Accrued expenses and other liabilities

9,048

9,387

Short-term debt

592

3,035

Liabilities of businesses held for sale

0

2,410

Total current liabilities

56,342

57,979

Non-current insurance and contractholder liabilities

9,938

10,254

Deferred tax liabilities, net

7,145

6,975

Separate account liabilities

4,238

3,215

Long-term debt

30,871

28,937

7,511

7,278

TOTAL LIABILITIES

116,045

114,638

Contingencies — Note 22

Shareholders' equity

Common stock

^[1]

4

Additional paid-in capital

31,790

31,288

Accumulated other comprehensive loss

(2,806)

(2,341)

Retained earnings

47,865

43,519

Less: Treasury stock, at cost

(35,140)

(31,437)

TOTAL SHAREHOLDERS' EQUITY

41,713

41,033

Noncontrolling interests

161

210

Total equity

41,874

41,243

Total liabilities and equity

$ 157,919

$ 155,881

[1]	Par value per share, $0.01; shares issued, 405 million as of December 31, 2025 and 403 million as of December 31, 2024; authorized shares, 600 million.

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01	$ 0.01
Common stock, shares issued (in shares)	404,600,000	402,512,000	399,894,000
Common stock, shares authorized	600,000,000	600,000,000	600,000,000

Consolidated Statements of Changes in Total Equity - USD ($) $ in Millions	Total	Shareholders' Equity	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss)	Retained Earnings	Treasury Stock	Other Non- controlling Interests
Balance at Dec. 31, 2022	$ 44,688	$ 44,675	$ 4	$ 30,233	$ (1,658)	$ 37,940	$ (21,844)	$ 13
Changes in Total Equity
Effect of issuing stock for employee benefit plans	365	365		477			(112)
Other comprehensive income (loss)	(206)	(206)			(206)
Net income	5,192	5,164				5,164		28
Common dividends declared	(1,452)	(1,452)				(1,452)
Repurchase of common stock	(2,282)	(2,282)		0			(2,282)
Other transactions impacting noncontrolling interests	(61)	(41)		(41)				(20)
Balance at Dec. 31, 2023	46,244	46,223	4	30,669	(1,864)	41,652	(24,238)	21
Balance at Dec. 31, 2022	66
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	0
Other transactions impacting noncontrolling interests	(139)
Balance at Dec. 31, 2023	107
Changes in Total Equity
Effect of issuing stock for employee benefit plans	499	499		619			(120)
Other comprehensive income (loss)	(477)	(477)			(477)
Net income	3,778	3,434				3,434		344
Common dividends declared	(1,567)	(1,567)				(1,567)
Repurchase of common stock	(7,079)	(7,079)		0			(7,079)
Other transactions impacting noncontrolling interests	(155)	0		0				(155)
Balance at Dec. 31, 2024	41,243	41,033	4	31,288	(2,341)	43,519	(31,437)	210
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	0
Other transactions impacting noncontrolling interests	(107)
Balance at Dec. 31, 2024	0
Changes in Total Equity
Effect of issuing stock for employee benefit plans	388	388		502			(114)
Other comprehensive income (loss)	(465)	(465)			(465)
Net income	6,288	5,957				5,957		331
Common dividends declared	(1,611)	(1,611)				(1,611)
Repurchase of common stock	(3,589)	(3,589)		0			(3,589)
Other transactions impacting noncontrolling interests	(380)	0		0				(380)
Balance at Dec. 31, 2025	41,874	$ 41,713	$ 4	$ 31,790	$ (2,806)	$ 47,865	$ (35,140)	$ 161
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	0
Other transactions impacting noncontrolling interests	0
Balance at Dec. 31, 2025	$ 0

Consolidated Statements of Changes in Total Equity (Parenthetical) - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Statement of Stockholders' Equity [Abstract]
Common dividends declared (in dollars per share)	$ 6.04	$ 5.60	$ 4.92

Consolidated Statements of Cash Flows - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

Cash Flows from Operating Activities

Net income

$ 6,288

$ 3,778

$ 5,372

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

2,775

3,035

Investment losses, net

24

2,737

78

Deferred income tax expense (benefit)

326

(95)

(1,659)

Net (gain) loss on sale of businesses

(13)

(24)

1,499

Net changes in assets and liabilities, net of non-operating effects:

Accounts receivable, net

(4,630)

(7,369)

(1,663)

Inventories

(646)

(1,032)

(868)

Reinsurance recoverable and Other assets

(897)

(485)

(539)

Insurance liabilities

1,247

(591)

584

Pharmacy and other service costs payable

1,868

8,757

2,030

Accounts payable and Accrued expenses and other liabilities

2,797

1,138

3,481

NET CASH PROVIDED BY OPERATING ACTIVITIES

462

774

463

9,601

10,363

11,813

Proceeds from investments sold:

Debt securities and equity securities

782

856

1,078

Investment maturities and repayments:

Debt securities and equity securities

986

839

972

Commercial mortgage loans

223

188

186

Other sales, maturities and repayments (primarily short-term and other long-term investments)

884

752

586

Investments purchased or originated:

Debt securities and equity securities

(5,788)

(1,386)

(4,334)

Commercial mortgage loans

(117)

(54)

(118)

Other (primarily short-term and other long-term investments)

(1,416)

(1,309)

(1,205)

Property and equipment purchases, net

(1,212)

(1,406)

(1,573)

Acquisitions, net of cash acquired

(597)

(131)

(447)

Divestitures, net of cash sold

2,984

521

13

Renewable energy tax credit equity investments

(1,102)

(1,030)

(313)

NET CASH USED IN INVESTING ACTIVITIES

(34)

58

(19)

(4,407)

(2,102)

(5,174)

Deposits and interest credited to contractholder deposit funds

152

166

167

Withdrawals and benefit payments from contractholder deposit funds

(253)

(228)

(223)

Net change in short-term debt, excluding term loan

(927)

(402)

1,198

Net proceeds on issuance of term loan

1,999

0

Repayment of term loan

(2,000)

0

Repayment of long-term debt

(4,197)

(3,000)

(2,967)

Net proceeds on issuance of long-term debt

4,458

4,462

1,491

Repurchase of common stock

(3,621)

(7,034)

(2,284)

Issuance of common stock

203

305

187

Common stock dividend paid

(1,611)

(1,567)

(1,450)

NET CASH USED IN FINANCING ACTIVITIES

(624)

(349)

(413)

(6,421)

(7,647)

(4,294)

Effect of foreign currency rate changes on cash, cash equivalents and restricted cash

32

(20)

16

Net (decrease) increase in cash, cash equivalents and restricted cash

(1,195)

594

2,361

Cash, cash equivalents and restricted cash January 1, including held for sale assets

^[1]

8,931

8,337

5,976

Cash, cash equivalents and restricted cash December 31, including held for sale assets

^[1]

7,736

8,931

8,337

Cash and cash equivalents reclassified to assets of businesses held for sale

0

(1,339)

(467)

Cash, cash equivalents and restricted cash and cash equivalents December 31,

^[1]

7,736

7,592

7,870

Supplemental Disclosure of Cash Information:

Interest paid

$ 1,350

$ 1,342

$ 1,330

[1]	Restricted cash and cash equivalents were reported in other long-term investments and Other assets.

Description of Business	12 Months Ended
Description of Business	Dec. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 – Description of Business The Cigna Group®, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. Powered by our dedicated people and valued brands, we advance our mission to improve the health and vitality of those we serve. Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. The majority of these products and services are offered through employers and other entities, such as governmental and nongovernmental organizations, unions and associations. Certain subsidiaries also offer health and dental insurance products to individuals in the United States and select international markets. In addition to these operations, The Cigna Group also has certain run-off operations. A full description of our segments follows: The Evernorth Health Services® reportable segment includes the Pharmacy Benefit Services and the Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives. Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services, such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services. The Cigna Healthcare® reportable segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as for individual and family plan customers. International Health provides health care solutions in our international markets, as well as health solutions for globally mobile individuals and employees of multinational organizations. U.S. Healthcare also included the Medicare Advantage and related businesses until the divestiture of such businesses to Health Care Services Corporation ("HCSC") on March 19, 2025 (see Note 5 to the Consolidated Financial Statements for further information). Other Operations comprises the remainder of our business operations, which includes certain continuing business (corporate-owned life insurance ("COLI")), as well as run-off and other non-strategic businesses. Our run-off businesses include the (i) variable annuity reinsurance business that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013; (ii) settlement annuity business; and (iii) individual life insurance and annuity and retirement benefits businesses, which were sold through reinsurance agreements. Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments.

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2025
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment, tax and receivable valuations, interest rates, and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment. Recent Accounting Pronouncements There were no new accounting standards adopted during the year ended December 31, 2025 that had a material impact on our Consolidated Financial Statements. Accounting Guidance Not Yet Adopted Accounting Standards Update ("ASU") 2025-06, Targeted Improvements to the Accounting for Internal-Use Software (Subtopic 350-40). Required to be adopted January 1, 2028, with early adoption permitted and requires the following: •Seeks to improve the operability of the recognition guidance considering different methods of software development, mainly more iterative methods, by: ◦Aligning internal-use software capitalization requirements to probable completion and required funding and authorization. ◦Clarifying certain criteria for probable completion, including that the significant performance requirements of the software be identified and no longer subject to substantial revision. •Transition options include prospective from the date of adoption as well as retrospective and modified retrospective adoption. The Company is currently evaluating the impact of this guidance on our results of operations and financial position, as well as potential impacts to information systems and controls. ASU 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40). Required to be adopted for the annual reporting period ending December 31, 2027 and for interim reporting periods beginning January 1, 2028 and requires: •Additional expense detail in the footnotes disaggregating income statement captions including any of the following: inventory purchases; employee compensation; depreciation; and intangible asset amortization, as well as a qualitative description of remaining expenses to reconcile to the total expense within those income statement captions; •Disclosure of the definition and total amount of selling expenses; and •Transition options include prospective from the date of adoption as well as retrospective adoption. The only financial statement impact resulting from adoption will be increased disclosure. The Company continues to evaluate the effects the adoption requirements on information systems and controls. Significant Accounting Policies The Company's accounting policies are described either in this Note or in the applicable Notes to the Consolidated Financial Statements as listed in the table of contents on page 60. A.Cash and Cash Equivalents Cash and cash equivalents are carried at cost that approximates fair value. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase. The Company reclassifies cash overdraft positions to liabilities when the legal right of offset does not exist. B.Inventories Inventories consist of prescription drugs and medical supplies and are stated at the lower of first-in-first-out cost or net realizable value. C.Translation of Foreign Currencies The Company generally conducts its international business through foreign operating entities that maintain assets and liabilities in local currencies that are their functional currencies. The Company uses exchange rates as of the balance sheet date to translate assets and liabilities into U.S. dollars. Translation gains or losses on functional currencies, net of applicable taxes, are recorded in Accumulated other comprehensive loss. The Company uses average monthly exchange rates during the year to translate revenues and expenses into U.S. dollars. D.Pharmacy Revenues and Costs Pharmacy Revenues. Pharmacy revenues are primarily derived from providing pharmacy benefit management services to clients and customers. Pharmacy revenues are recognized when control of the promised goods or services is transferred to clients and customers in an amount that reflects the consideration the Company expects to receive for those goods or services. The Company provides or makes available various services supporting benefit management and claims administration and is generally obligated to provide prescription drugs to clients' members using multiple distribution methods, including retail networks, home delivery and specialty pharmacies. These goods and services are integrated into a single performance obligation to process claims, dispense prescription drugs and provide other services over the contract period (generally three years). This performance obligation is satisfied as the business stands ready to fulfill its obligation. Revenues for dispensing prescription drugs through retail pharmacies are reported gross and consist of the prescription price (ingredient cost and dispensing fee) contracted with clients, including the customer copayment, and any associated fees for services, because the Company acts as the principal in these arrangements. When a prescription is presented to a retail network pharmacy, the Company is solely responsible for customer eligibility, drug utilization review, drug-to-drug interaction review, any required clinical intervention, plan provision information, payment to the pharmacy and client billing. These revenues are recognized based on the full prescription price when the pharmacy claim is processed and approved for payment. The Company also provides benefit design and formulary consultation services to clients and negotiates separate contractual relationships with clients and network pharmacies. These factors indicate that the Company has control over these transactions until the prescription is processed. Revenues are billed, due and recognized at contract rates either on a periodic basis or as services are provided (such as based on volume of claims processed). This recognition pattern aligns with the benefits from services provided. Home delivery and specialty pharmacy revenues are due and recognized as each prescription is shipped, net of reserves for discounts and contractual allowances estimated based on historical experience. Any differences between estimates and actual collections are reflected in Pharmacy revenues when payments are received. Historically, adjustments to original estimates and returns have not been material. The Company has elected the practical expedient to account for shipping and handling as a fulfillment activity. We may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid at the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. The liability for these financial and performance guarantees was $1.8 billion as of December 31, 2025 and $1.9 billion as of December 31, 2024. The Company administers programs through which we may receive rebates and other vendor consideration from pharmaceutical manufacturers. The amounts of such rebates or other vendor consideration shared with pharmacy benefit management services clients vary based on the contractual arrangement with the client and in some cases the type of consideration received from the pharmaceutical manufacturer. Rebates and other vendor consideration payable to pharmacy benefit management services clients are recorded as a reduction of Pharmacy revenues. Estimated amounts payable to clients are based on contractual sharing arrangements between the Company and the client and these amounts are adjusted when amounts are collected from pharmaceutical manufacturers in accordance with the contractual arrangement between the Company and the client. Historically, these adjustments have not been material. Other pharmacy service revenues are earned by distributing specialty pharmaceuticals and medical supplies to providers, clinics and hospitals. These revenues are billed, due and recognized at contracted rates as prescriptions and supplies are shipped and services are provided. Pharmacy Costs. Pharmacy costs include the cost of prescriptions sold, network pharmacy claim costs and copayments. Also included are direct costs of dispensing prescriptions including supplies, shipping and handling, and direct costs associated with clinical programs, such as drug utilization management and medication adherence counseling. Home delivery and specialty pharmacy costs are recognized when the drug is shipped, and retail network costs are recognized when the drug is processed and approved for payment. Rebates and other vendor consideration received when providing pharmacy benefit management services are recorded as a reduction of pharmacy costs. Rebates are recognized as prescriptions are shipped or processed and approved for payment. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected, net of contractual allowances, has not been material. The Company maintains reimbursement guarantees with certain retail network pharmacies. For each such guarantee, the Company records a pharmacy and other service costs payable or prepaid asset for applicable retail network claims based on our actual performance throughout the period against the contractual reimbursement rate. The Company's contracts with certain retail pharmacies give the Company the right to adjust reimbursement rates during the annual guarantee period. E.Premiums and Related Expenses Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses are recognized when incurred and, for our Cigna Healthcare business, are presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for experience-rated refunds based on contract terms and calculated using the customer's experience (including estimates of incurred but not reported claims). The Patient Protection and Affordable Care Act ("ACA") established a risk adjustment program that transfers funds among insurers based on the relative risk of their covered populations of individuals who purchased insurance on a public exchange. We recognize receivables or payables from the Centers for Medicare and Medicaid Services ("CMS") for the Company's Individual and Family Plans as adjustments to premium revenue when amounts are reasonably estimable and collection is reasonably assured, using year-to-date experience and industry data. Final settlements are determined by the United States Department of Health and Human Services ("HHS") in the subsequent year. Premium revenue may also include an adjustment to reflect the estimated effect of rebates due to customers under medical loss ratio provisions of the ACA. These rebate liabilities are settled in the subsequent year. Liabilities related to experience-rated refunds, risk adjustment programs and the minimum medical loss ratio are included in Accrued expenses and other liabilities (current). Premiums for supplemental health, accident and individual life insurance and annuity long-duration products are recognized as revenue when due. Cigna Healthcare long-duration premium revenues are associated with contracts that provide coverage greater than one year or are guaranteed to be renewed at the option of the policyholder beyond one year. Benefits and expenses are matched with premiums. Revenue for universal life products is recognized as follows: •Investment income on assets supporting universal life products is recognized in Net investment income/losses as earned. •Charges for mortality, administration and policy surrender are recognized in Premiums as earned. Administrative fees are considered earned when services are provided. Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by policyholders. Expenses are recognized when claims are incurred and income is credited to policyholders in accordance with contract provisions. The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current). See Note 9 to the Consolidated Financial Statements for further information. F.Fees and Related Expenses The majority of the Company's service fee revenues are derived from the following programs: •Administrative Services Only ("ASO") arrangements allow plan sponsors to self-fund claims and assume the risk of medical or other benefit costs. In return for fees from these clients, the Company provides access to our participating provider networks and other services supporting benefit management. •Fee-for-service clinical solutions offered to clients, such as drug utilization management and medication adherence counseling help clients to drive better health outcomes at a lower cost by identifying and addressing potentially unsafe or wasteful prescribing, dispensing and utilization of prescription drugs, and communicating with, or supporting communications with, physicians, pharmacies and patients. •Wholesale Marketplace Drug Formulary Management services include either our drug formulary administrative service arrangements or our formulary processing arrangements. Drug formulary administrative services may include formulary consultation, administration of rebate contracts, rebate submission, collection from drug manufacturers and the distribution of rebates to clients. Services may also include facilitating audits of data submissions and reporting of rebates to clients. •Health benefit management solutions are offered primarily to sponsors of health benefit plans to drive cost reductions and improve quality outcomes for clients as well as provide behavioral health services to third-party health plans, employers and administrators. In certain arrangements, the Company assumes the financial obligation for third-party provider costs for medical services provided to the health plan's customers. Arrangements are generally short-term (one year or less) except for certain three-year health benefit management solutions contracts, and each consists of a single performance obligation. Performance obligations are satisfied as services are provided to clients, either on a stand-ready or utilization basis. Fees are billed, due and recognized at contracted rates on a periodic basis, generally monthly or agreed-upon arrangements terms. Fee revenues for services are generally recorded on a gross basis with the associated direct and indirect costs presented in Pharmacy and other service costs, or Selling, general and administrative expenses. Retained rebates reported in Fees and other revenues in our formulary processing arrangements are either recognized gross as services are provided to clients, consistent with the related service fee, or net as rebates are processed. The latter applies in arrangements in which the Company is permitted to retain a portion of rebates collected in exchange for services, but the Company does not obtain control of the retained rebate until rebates are transferred to the client. Fees for services may include variable consideration as a component of the transaction price, which is estimated at contract inception, recognized and adjusted through the contract period through Accrued expenses and other liabilities. Variable consideration includes certain health benefit management contracts requiring the Company to share the results of medical cost experience that differ from specified targets and ASO performance guarantees that compensate clients if certain service standards, clinical outcomes or financial metrics are not met.

Accounts Receivable, Net

12 Months Ended

Dec. 31, 2025

Receivables [Abstract]

Accounts Receivable, Net

Note 3 – Accounts Receivable, Net

Accounting Policy. We bill pharmaceutical manufacturers based on management's interpretation of contractual terms and estimate a contractual allowance based on the best information available at the time a claim is processed. Contractual allowances for certain rebates receivable from pharmaceutical manufacturers are determined by reviewing payment experience and specific known items that could be adjusted under contract terms. The Company's estimation process for contractual allowances for pharmaceutical manufacturer receivables generally results in an allowance for balances outstanding greater than 90 days.

Contractual allowances for certain receivables from third-party payors are based on their contractual terms and are estimated based on the Company's best information available at the time revenue is recognized.

The allowance for expected credit losses for current accounts receivable is based primarily on past collections experience relative to the length of time receivables are past due; however, when available evidence reasonably supports an assumption that counterparty credit risk over the expected payment period will differ from current and historical payment collections, a forecasting adjustment is reflected in the allowance for expected credit losses.

Discounts and claims adjustments issued to customers in the form of client credits and other non-credit adjustments are based on the current status of each customer's receivable balance, current economic and market conditions and a variety of other factors, including the length of time the receivables are past due, the financial health of customers and our past experience.

Receivables and any associated allowance are written off only when all collection attempts have failed and such amounts are determined unrecoverable. We regularly review the adequacy of these allowances based on a variety of factors, including age of the outstanding receivable and collection history. When circumstances related to specific collection patterns change, estimates of the recoverability of receivables are adjusted.

The Company's accounts receivable include amounts due from clients, third-party payors, customers and pharmaceutical manufacturers, and are presented net of allowances. These balances include the following:

•Noninsurance customer receivables - amounts due from customers for noninsurance services, primarily pharmacy benefit management and ASO contracts.

•Pharmaceutical manufacturers receivables - amounts due from pharmaceutical manufacturers.

•Insurance customer receivables - amounts due from customers under insurance and managed care contracts, primarily premiums receivable and amounts due from CMS.

•Other receivables - all other accounts receivable not included in the categories above.

The following amounts were included within Accounts receivable, net:


(In millions)	December 31, 2025		December 31, 2024
Noninsurance customer receivables	$	14,707	$	11,879
Pharmaceutical manufacturers receivables	12,437		10,914
Insurance customer receivables	1,385		3,199
Other receivables	239		162
Total			$	26,154
Accounts receivable, net classified as assets of businesses held for sale			(1,927)
Total	$	28,768	$	24,227

These receivables are reported net of our allowances of $6.8 billion and $5.0 billion as of December 31, 2025 and 2024, respectively. As of December 31, 2025 and 2024, these allowances were primarily comprised of $6.2 billion and $4.3 billion, respectively,

associated with contractual allowances for certain pharmaceutical manufacturers rebate receivables; $270 million and $388 million, respectively, associated with contractual allowances for third-party payor noninsurance customer receivables; and $199 million and $84 million, respectively, associated with allowances for current expected credit losses. The remaining allowances include discounts and claims adjustments issued to customers in the form of client credits and other non-credit adjustments.

Accounts Receivable Factoring Facility

The Company maintains an uncommitted factoring facility (the "Facility") with a total capacity of $1.5 billion under which certain accounts receivable may be sold on a non-recourse basis to a financial institution. The Facility automatically renewed in July 2025 and is subject to one-year renewal terms unless terminated by either party. The transactions under the Facility are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institution. Although the sale is made without recourse, we provide collection services related to the transferred assets. Amounts associated with this Facility are reflected within Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Factoring fees paid under this Facility are reflected in Interest expense and other in the Consolidated Statements of Income.

We sold pharmaceutical manufacturers receivables under the Facility of $4.4 billion and $5.5 billion during the years ended December 31, 2025 and December 31, 2024, respectively. For the years ended December 31, 2025, 2024 and 2023, factoring fees paid were not material. As of December 31, 2025 and December 31, 2024, all sold accounts receivable had been collected from pharmaceutical manufacturers and had been removed from the Company's Consolidated Balance Sheets. As of December 31, 2025 and December 31, 2024, there were $0.4 billion and $1.0 billion, respectively, of collections from pharmaceutical manufacturers that had not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.

Supplier Finance Program

12 Months Ended

Dec. 31, 2025

Payables and Accruals [Abstract]

Supplier Finance Program

Note 4 – Supplier Finance Program

The Company facilitates a voluntary supplier finance program (the "Program") that provides suppliers the opportunity to sell their accounts receivable due from us (i.e., our payment obligations to the suppliers) to a financial institution, on a non-recourse basis, in order to be paid earlier than our payment terms require. The Cigna Group is not a party to the Program and agrees to commercial terms with its suppliers independently of their participation in the Program. Amounts due to suppliers that participate in the Program are generally paid within one month following the invoice date. A supplier's participation in the Program has no impact on the Company's payment terms and the Company has no economic interest in a supplier's decision to participate in the Program. The suppliers, at their sole discretion, determine which invoices, if any, to sell to the financial institution. No guarantees or pledged assets are provided by the Company or any of our subsidiaries under the Program.

The obligations confirmed as valid within the Program by the financial institutions were as follows and are reflected in Accounts payable in the Consolidated Balance Sheets:


	For the Years Ended December 31,
(in millions)	2025		2024
Confirmed obligations outstanding at the beginning of the year	$	1,637	$	1,536
Invoices confirmed during the year	39,108		39,091
Less: confirmed invoices paid during the year	39,143		38,990
Confirmed obligations outstanding at the end of the year	$	1,602	$	1,637

The amounts confirmed as valid for both periods are predominately associated with one supplier.

Divestiture

12 Months Ended

Dec. 31, 2025

Discontinued Operations and Disposal Groups [Abstract]

Divestiture

Note 5 – Divestiture

Accounting Policy. The Company classifies assets and liabilities as held for sale ("disposal group") when management commits to a plan to sell the disposal group, the sale is probable within one year and the disposal group is available for immediate sale in its present condition. The Company considers various factors, particularly whether actions required to complete the plan indicate it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. Assets held for sale are measured at the lower of carrying value or fair value less costs to sell. Any loss resulting from the measurement is recognized in the period the held for sale criteria are met. Conversely, gains are not recognized until the date of the sale. When the disposal group is classified as held for sale, depreciation and amortization for most long-lived assets ceases, and the Company tests the assets for impairment. Deferred policy acquisition costs continue to be amortized.

The Company completed the sale of our Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies® businesses (the "Disposal Group") on March 19, 2025 (the "HCSC transaction"). The final purchase price and total cash proceeds collected in 2025 were $4.9 billion, representing an increase from the initial $3.3 billion purchase price, driven by higher statutory surplus for the legal entities when conveyed to HCSC and post-closing contractual adjustments.

The Company recognized within Net gain (loss) on sale of businesses in the Consolidated Statements of Income a gain of $9 million pre-tax ($401 million after-tax) for the year ended December 31, 2025, a loss of $472 million ($363 million after-tax) for the year ended December 31, 2024, and a loss of $1.5 billion ($1.4 billion after-tax) for the year ended December 31, 2023. See Note 21 to the Consolidated Financial Statements for discussion of tax matters for the year ended December 31, 2025 resulting in an after-tax gain on sale of businesses. The estimated loss on sale for both the years ended December 31, 2024 and December 31, 2023 primarily represented goodwill impairments of $302 million pre-tax in 2024 and $1.2 billion pre-tax in 2023.

The Company determined that the Disposal Group met the criteria to be classified as held for sale and aggregated and classified the assets and liabilities as held for sale in our Consolidated Balance Sheets as of December 31, 2024. The assets and liabilities held for sale as of December 31, 2024 were as follows:


(In millions)	December 31, 2024
Cash and cash equivalents	$	1,339
Investments	1,444
Accounts receivable, net	1,927
Other assets, including Goodwill (1)	2,294
Total assets of businesses held for sale	7,004
Insurance and contractholder liabilities	1,579
All other liabilities	831
Total liabilities of businesses held for sale	$	2,410

(1) Included Goodwill of $94 million

Integration and Transaction-Related Costs

In 2025, 2024 and 2023, the Company incurred transaction-related costs associated with the HCSC transaction. These costs incurred consisted primarily of certain projects to separate the Company's systems, products and services; fees for legal, advisory and other professional services; and certain employment-related costs. These costs were $327 million pre-tax ($247 million after-tax) for the year ended December 31, 2025, compared with $275 million pre-tax ($211 million after-tax) for the year ended December 31, 2024, and $45 million pre-tax ($35 million after-tax) for the year ended December 31, 2023.

Earnings Per Share

12 Months Ended

Dec. 31, 2025

Earnings Per Share [Abstract]

Earnings Per Share

Note 6 – Earnings Per Share

Accounting Policy. The Company computes basic earnings per share using the weighted-average number of unrestricted common and deferred shares outstanding. Diluted earnings per share also includes the dilutive effect of outstanding employee stock options and restricted stock using the treasury stock method and the effect of strategic performance shares.

Basic and diluted earnings per share were computed as follows:




	For the Years Ended December 31,
	2025						2024						2023
(Shares in thousands, dollars in millions, except per share amounts)	Basic		Effect of Dilution		Diluted		Basic		Effect of Dilution		Diluted		Basic		Effect of Dilution		Diluted
Shareholders' net income	$	5,957			$	5,957	$	3,434			$	3,434	$	5,164			$	5,164
Shares:
Weighted average	266,744				266,744		280,294				280,294		293,892				293,892
Common stock equivalents			1,819		1,819				2,924		2,924				2,990		2,990
Total shares	266,744		1,819		268,563		280,294		2,924		283,218		293,892		2,990		296,882
Earnings per share	$	22.33	$	(0.15)	$	22.18	$	12.25	$	(0.13)	$	12.12	$	17.57	$	(0.18)	$	17.39

The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:



	For the Years Ended December 31,
(In millions)	2025	2024	2023
Anti-dilutive options	2.0	1.1	0.9

Debt

12 Months Ended

Dec. 31, 2025

Debt Disclosure [Abstract]

Debt

Note 7 – Debt

The outstanding amounts of debt (net of issuance costs, discounts or premiums) and finance leases were as follows:


(In millions)	December 31, 2025		December 31, 2024
Short-term debt
Commercial paper	$	—	$	880
$900 million, 3.250% Notes due April 2025	—		897
$1,216 million, 4.125% Notes due November 2025	—		1,215

$550 million, 1.250% Notes due March 2026	549		—
Other, including finance leases	43		43
Total short-term debt	$	592	$	3,035
Long-term debt
$1,284 million, 4.500% Notes due February 2026	$	—	$	1,285
$700 million, 5.685% Notes due March 2026	—		699
$550 million, 1.250% Notes due March 2026	—		549
$1,500 million, 3.400% Notes due March 2027	1,481		1,466
$259 million, 7.875% Debentures due May 2027	260		259
$600 million, 3.050% Notes due October 2027	599		598
$3,800 million, 4.375% Notes due October 2028	3,792		3,790
$1,000 million, 5.000% Notes due May 2029	996		995
$1,400 million, 2.400% Notes due March 2030 (1)	1,406		1,386
$1,000 million, 4.500% Notes due September 2030	993		—
$1,500 million, 2.375% Notes due March 2031 (1)	1,420		1,384
$750 million, 5.125% Notes due May 2031 (1)	750		745
$1,250 million, 4.875% Notes due September 2032	1,243		—
$45 million, 8.080% Step Down Notes due January 2033	45		45
$800 million, 5.400% Notes due March 2033 (1)	796		795
$1,250 million, 5.250% Notes due February 2034 (1)	1,250		1,226
$1,500 million, 5.250% Notes due January 2036	1,488		—
$190 million, 6.150% Notes due November 2036	190		190
$2,200 million, 4.800% Notes due August 2038 (1)	2,194		2,193
$750 million, 3.200% Notes due March 2040	748		744
$121 million, 5.875% Notes due March 2041	119		119
$448 million, 6.125% Notes due November 2041	484		485
$317 million, 5.375% Notes due February 2042	315		315
$1,500 million, 4.800% Notes due July 2046	1,469		1,469
$1,000 million, 3.875% Notes due October 2047	990		990
$3,000 million, 4.900% Notes due December 2048	2,972		2,971
$1,184 million, 3.400% Notes due March 2050	1,172		1,237
$1,429 million, 3.400% Notes due March 2051	1,410		1,479
$1,500 million, 5.600% Notes due February 2054	1,486		1,482
$750 million, 6.000% Notes due January 2056	735		—
Other, including finance leases	68		41
Total long-term debt	$	30,871	$	28,937

(1)The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments as of December 31, 2025. See Note 11 to the Consolidated Financial Statements for further information about the Company's interest rate risk management and these derivative instruments.

Debt Issuance. In September 2025, we issued $4.5 billion of new senior notes, as detailed in the table below. The proceeds from this debt issuance were used to repay the $2.0 billion of loans outstanding under the Term Loan Facility as described below. We used the remaining net proceeds for general corporate purposes, including investments and repayment of indebtedness. Interest on this debt is paid semiannually.

Principal

Maturity Date

Interest Rate

Net Proceeds

Redeemable Date(1)

"Make Whole" Premium (2)

$1,000 million

September 15, 2030

4.500%

$994 million

August 15, 2030

15

$1,250 million

September 15, 2032

4.875%

$1,245 million

July 15, 2032

15

$1,500 million

January 15, 2036

5.250%

$1,490 million

October 15, 2035

15

$750 million

January 15, 2056

6.000%

$736 million

July 15, 2055

20

(1) Redeemable at any time prior to this date at a "make whole" premium, defined below. Redeemable at par on or after this date.

(2) "Make whole" premium calculated using a comparable U.S. Treasury rate plus the amount of basis points set forth in this column.

Term Loan. In August 2025, the Company entered into a new 364-day term loan facility (the "Term Loan Facility") and borrowed $2.0 billion to partially fund an investment in Shields Health Solutions ("Shields"), a leading specialty pharmacy management company. The full outstanding balance was repaid and the Term Loan Facility was terminated in September 2025, using proceeds from the debt issuance described above.

Revolving Credit Agreement. Our Credit Agreement (defined below) provides us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. As of December 31, 2025, there was no outstanding balance under the Credit Agreement.

In April 2025, the Company replaced its previous revolving credit agreements and entered into a $6.5 billion, five-year revolving credit and letter of credit agreement that will mature in April 2030, with an option to extend the maturity date for an additional one-year period, subject to consent of the banks (the "Credit Agreement"). The Company can borrow up to $6.5 billion under the Credit Agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit.

The Credit Agreement includes an option to increase commitments up to $1.5 billion for a maximum total commitment of $8.0 billion. The Credit Agreement allows for borrowings at either a base rate, term Secured Overnight Financing Rate ("SOFR") or daily simple SOFR, plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.

The Credit Agreement also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreement, may not exceed 60%, subject to certain exceptions upon the consummation of an acquisition.

Commercial Paper. Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $6.5 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. There was no commercial paper balance as of December 31, 2025.

Debt Maturities. Maturities of outstanding long-term debt as of December 31, 2025 are as follows:


(In millions)	Scheduled Maturities (1)
2026	$	550
2027	$	2,359
2028	$	3,800
2029	$	1,000
2030	$	2,400
Maturities after 2030	$	21,485

(1) Long-term debt maturity amounts include current maturities of long-term debt. Finance leases are excluded from this table.

Interest Expense. Interest expense on long-term and short-term debt was $1.4 billion in 2025, $1.5 billion in 2024 and $1.4 billion in 2023.

Debt Covenants. The Company was in compliance with its debt covenants as of December 31, 2025.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Common and Preferred Stock

12 Months Ended

Dec. 31, 2025

Common and Preferred Stock

Note 8 – Common and Preferred Stock

The Cigna Group has a total of 25 million shares of $1 par value preferred stock authorized for issuance. No shares of preferred stock were outstanding at December 31, 2025, 2024 or 2023.

The following table presents the share activity of The Cigna Group:


	For the Years Ended December 31,
(Shares in thousands)	2025	2024	2023
Common: Par value $0.01; 600,000 shares authorized
Outstanding- January 1,	273,789	292,504	298,676
Net issued for stock option exercises and other benefit plans	1,569	2,198	1,619
Repurchased common stock	(11,894)	(20,913)	(7,791)
Outstanding- December 31,	263,464	273,789	292,504
Treasury stock	141,136	128,723	107,390
Issued- December 31,	404,600	402,512	399,894

Dividends

The following table provides details of the Company's dividend payments:


Record Date	Payment Date	Amount per Share	Total Amount Paid (in millions)
2025
March 5, 2025	March 20, 2025	$1.51	$412
June 3, 2025	June 18, 2025	$1.51	$401
September 4, 2025	September 18, 2025	$1.51	$402
December 4, 2025	December 18, 2025	$1.51	$396
2024
March 6, 2024	March 21, 2024	$1.40	$401
June 4, 2024	June 20, 2024	$1.40	$392
September 4, 2024	September 19, 2024	$1.40	$390
December 4, 2024	December 19, 2024	$1.40	$384
2023
March 8, 2023	March 23, 2023	$1.23	$368
June 7, 2023	June 22, 2023	$1.23	$362
September 6, 2023	September 21, 2023	$1.23	$362
December 6, 2023	December 21, 2023	$1.23	$358

On February 5, 2026, the Board of Directors of The Cigna Group (the "Board") declared the first quarter cash dividend of $1.56 per share of The Cigna Group common stock to be paid on March 19, 2026 to shareholders of record on March 5, 2026. The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by the Board and the Board's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant.

Insurance and Contractholder Liabilities

12 Months Ended

Dec. 31, 2025

Insurance Loss Reserves [Abstract]

Insurance and Contractholder Liabilities

Note 9 – Insurance and Contractholder Liabilities

A.Account Balances – Insurance and Contractholder Liabilities

The Company's insurance and contractholder liabilities were comprised of the following:


	December 31, 2025						December 31, 2024
(In millions)	Current		Non-current		Total		Current		Non-current		Total
Unpaid claims and claim expenses
Cigna Healthcare	$	4,180	$	61	$	4,241	$	4,932	$	86	$	5,018
Other	167		176		343		147		144		291
Future policy benefits
Cigna Healthcare	38		153		191		91		507		598
Other Operations	142		3,081		3,223		157		3,140		3,297
Contractholder deposit funds
Cigna Healthcare	—		—		—		9		115		124
Other Operations	336		5,778		6,114		366		5,958		6,324
Market risk benefits	25		649		674		25		760		785
Unearned premiums	822		40		862		753		31		784
Total							6,480		10,741		17,221
Insurance and contractholder liabilities classified as liabilities of businesses held for sale (1)							(1,092)		(487)		(1,579)
Total insurance and contractholder liabilities	$	5,710	$	9,938	$	15,648	$	5,388	$	10,254	$	15,642

(1) Amounts classified as liabilities of businesses held for sale include $983 million of Unpaid claims, $408 million of Future policy benefits, $85 million of Unearned premiums and $103 million of Contractholder deposit funds as of December 31, 2024.

Insurance and contractholder liabilities expected to be paid within one year are classified as current.

Accounting Policy - Unearned Premium. The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current).

The Company evaluates certain insurance contracts subject to premium deficiency testing and recognizes a premium deficiency loss and corresponding reserve when expected claims costs, claims adjustment expenses, maintenance costs, and unamortized acquisition costs exceed unearned premium. Anticipated investment income is considered in the calculation of premium deficiency.

Unpaid Claims and Claim Expenses – Cigna Healthcare

This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities.

Accounting Policy. The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.

The Company compares key assumptions used to establish the medical costs payable to actual experience for each reporting period. The unpaid claims liability is adjusted through current period Shareholders' net income when actual experience differs from these assumptions. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trend.

The liability is primarily calculated using "completion factors" developed by comparing the claim incurral date to the date claims were paid. Completion factors are impacted by several key items including changes in: (i) electronic (auto-adjudication) versus manual claim processing; (ii) frequency and timeliness of provider claims submissions; (iii) number of customers; and (iv) the mix of products. The Company uses historical completion factors combined with an analysis of current trends and operational factors to

develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period.

The Company relies more heavily on medical cost trend analysis that reflects expected claim payment patterns and other relevant operational considerations for more recent months. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of health benefits offered, including inpatient, outpatient and pharmacy; the impact of copays and deductibles; changes in provider practices; and changes in consumer demographics and consumption behavior.

The total of incurred but not reported liabilities plus expected development on reported claims and reported claims in process was $4.0 billion as of December 31, 2025 and $4.6 billion as of December 31, 2024. The decrease was driven by the HCSC transaction.

Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:


	For the Years Ended December 31,
(In millions)	2025 (1)		2024 (1)		2023 (1)
Beginning balance	$	5,018	$	5,092	$	4,176
Less: Reinsurance and other amounts recoverable	159		236		221
Beginning balance, net	4,859		4,856		3,955

Incurred costs related to:
Current year	33,816		38,347		35,953
Prior years	(342)		(456)		(279)
Total incurred	33,474		37,891		35,674
Paid costs related to:
Current year	28,769		33,718		31,322
Prior years	4,147		4,170		3,451
Total paid	32,916		37,888		34,773
Less: Divestiture and other	1,323		—		—
Ending balance, net	4,094		4,859		4,856
Add: Reinsurance and other amounts recoverable	147		159		236
Ending balance	$	4,241	$	5,018	$	5,092

(1) Includes unpaid claims amounts classified as liabilities of businesses held for sale prior to the completion of the HCSC transaction. As of December 31, 2024 and December 31, 2023, includes $983 million and $823 million, respectively, classified as liabilities of businesses held for sale.

Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 to the Consolidated Financial Statements for additional information on reinsurance.

Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:


	For the Years Ended December 31,
	2025				2024
(Dollars in millions)	$		% (1)		$		% (2)
Actual completion factors and other	$	200	0.5	%	$	223	0.6	%
Medical cost trend	142		0.4		233		0.7

Total favorable variance	$	342	0.9	%	$	456	1.3	%

(1)Percentage of current year incurred costs as reported for the year ended December 31, 2024.

(2)Percentage of current year incurred costs as reported for the year ended December 31, 2023.

Favorable prior year development in both years primarily reflects lower than expected utilization of medical services as compared to our assumptions.

The following table depicts the incurred and paid claims development and unpaid claims liability as of December 31, 2025 (net of reinsurance) reported in the Cigna Healthcare segment. The information about incurred and paid claims development for the year ended December 31, 2024 is presented as supplementary information and is unaudited.


	Incurred Costs
Incurral Year	2024 (Unaudited)		2025		Unpaid Claims and Claim Expenses
(In millions)
2024	$	37,179	$	36,853	88
2025			33,530		4,006
Cumulative incurred costs for the periods presented			$	70,383

	Cumulative Costs Paid
Incurral Year	2024 (Unaudited)		2025
(In millions)
2024	$	32,719	$	36,544
2025			28,635
Cumulative paid costs for the periods presented			$	65,179

Outstanding liabilities for the periods presented, net of reinsurance			$	5,204
Divestiture and other			(1,110)
Net unpaid claims and claims expenses - Cigna Healthcare			4,094
Reinsurance and other amounts recoverable			147
Unpaid claims and claim expenses - Cigna Healthcare			$	4,241

Incurred claims do not typically remain outstanding for multiple years; more than 95% of health claims incurred in a year are paid by the end of the following year.

There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. Customers for whom no insured medical claim was paid are excluded from the calculation. Claims that did not result in a liability are not included in the frequency metric. The claim frequency for 2025 and 2024 was approximately 4.9 million and 5.3 million, respectively.

Future Policy Benefits

Accounting Policy. Future policy benefits represent the present value of estimated future obligations, estimated using actuarial methods, for long-duration insurance policies and annuity products currently in force, consisting primarily of reserves for annuity contracts, life insurance benefits and certain supplemental health products that are guaranteed renewable beyond one year.

Contracts are grouped at a level no higher than issue year, based on the original contract issue date, and at lower levels of disaggregation within each issue year for certain businesses to reflect factors including product type, plan type and currency. Management estimates these obligations based on assumptions for premiums, interest rates, mortality or morbidity, future claim adjudication expenses, and surrenders. Mortality, morbidity and surrender assumptions are based on the Company's own experience and published actuarial tables and are updated at least annually, to the extent changes in circumstances require. Interest rate assumptions are based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instruments"). For interest accretion purposes, interest rates are fixed at the year of the cohort's inception; however, for purposes of liability measurement, they are updated to the current rate quarterly, with all changes in the interest rate from inception to current period reported through Accumulated other comprehensive loss. For contracts issued domestically, we use observable inputs from a published spot rate curve for terms up to 30 years and extrapolate for longer terms using a constant forward rate approach. For contracts issued by foreign operating entities with functional currencies other than the U.S. dollar, we use observable inputs to approximate a risk-free rate and add a credit spread adjustment to align with a low credit risk fixed income instrument. For terms beyond the last observable risk-free rates, which vary by international market, we extrapolate to the ultimate forward rate assuming a constant credit spread.

For the annuity business, the premium paying period is shorter than the benefit coverage period, and a deferred profit liability is reported in future policy benefits representing gross premium received in excess of net premiums. Deferred profit liability is amortized based on expected future benefit payments.

As of December 31, 2025, approximately 36% of the liability for future policy benefits was supported by assets in trust for the benefit of the ceding company under reinsurance agreements.

Cigna Healthcare

Future policy benefits for the Cigna Healthcare segment were primarily related to the businesses divested to HCSC on March 19, 2025. Excluding the divestiture, changes in the future policy benefits for the years ended December 31, 2025 and December 31, 2024 were not material.

Other Operations

The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:


	As of
	December 31, 2025		December 31, 2024
Interest accretion rate	5.64	%	5.64	%
Current discount rate	5.18	%	5.42	%
Weighted average duration	10.6 years		10.8 years

Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations' traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.

Future policy benefits for Other Operations include deferred profit liability of $347 million and $366 million as of December 31, 2025 and December 31, 2024, respectively. As of December 31, 2025, December 31, 2024 and December 31, 2023, future policy benefits excluding deferred profit liability were $2.9 billion, $2.9 billion and $3.2 billion, respectively. Undiscounted expected future policy benefits were $4.2 billion and $4.3 billion as of December 31, 2025 and December 31, 2024, respectively. As of December 31, 2025 and December 31, 2024, $0.8 billion and $0.9 billion, respectively, of the future policy benefit reserve was recoverable through treaties with external reinsurers.

Contractholder Deposit Funds

Accounting Policy. Liabilities for contractholder deposit funds primarily include deposits received from customers for investment-related and universal life products as well as investment earnings on their fund balances in Other Operations. These liabilities are adjusted to reflect administrative charges and, for universal life fund balances, mortality charges. Interest credited on these funds is accrued ratably over the contract period.

Contractholder deposit fund liabilities within Other Operations were $6.1 billion, $6.3 billion and $6.5 billion as of December 31, 2025, December 31, 2024 and December 31, 2023, respectively. Approximately 37% and 38% of the balance is reinsured externally as of December 31, 2025 and December 31, 2024, respectively. Activity in these liabilities is presented net of reinsurance in the Consolidated Statements of Cash Flows. The net year-to-date decrease in contractholder deposit fund liabilities generally relates to withdrawals and benefit payments from contractholder deposit funds, partially offset by deposits and interest credited to contractholder deposit funds.

As of December 31, 2025, the weighted average crediting rate, net amount at risk and cash surrender value for contractholder deposit fund liabilities not effectively exited through reinsurance were 3.29%, $2.5 billion and $2.8 billion, respectively. The comparative amounts as of December 31, 2024 were 3.33%, $2.8 billion and $2.8 billion, respectively. More than 99% of the $3.9 billion liability as of December 31, 2025 and the $4.0 billion liability as of December 31, 2024 not reinsured externally is for contracts with guaranteed interest rates of 3% - 4%, and approximately $1.2 billion represented contracts with policies at the guarantee for both period ends. At these same period ends, $1.1 billion and $1.2 billion was 50 - 150 basis points ("bps") above the guarantee, and the remaining $1.6 billion as of both December 31, 2025 and December 31, 2024 represented contracts above the guarantee that pay the policyholder based on the greater of a guaranteed minimum cash value or the actual cash value. As of both December 31, 2025 and December 31, 2024, more than 90% of these contracts have actual cash values of at least 110% of the guaranteed cash value.

Market Risk Benefits

Liabilities for market risk benefits ("MRBs") consist of variable annuity reinsurance contracts in Other Operations. These liabilities arise under annuities and riders to annuities written by ceding companies that guarantee the benefit received at death and, for a subset of policies, also provide contractholders the option, within 30 days of a policy anniversary after the appropriate waiting period, to elect minimum income payments. The Company's capital market risk exposure on variable annuity reinsurance contracts arises when the reinsured guaranteed minimum benefit exceeds the contractholder's account value in the related underlying mutual funds at the time the insurance benefit is payable under the respective contract. The Company receives and pays premium periodically based on the terms of the reinsurance agreements.

Accounting Policy. Variable annuity reinsurance liabilities are measured as MRBs at fair value, net of nonperformance risk, with fluctuations in value gross of reinsurer nonperformance risk reported in benefit expenses, while fluctuations in the Company's own nonperformance risk (own credit risk) are reported in Accumulated other comprehensive loss. Nonperformance risk reflects risk that a party might default and therefore not fulfill its obligations (i.e., nonpayment risk). The nonperformance risk adjustment reflects a market participant's view of nonpayment risk by adding an additional spread to the discount rate in the calculation of both (a) the variable annuity reinsurance liabilities to be paid by the Company and (b) the variable annuity reinsurance assets to be paid by the reinsurers, after considering collateral. The Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy described in Note 12 to the Consolidated Financial Statements because assumptions related to future annuitant behavior are largely unobservable. As discussed further in Note 10 to the Consolidated Financial Statements, due to the reinsurance agreements covering these liabilities, the liabilities do not generally impact net income except for the change in nonperformance risk on the reinsurance recoverable, which is reported in benefit expenses and does not offset the nonperformance risk valuation on the liability. Variable annuity liabilities are established using capital market assumptions and assumptions related to future annuitant behavior (including mortality, lapse and annuity election rates).

Market risk benefits activity was as follows:


	For the Years Ended December 31,
(In millions)	2025		2024
Balance, beginning of year	$	785	$	1,003
Balance, beginning of year, before the effect of nonperformance risk (own credit risk)	838		1,085
Changes due to expected run-off	(20)		(12)
Changes due to capital markets versus expected	(63)		(233)
Changes due to policyholder behavior versus expected	(24)		(39)
Assumption changes	(17)		37
Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)	714		838
Nonperformance risk (own credit risk), end of period	(40)		(53)
Balance, end of period	$	674	$	785
Reinsured market risk benefit, end of period	$	712	$	836

The following table presents the account value, net amount at risk, average attained age of contractholders (weighted by exposure) and the number of contractholders for guarantees assumed by the Company. The net amount at risk is the amount that the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. As of December 31, 2025, the account value and net amount at risk decreased, reflecting a reduction in contractholders and favorable equity market performance. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded.


(Dollars in millions, excludes impact of reinsurance ceded)	December 31, 2025		December 31, 2024
Account value	$	7,281	$	7,777
Net amount at risk	$	1,115	$	1,283
Average attained age of contractholders (weighted by exposure)	78.3 years		77.7 years
Number of contractholders (estimated)	110,000		130,000

Reinsurance

12 Months Ended

Dec. 31, 2025

Reinsurance Disclosures [Abstract]

Reinsurance

Note 10 – Reinsurance

The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured

liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.

Accounting Policy. Reinsurance recoverables represent amounts due from reinsurers for both paid and unpaid claims of the Company's insurance businesses. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. Most reinsurance recoverables are classified as non-current assets. The current portion of reinsurance recoverables is reported in Other current assets and consists primarily of recoverables on paid claims expected to be settled within one year. Reinsurance recoverables are presented net of allowances, consisting primarily of an allowance for expected credit losses, which is recognized on reinsurance recoverable balances each period and adjusted through Medical costs and other benefit expenses. Estimates of the allowance for expected credit losses are based on internal and external data used to develop expected loss rates over the anticipated duration of the recoverable asset that vary by external credit rating and collateral level.

Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value.

The Company's reinsurance recoverables as of December 31, 2025 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:


(In millions)	Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable		Collateral Provisions Exist That May Mitigate Risk of Credit Loss (1)		No Collateral		Total
Ongoing operations
A- equivalent and higher current ratings (2)	$	—	$	5	$	211	$	216
BBB- to BBB+ equivalent current credit ratings (2)	—		—		64		64
Not rated	85		1		4		90
Acquisition, disposition or run-off activities
BBB+ equivalent and higher current ratings (2)(3)	288		2,838		32		3,158

Not rated	—		5		1		6
Total reinsurance recoverables before market risk benefits	$	373	$	2,849	$	312	$	3,534
Allowance for uncollectible reinsurance							(23)
Market risk benefits							712
Total reinsurance recoverables (4)							$	4,223

(1)Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.

(2)Certified by a nationally recognized statistical ratings organization ("NRSRO").

(3)Comprised of six reinsurers, of which 76% is held by two reinsurers, Lincoln National Life Insurance Company and Lincoln Life and Annuity Company of New York.

(4)Includes $120 million of current reinsurance recoverables that are reported in Other current assets.

The Company entered into an agreement with Berkshire to effectively exit the variable annuity reinsurance business via a reinsurance transaction in 2013. Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 9 to the Consolidated Financial Statements. Berkshire reinsured 100% of the Company's future cash flows in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit, with approximately $3.0 billion remaining as of December 31, 2025. As a result of the reinsurance transaction, amounts payable are offset by a corresponding reinsurance recoverable, provided the increased recoverable remains within the overall Berkshire limit. As of both December 31, 2025 and 2024, market risk benefits (shown in the table net of nonperformance risk as of December 31, 2025) were predominantly reinsured by Berkshire, which is rated AA+ by an NRSRO. As of December 31, 2025, approximately 100% of the Berkshire recoverable is secured by assets in a trust.

Effects of Reinsurance

Net short-duration contract premiums (direct, assumed and ceded) were $39.3 billion, $43.9 billion and $42.3 billion for the years ended December 31, 2025, 2024 and 2023, respectively. Net long-duration contract premiums (direct, assumed and ceded) were $1.0 billion, $2.0 billion and $1.9 billion for the years ended December 31, 2025, 2024 and 2023, respectively. Reinsurance recoveries of $671 million, $573 million and $456 million as of December 31, 2025, 2024 and 2023, respectively, have been netted against Medical costs and other benefit expenses in the Company’s Consolidated Statements of Income.

Both short- and long-duration premiums are primarily direct premiums; the amounts assumed and ceded were not material. Written premiums for short-duration contracts were not materially different from the recognized premium amounts.

Investments

12 Months Ended

Dec. 31, 2025

Investments [Abstract]

Investments

Note 11 – Investments

The following table summarizes the Company's investments by category and current or long-term classification:


	December 31, 2025						December 31, 2024
(In millions)	Current		Long-Term		Total		Current		Long-Term		Total
Debt securities	$	691	$	7,671	$	8,362	$	463	$	8,960	$	9,423
Equity securities	22		3,534		3,556		7		554		561
Commercial mortgage loans	86		1,147		1,233		108		1,243		1,351
Policy loans	—		1,082		1,082		—		1,156		1,156
Other long-term investments	—		5,037		5,037		—		4,576		4,576
Short-term investments	257		—		257		170		—		170
Total							$	748	$	16,489	$	17,237
Investments classified as assets of businesses held for sale (1)							(83)		(1,361)		(1,444)
Investments per Consolidated Balance Sheets	$	1,056	$	18,471	$	19,527	$	665	$	15,128	$	15,793

(1) Investments related to the HCSC transaction that were held for sale as of December 31, 2024. These investments were primarily comprised of debt securities.

Accounting Policy. Debt securities, commercial mortgage loans, derivative financial instruments and short-term investments with contractual maturities during the next 12 months are classified on the balance sheet as current investments unless they are held as statutory deposits or restricted for other purposes, in which case they are classified as Long-term investments. All other investments are classified as Long-term investments, with the exception of equity security funds that are used in our cash management strategy and are classified as current investments. See Note 12 to the Consolidated Financial Statements for information about the valuation of the Company's investment portfolio.

Investment Portfolio

Debt Securities

Accounting Policy. Debt securities (including bonds, mortgage and other asset-backed securities, and preferred stocks redeemable by the investor) are classified as available for sale and are carried at fair value with changes in fair value recorded either in Accumulated other comprehensive loss within Shareholders' equity or in credit loss expense based on fluctuations in the allowance for credit losses, as further discussed below. When the Company intends to sell or determines that it is more likely than not to be required to sell an impaired debt security, the excess of amortized cost over fair value is directly written down with a charge to Net investment gains/losses. Certain asset-backed securities are considered variable interest entities. See Note 13 to the Consolidated Financial Statements for additional information.

The Company reviews declines in fair value from a debt security's amortized cost basis to determine whether a credit loss exists and, when appropriate, recognizes a credit loss allowance with a corresponding charge to credit loss expense, presented in Net investment gains/losses in the Company's Consolidated Statements of Income. The allowance for credit loss represents the excess of amortized cost over the greater of its fair value or the net present value of the debt security's projected future cash flows (based on qualitative and quantitative factors, including the probability of default and the estimated timing and amount of recovery). Each period, the allowance for credit loss is adjusted as needed through credit loss expense.

The Company does not measure an allowance for credit losses for accrued interest receivables. When interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured, accrued interest, reported in Other current assets, is written off through a charge to Net investment income/losses and interest income is recognized on a cash basis.

The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of December 31, 2025:



(In millions)	Amortized Cost		Fair Value
Due in one year or less	$	695	$	598
Due after one year through five years	3,700		3,703
Due after five years through ten years	2,030		1,995
Due after ten years	1,968		1,822
Mortgage and other asset-backed securities	267		244
Total	$	8,660	$	8,362

Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties.

Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:


(In millions)	Amortized Cost		Allowance for Credit Loss		Unrealized Appreciation		Unrealized Depreciation		Fair Value
December 31, 2025
Federal government and agency	$	215	$	—	$	15	$	(3)	$	227
State and local government	24		—		1		—		25
Foreign government	450		—		12		(6)		456
Corporate	7,704		(137)		175		(332)		7,410
Mortgage and other asset-backed	267		—		3		(26)		244
Total	$	8,660	$	(137)	$	206	$	(367)	$	8,362


December 31, 2024
Federal government and agency	$	276	$	—	$	14	$	(9)	$	281
State and local government	37		—		1		(1)		37
Foreign government	350		—		5		(11)		344
Corporate	9,091		(111)		102		(659)		8,423
Mortgage and other asset-backed	371		—		1		(34)		338
Total	$	10,125	$	(111)	$	123	$	(714)	$	9,423

Review of Declines in Fair Value. Management reviews debt securities in an unrealized loss position to determine whether a credit loss allowance is needed based on criteria that include severity of decline; financial health and specific prospects of the issuer; and changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.

The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded (by investment grade and the length of time these securities have been in an unrealized loss position). Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased.


	December 31, 2025							December 31, 2024
(Dollars in millions)	Fair Value		Amortized Cost		Unrealized Depreciation		Number of Issues	Fair Value		Amortized Cost		Unrealized Depreciation		Number of Issues
One year or less
Investment grade	$	384	$	386	$	(2)	149	$	1,203	$	1,227	$	(24)	545
Below investment grade	120		125		(5)		239	245		250		(5)		739
More than one year
Investment grade	3,044		3,382		(338)		799	4,687		5,319		(632)		1,297
Below investment grade	185		207		(22)		86	416		469		(53)		123
Total	$	3,733	$	4,100	$	(367)	1,273	$	6,551	$	7,265	$	(714)	2,704

Equity Securities

Accounting Policy. Equity securities with a readily determinable fair value consist primarily of public equity investments in the health care sector and mutual funds that invest in fixed income debt securities while those without a readily determinable fair value consist of private equity investments. Changes in the fair values of equity securities that have a readily determinable fair value are reported in Net investment gains/losses. Equity securities without a readily determinable fair value are carried at cost minus impairment plus or minus changes resulting from observable price changes.

The following table provides the values of the Company's equity security investments:


	December 31, 2025				December 31, 2024
(In millions)	Cost		Carrying Value		Cost		Carrying Value
Equity securities with readily determinable fair values	$	78	$	92	$	635	$	37
Equity securities with no readily determinable fair value	6,792		3,464		3,215		524
Total	$	6,870	$	3,556	$	3,850	$	561

In the third quarter of 2025, the Company invested $3.5 billion in preferred stock of Shields, and a compounding dividend is recorded in Fees and other revenues within the Consolidated Statements of Income. The investment is included in equity securities with no readily determinable fair value in the table above.

Commercial Mortgage Loans

Accounting Policy. Commercial mortgage loans are carried at unpaid principal balances, net of an allowance for expected credit losses, and classified as either current or long-term investments based on their contractual maturities. Changes in the allowance for expected credit losses are recognized as credit loss expense and presented in Net investment gains/losses in the Company's Consolidated Statements of Income.

Each period, the Company establishes (or adjusts) its allowance for expected credit losses for commercial mortgage loans. The allowance for expected credit losses is based on a credit risk category that is assigned to each loan at origination using key credit quality indicators, including debt service coverage and loan-to-value ratios. Credit risk categories are updated as key credit quality indicators change. An expected loss rate, assigned based on the credit risk category, is applied to each loan's unpaid principal balance to develop the aggregate allowance for expected credit losses. Commercial mortgage loans are considered impaired and written off against the allowance when it is probable that the Company will not collect all amounts due per the terms of the promissory note. In situations involving foreclosure or the use of real estate operations to recover value, the allowance for credit losses is determined by the extent to which the mortgage loan’s carrying value exceeds the fair value of its underlying collateral.

Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high-quality, primarily completed and substantially leased operating properties.

Credit Quality. The Company regularly evaluates and monitors credit risk. Mortgage origination professionals employ an internal credit quality rating system designed to evaluate the relative risk of the transaction at origination that is then updated each year as part of the annual portfolio loan review. The Company evaluates and monitors credit quality on a consistent and ongoing basis. The annual portfolio review performed in the second quarter of 2025 confirmed ongoing strong overall credit quality in line with the previous year's results.

Quality ratings are based on our evaluation of a number of key inputs related to the loan. The two most significant contributors to the credit quality rating are the debt service coverage and loan-to-value ratios. The debt service coverage ratio measures the amount of property cash flow available to meet annual interest and principal payments on debt, with a ratio below 1.0 indicating that there is not enough cash flow to cover the required loan payments. The loan-to-value ratio, commonly expressed as a percentage, compares the amount of the loan to the fair value of the underlying property collateralizing the loan.

The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:


(Dollars in millions)	December 31, 2025					December 31, 2024
Loan-to-Value Ratio	Carrying Value		Average Debt Service Coverage Ratio	Average Loan-to-Value Ratio		Carrying Value		Average Debt Service Coverage Ratio	Average Loan-to-Value Ratio
Below 60%	$	355	2.13			$	547	2.07
60% to 79%	694		1.81			595		1.83
80% to 100%	184		0.79			209		0.51



Total	$	1,233	1.72	71	%	$	1,351	1.70	69	%

Policy Loans

Accounting Policy. Policy loans, primarily associated with our corporate-owned life insurance business, are carried at unpaid principal balances plus accumulated interest, the total of which approximates fair value. These loans are collateralized by life insurance policy cash values and therefore have minimal exposure to credit loss. Interest rates are reset annually based on a rolling average of benchmark interest rates.

Other Long-Term Investments

Accounting Policy. Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans, and health care-related investments. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the

underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one-quarter lag due to the timing of when financial information is received from the general partner or manager of the investments.

Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Depreciation is generally recorded using the straight-line method based on the estimated useful life of each asset. Investment real estate as of December 31, 2025 and 2024 is expected to be held longer than one year and may include real estate acquired through the foreclosure of commercial mortgage loans.

Additionally, foreign currency swaps carried at fair value and certain restricted deposits are reported in the table below as "Other." See discussion below for information on the Company's accounting policies for derivative financial instruments.

Other long-term investments and related commitments are diversified by issuer, property type and geographic region. These investments are primarily unconsolidated variable interest entities (see Note 13 to the Consolidated Financial Statements for additional information). The following table provides unfunded commitment and carrying value information for these investments. The Company expects to disburse approximately 30% of the committed amounts in 2026.

Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income/losses. The amount of these cash distributions was $314 million in 2025, $344 million in 2024 and $253 million in 2023.



					Unfunded Commitments as of
	Carrying Value as of December 31,
(In millions)	2025		2024		December 31, 2025
Real estate investments	$	1,895	$	1,763	$	1,106
Securities partnerships	2,948		2,587		2,058
Other	194		226		—
Total	$	5,037	$	4,576	$	3,164

Short-Term Investments

Accounting Policy. Security investments with maturities of greater than three months to one year from time of purchase are classified as short-term, available for sale and carried at fair value that approximates cost.

Concentration of Risk

The Company did not have a concentration of investments in a single issuer or borrower exceeding 10% of shareholders' equity as of December 31, 2025 or 2024.

Derivative Financial Instruments

The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt. The Company also has derivative instruments associated with certain equity securities; see Note 12 to the Consolidated Financial Statements for further discussion.

Accounting Policy. Derivatives are recorded in our Consolidated Balance Sheets at fair value and are classified as current or non-current according to their contractual maturities. Further information on our policies for determining fair value are discussed in Note 12. The Company applies hedge accounting when derivatives are designated, qualified and highly effective as hedges. Under hedge accounting, the changes in fair value of the derivative and the hedged risk are generally recognized together and offset each other when reported in Shareholders' net income. Various qualitative or quantitative methods appropriate for each hedge are used to formally assess and document hedge effectiveness at inception and each period throughout the life of a hedge.

Fair Value Hedges of the Foreign Exchange-Related Changes in Fair Values of Certain Foreign-Denominated Bonds:

This program hedges the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars. Swap fair values are reported in Long-term investments or Other non-current liabilities. Offsetting changes in fair values attributable to the foreign exchange risk of the swap contracts and the hedged bonds are reported in Net investment gains/losses. The portion of the swap contracts' changes in fair value excluded from the assessment of hedge effectiveness is recorded in Other comprehensive loss and recognized in Net investment

income/losses as swap coupon payments are accrued, offsetting the foreign-denominated coupons received on the designated bonds. Net cash flows are reported in Operating activities, while exchanges of notional principal amounts are reported in Investing activities.

Fair Value Hedges of the Interest Rate Exposure on the Company's Long-Term Debt:

This program converts a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Using fair value hedge accounting, the fair values of the swap contracts are reported in other assets or other liabilities. The critical terms of these swaps match those of the long-term debt being hedged. As a result, the carrying value of the hedged debt is adjusted to reflect changes in its fair value driven by SOFR. The effects of those adjustments on interest expense are offset by the effects of corresponding changes in the swaps' fair value. The net impact from the hedge reported in Interest expense and other reflects interest expense on the hedged debt at the variable interest rate. Cash flows relating to these contracts are reported in Operating activities.

Net Investment Hedges of Certain Foreign Subsidiaries Operating Principally in Currencies Other than the U.S. Dollar:

This program reduces the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros. The fair values of the foreign currency swap and forward contracts are reported in other assets or other liabilities. The changes in fair values of these instruments are reported in Other comprehensive loss, specifically in translation of foreign currencies. The portion of the change in fair values relating to foreign exchange spot rates will be recognized in earnings upon deconsolidation of the hedged foreign subsidiaries. Cash flows relating to these contracts are reported in Investing activities.

The effects of derivative financial instruments used in our individual hedging strategies were not material to the Consolidated Financial Statements as of December 31, 2025 and December 31, 2024. The gross fair values of our derivative financial instruments are presented in Note 12 to the Consolidated Financial Statements. The following table summarizes the types and notional quantity of derivative instruments held by the Company:


	Notional Value as of
(In millions)	December 31, 2025		December 31, 2024
Type of Instrument
Fair value hedge - Foreign currency swap contracts	$	908	$	975
Fair value hedge - Interest rate swap contracts	$	3,150	$	2,700
Net investment hedge - Foreign currency swap contracts	$	415	$	415

Net Investment Income

Accounting Policy. When interest and principal payments on investments are current, the Company recognizes interest income when it is earned. The Company recognizes interest income on a cash basis when interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured. For unconsolidated entities that are included in other long-term investments, investment income is generally recognized according to the Company's share of the reported income or loss on the underlying investments. Investment income attributed to the Company's separate accounts is excluded from our earnings because associated gains and losses generally accrue directly to separate account policyholders.

The components of Net investment income were as follows:


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Debt securities	$	454	$	492	$	500
Equity securities (1)	6		(114)		123
Commercial mortgage loans	52		61		65
Policy loans	51		56		60
Other long-term investments	232		75		123
Short-term investments and cash	294		447		339
Total investment income	1,089		1,017		1,210
Less investment expenses	43		44		44
Net investment income	$	1,046	$	973	$	1,166

(1)Includes a $182 million impairment of dividend receivable for the year ended December 31, 2024.

Investment Gains and Losses

Accounting Policy. Investment gains and losses are based on specifically identified assets and result from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments.

Net investment losses before income taxes were $24 million, $2,737 million and $78 million for the years ended December 31, 2025, 2024 and 2023, respectively. Net investment losses in 2024 were primarily driven by the impairment of equity securities in 2024. These amounts exclude investment gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders.

Fair Value Measurements

12 Months Ended

Dec. 31, 2025

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 12 – Fair Value Measurements

Accounting Policy. The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value.

Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor.

The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument's fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).

The Company estimates fair values using prices from third parties or internal pricing methods. Fair value estimates received from third-party pricing services are based on reported trade activity and quoted market prices when available and other market information that a market participant would use to estimate fair value. The internal pricing methods are performed by the Company's investment professionals and generally involve using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality as well as other qualitative factors. In instances where there is little or no market activity for the same or similar instruments, fair value is estimated using methods, models and assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. These valuation techniques involve some level of estimation and judgment that becomes significant with increasingly complex instruments or pricing models.

The Company is responsible for determining fair value and for assigning the appropriate level within the fair value hierarchy based on the significance of unobservable inputs. The Company reviews methodologies, processes and controls of third-party pricing services and compares prices on a test basis to those obtained from other external pricing sources or internal estimates. The Company performs ongoing analyses of both prices received from third-party pricing services and those developed internally to determine that they represent appropriate estimates of fair value. The controls executed by the Company include evaluating changes in prices and monitoring for potentially stale valuations. The Company also performs sample testing of sales values to confirm the accuracy of prior fair value estimates. The minimal exceptions identified during these processes indicate that adjustments to prices are infrequent and do not significantly impact valuations. An annual due diligence review of the most significant pricing service is conducted to review their processes, methodologies and controls. This review includes a walk-through of inputs for a sample of securities held across various asset types to validate the documented pricing process.

Financial Assets and Financial Liabilities Carried at Fair Value

The following table provides information about the Company's investment and derivative financial assets and liabilities carried at fair value on a recurring basis. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders.


(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)				Total
	December 31, 2025		December 31, 2024		December 31, 2025		December 31, 2024		December 31, 2025		December 31, 2024		December 31, 2025		December 31, 2024
Financial assets at fair value
Debt securities
Federal government and agency	$	105	$	165	$	122	$	116	$	—	$	—	$	227	$	281
State and local government	—		—		25		37		—		—		25		37
Foreign government	—		—		446		344		10		—		456		344
Corporate	—		—		7,133		8,049		277		374		7,410		8,423
Mortgage and other asset-backed	—		—		206		295		38		43		244		338
Total debt securities	105		165		7,932		8,841		325		417		8,362		9,423
Equity securities (1)	54		1		36		36		2		—		92		37
Short-term investments	—		—		257		170		—		—		257		170
Derivative assets	—		—		68		168		923		—		991		168
Financial liabilities at fair value
Derivative liabilities	$	—	$	—	$	22	$	1	$	354	$	—	$	376	$	1

(1)Excludes certain equity securities that have no readily determinable fair value.

Level 1 Financial Assets

Inputs for instruments classified in Level 1 include unadjusted quoted prices for identical assets in active markets accessible at the measurement date. Active markets provide pricing data for trades occurring at least weekly and include exchanges and dealer markets. Assets in Level 1 include actively traded U.S. government bonds and exchange-listed equity securities.

Level 2 Financial Assets and Financial Liabilities

Inputs for instruments classified in Level 2 include quoted prices for similar assets or liabilities in active markets, quoted prices from those willing to trade in markets that are not active, or other inputs that are market-observable or can be corroborated by market data for the term of the instrument. Such other inputs include market interest rates and volatilities, spreads, and yield curves. An instrument is classified in Level 2 if the Company determines that unobservable inputs are insignificant.

Debt and Equity Securities. Third-party pricing services and internal methods often use recent trades of securities with similar features and characteristics because many debt securities do not trade daily. Pricing models are used to determine these prices when recent trades are not available. These models calculate fair values by discounting future cash flows at estimated market interest rates. Such market rates are derived by calculating the appropriate spreads over comparable U.S. Treasury securities based on the credit quality, industry and structure of the asset. Typical inputs and assumptions to pricing models include, but are not limited to, a combination of benchmark yields, reported trades, issuer spreads, liquidity, benchmark securities, bids, offers, reference data, and industry and economic events. For mortgage-backed securities, inputs and assumptions may also include characteristics of the issuer, collateral attributes, prepayment speeds and credit rating. Nearly all of these instruments are valued using recent trades or pricing models.

Short-term Investments are carried at fair value that approximates cost. The Company compares market prices for these securities to recorded amounts on a regular basis to validate that current carrying amounts approximate exit prices. The short-term nature of the investments and corroboration of the reported amounts over the holding period support their classification in Level 2.

Derivative Assets and Liabilities classified in Level 2 represent over-the-counter instruments, such as foreign currency forward and swap contracts. Fair values for these instruments are determined using market-observable inputs, including forward currency and

interest rate curves and widely published market-observable indices. Credit risk related to the counterparty and the Company is considered when estimating the fair values of these derivatives. The nature and use of these derivative financial instruments are described in Note 11.

Level 3 Financial Assets and Financial Liabilities

Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9E, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.

The Company classifies certain newly issued, privately placed, complex or illiquid securities in Level 3. Approximately 4% of debt securities are priced using significant unobservable inputs and classified in this category.

Fair values of mortgage and other asset-backed securities, as well as corporate and government debt securities, are primarily determined using pricing models that incorporate the specific characteristics of each asset and related assumptions, including the investment type and structure, credit quality, industry and maturity date in comparison to current market indices, spreads, and liquidity of assets with similar characteristics. Inputs and assumptions for pricing may also include characteristics of the issuer, collateral attributes, and prepayment speeds for mortgage and other asset-backed securities. Recent trades in the subject security or similar securities are assessed when available, and the Company may also review published research in its evaluation, as well as the issuer's financial statements.

Information about Debt Securities. The significant unobservable input used to value our corporate and government debt securities, and mortgage and other asset-backed securities, is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security.

The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.


	Fair Value as of					Unobservable Adjustment Range (Weighted Average by Quantity) as of
(Fair value in millions)	December 31, 2025		December 31, 2024		Unobservable Input December 31, 2025	December 31, 2025		December 31, 2024
Debt securities
Corporate	$	286	$	373	Liquidity	60 - 920 (175)	bps	60 - 1520 (370)	bps
Mortgage and other asset-backed securities	38		43		Liquidity	105 - 350 (160)	bps	100 - 550 (280)	bps
Other debt securities	1		1
Total Level 3 debt securities	$	325	$	417

Information about Derivative Instruments. Derivative instruments associated with certain equity securities are valued each reporting period using a Monte Carlo simulation of enterprise value and are recorded in Other assets and Other non-current liabilities in the Consolidated Balance Sheets. The estimation of enterprise value is derived from a discounted cash flow model utilizing management's forecasts and industry benchmarks. The significant unobservable Level 3 measurement inputs used as of December 31, 2025 are: volatility of adjusted earnings before interest, taxes, depreciation and amortization ("adjusted EBITDA") (55%), volatility of equity (85%), correlation (35%), purchaser credit spread (0.7%) and weighted average cost of capital (13.5%). Changes in these assumptions could increase or decrease the fair value measurements. See Note 11A to the Consolidated Financial Statements for further information.

Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value

The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.



	Years Ended December 31,
(In millions)		2025		2024

Beginning balance		$	417	$	447
Losses included in Shareholders' net income		(90)		(69)
Gains (losses) included in Other comprehensive loss		33		(9)

Purchases, sales and settlements
Purchases		655		17
Sales		(8)		(2)
Settlements		(105)		(21)
Total purchases, sales and settlements		542		(6)
Transfers into / (out of) Level 3
Transfers into Level 3		59		72
Transfers out of Level 3		(65)		(18)
Total transfers into / (out of) Level 3		(6)		54
Ending balance		$	896	$	417
Total losses included in Shareholders' net income attributable to instruments held at the reporting date		$	(94)	$	(69)
Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period		$	19	$	(9)

Total gains and losses included in Shareholders' net income in the table above are reflected in the Consolidated Statements of Income as Net investment gains/losses and as Net investment income/losses. Gains and losses included in Other comprehensive loss, net of tax, in the table above are reflected in Net unrealized (depreciation) appreciation on securities and derivatives in the Consolidated Statements of Comprehensive Income.

Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads. Transfers between Level 2 and Level 3 during 2025 and 2024 primarily reflected changes in liquidity estimates for certain private placement issuers across several sectors. See discussion under Level 3 Financial Assets and Financial Liabilities above for more information.

Separate Accounts

Accounting Policy. Separate account assets and liabilities are contractholder funds maintained in accounts with specific investment objectives. Our subsidiaries or external advisors manage invested assets of separate accounts on behalf of contractholders, including The Cigna Group Pension Plan, variable universal life products sold through our corporate-owned life insurance products and the run-off businesses. The assets of these accounts are legally segregated and are not subject to claims that arise out of any of the Company's other businesses. These separate account assets are carried at fair value with equal amounts recorded for related separate account liabilities. The investment income and fair value gains and losses of separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. Fees and charges earned for mortality risks, asset management or administrative services are reported in either Premiums or Fees and other revenues. Investments that are measured using the practical expedient of net asset value are excluded from the fair value hierarchy. The separate account activity for the years ended December 31, 2025 and 2024 was primarily driven by changes in the market values of the underlying separate account investments.

Fair values of Separate account assets were as follows:


	Quoted Prices in Active Markets for Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)				Total
(In millions)	December 31, 2025		December 31, 2024		December 31, 2025		December 31, 2024		December 31, 2025		December 31, 2024		December 31, 2025		December 31, 2024
Guaranteed separate accounts (see Note 22)	$	247	$	231	$	330	$	345	$	—	$	—	$	577	$	576
Non-guaranteed separate accounts (1)	271		267		5,769		5,575		209		228		6,249		6,070
Subtotal	$	518	$	498	$	6,099	$	5,920	$	209	$	228	6,826		6,646
Non-guaranteed separate accounts priced at net asset value as a practical expedient (1)													661		632
Total													$	7,487	$	7,278

(1)Non-guaranteed separate accounts include $3.8 billion as of both December 31, 2025 and December 31, 2024 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of both December 31, 2025 and December 31, 2024. Non-guaranteed separate accounts are primarily comprised of securities partnerships, real estate and real estate funds.

Separate account assets classified in Level 1 primarily include exchange-listed equity securities. Level 2 assets primarily include corporate and structured bonds valued using recent trades of similar securities or pricing models that discount future cash flows at estimated market interest rates, as described above, and actively traded institutional and retail mutual fund investments.

Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly issued, privately placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the years ended December 31, 2025 or 2024.

Assets and Liabilities Measured at Fair Value under Certain Conditions

Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.

For the year ended December 31, 2025, impairments recognized requiring the assets and liabilities described above to be measured at fair value were not material. For the year ended December 31, 2024, we determined our investment in VillageMD was fully impaired and recorded a $2.7 billion loss in Net investment gains/losses in the Company's Consolidated Statements of Income. Observable price changes for equity securities with no readily determinable fair value were not material for the years ended December 31, 2025 or December 31, 2024.

Fair Value Disclosures for Financial Instruments Not Carried at Fair Value

The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.


	Classification in Fair Value Hierarchy	December 31, 2025				December 31, 2024
(In millions)		Fair Value		Carrying Value		Fair Value		Carrying Value
Commercial mortgage loans	Level 3	$	1,195	$	1,233	$	1,256	$	1,351
Long-term debt, including current maturities, excluding finance leases	Level 2	$	29,907	$	31,352	$	28,392	$	31,008

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

Equity Method Investments and Joint Ventures [Abstract]

Variable Interest Entities	12 Months Ended
Variable Interest Entities	Dec. 31, 2025
Variable Interest Entities [Abstract]
Variable Interest Entities	Note 13 – Variable Interest Entities When the Company becomes involved with a variable interest entity and when there is a change in the Company's involvement with an entity, the Company must determine if it is the primary beneficiary and must consolidate the entity. The Company is considered the primary beneficiary if it has the power to direct the entity's most significant economic activities and has the right to receive benefits or obligation to absorb losses that could be significant to the entity. The Company evaluates the following criteria: the structure and purpose of the entity; the risks and rewards created by and shared through the entity; and the Company's ability to direct its activities, receive its benefits and absorb its losses relative to the other parties involved with the entity, including its sponsors, equity holders, guarantors, creditors and servicers. The Company determined it was not a primary beneficiary in any material variable interest entity as of December 31, 2025 or 2024. The Company's involvement in variable interest entities for which it is not the primary beneficiary is described below. Securities Limited Partnerships and Real Estate Limited Partnerships. The Company owns interests in securities limited partnerships and real estate limited partnerships that are defined as unconsolidated variable interest entities. These partnerships invest in the equity or mezzanine debt of privately held companies and real estate properties. General partners unaffiliated with the Company control decisions that most significantly impact the partnership's operations, and the limited partners do not have substantive kick-out or participating rights. The Company has invested in approximately 215 limited partnerships that have a carrying value of $3.7 billion as of December 31, 2025 reported in other long-term investments. As of December 31, 2025, we have commitments to contribute an additional $2.8 billion to these entities, and the Company's maximum exposure to loss from these investments is $6.5 billion, calculated as the sum of our carrying value and the additional funding commitments. Our noncontrolling interest in each of these limited partnerships is generally less than 9% of the partnership ownership interests. See Note 11 to the Consolidated Financial Statements for further information on the Company's accounting policy for other long-term investments. The Company has guaranteed debt payments to mortgage lenders for certain real estate limited partnerships should potential environmental obligations arise. No liability has been incurred related to these guarantees, and the Company's maximum exposure to these guarantees was approximately $380 million as of December 31, 2025. Other Variable Interest Entities. The Company is involved in other types of variable interest entities, including certain asset-backed and corporate securities, real estate joint ventures that develop properties for residential and commercial use, and international health care joint ventures. As of December 31, 2025, the Company's maximum exposure to loss is $0.4 billion from certain asset-backed and corporate securities and $1.0 billion from real estate joint ventures, which represents the sum of our carrying value and the additional funding commitments for these entities. The carrying values and maximum exposures for the remaining unconsolidated variable interest entities were not material as of December 31, 2025. The Company has not provided, and does not intend to provide, financial support to any of the variable interest entities in excess of its maximum exposure. We perform ongoing qualitative analyses of our involvement with these variable interest entities to determine if consolidation is required.

Collectively Significant Operating Unconsolidated Subsidiaries

12 Months Ended

Dec. 31, 2025

Collectively Significant Operating Unconsolidated Subsidiaries

Note 14 – Collectively Significant Operating Unconsolidated Subsidiaries

In addition to equity method investments in certain limited partnerships and limited liability companies holding real estate, securities or loans (as disclosed in Note 11), we maintain a portfolio of operating joint ventures accounted for as equity method investments. Operating joint ventures had a carrying value of $(211) million as of December 31, 2025 and $656 million as of December 31, 2024, of which $(296) million as of December 31, 2025 and $43 million as of December 31, 2024 related to our joint venture in China. The carrying value of our joint venture in China includes the Company's share of Accumulated Other Comprehensive Income (Loss) ("AOCI") losses of $1,672 million as of December 31, 2025 and $979 million as of December 31, 2024, primarily related to the requirement to update discount rate assumptions for certain long-duration liabilities as well as the impact of unrealized investment gains and losses.

For the years ended December 31, 2025, 2024 and 2023, none of our equity method investments were individually significant.

In the fourth quarter of 2024, we sold a portion of an operating joint venture, reducing our ownership. As a result, we recognized $496 million within Net gain (loss) on sale of businesses in our Consolidated Statements of Income.

Accounting Policy. We record in our Consolidated Statements of Income our proportionate share of net income or loss generated by operating joint ventures within Fees and other revenues. In certain instances, income or loss is reported on a one-month lag due to the timing of when financial information is received.

The below summarized results of operations and financial position of the operating joint ventures reflects the latest available financial information and does not represent the Company's proportionate share of the assets, liabilities or earnings of such entities.


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Revenues	$	7,747	$	7,309	$	5,962
Net income	$	755	$	607	$	98


(In millions)	December 31, 2025		December 31, 2024
Total assets	$	39,547	$	34,395
Total liabilities	$	40,009	$	33,892

Accumulated Other Comprehensive Income (Loss)

12 Months Ended

Dec. 31, 2025

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Accumulated Other Comprehensive Income (Loss)

Note 15 – Accumulated Other Comprehensive Income (Loss)

AOCI includes net unrealized (depreciation) appreciation on securities and derivatives, change in discount rate and instrument-specific credit risk for certain long-duration insurance contractholder liabilities (see Note 9 to the Consolidated Financial Statements), foreign currency translation, and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.

Shareholders' other comprehensive loss, net of tax, for the years ended December 31, 2025, 2024 and 2023 is primarily attributable to the change in discount rates for certain long-duration liabilities and unrealized changes in the market values of securities and derivatives, including the impacts from unconsolidated entities reported on the equity method.

Changes in the components of AOCI were as follows:


	For The Years Ended December 31,
(In millions)		2025		2024		2023
Securities and derivatives


Beginning balance		$	832	$	171	$	(332)
Unrealized (depreciation) appreciation on securities and derivatives, before reclassification, net of tax benefit (expense) of $118, $(207) and $(146), respectively		(309)		601		474
Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(20), $(16) and $(8), respectively		71		60		29
Shareholders' other comprehensive (loss) income, net of tax		(238)		661		503
Ending balance		$	594	$	832	$	171
Net long-duration insurance and contractholder liabilities measurement adjustments


Beginning balance		$	(2,038)	$	(971)	$	(256)
Net current period change in discount rate for certain long-duration liabilities, before reclassification, net of tax benefit of $71, $357 and $222, respectively		(225)		(1,044)		(691)
Amounts reclassified to Shareholders' net income, net of tax expense of $16, $— and $— respectively		(56)		—		—
Net current period change in discount rate for certain long-duration liabilities, net of tax benefit of $87, $357 and $222, respectively		(281)		(1,044)		(691)
Net current period change in instrument-specific credit risk for market risk benefits, net of tax benefit of $3, $6 and $5, respectively		(10)		(23)		(24)
Shareholders' other comprehensive (loss), net of tax		(291)		(1,067)		(715)
Ending balance		$	(2,329)	$	(2,038)	$	(971)
Translation of foreign currencies


Beginning balance		$	(198)	$	(149)	$	(154)
Net translation of foreign currencies, before reclassification, net of tax (expense) benefit of $(9), $2 and $5, respectively		71		(60)		5
Amounts reclassified to Shareholders' net income, net of tax expense of $—, $— and $—, respectively		—		11		—
Shareholders' other comprehensive income (loss), net of tax		71		(49)		5
Ending balance		$	(127)	$	(198)	$	(149)
Postretirement benefits liability
Beginning balance		$	(937)	$	(915)	$	(916)
Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(8), $(7) and $(11), respectively		25		22		35
Net change due to valuation update, before reclassification, net of tax benefit of $9, $14 and $12, respectively		(32)		(44)		(34)
Shareholders' other comprehensive (loss) income, net of tax		(7)		(22)		1
Ending balance		$	(944)	$	(937)	$	(915)
Total Accumulated other comprehensive loss


Beginning balance		$	(2,341)	$	(1,864)	$	(1,658)
Shareholders' other comprehensive (loss), net of tax benefit of $180, $149 and $79, respectively		(465)		(477)		(206)
Ending balance		$	(2,806)	$	(2,341)	$	(1,864)

Strategic Optimization Program

12 Months Ended

Dec. 31, 2025

Restructuring and Related Activities [Abstract]

Strategic Optimization Program

Note 16 – Strategic Optimization Program

In the first quarter of 2025, the Company commenced an enterprise-wide initiative to evolve our business and deliver a more efficient and improved experience for our patients, providers and customers. At commencement, this program was expected to continue through December 2026; however, the Company is continuing to evaluate additional opportunities and expects that the program will continue through 2028. The program includes severance and other employee costs, asset impairments and accelerated asset amortization, and the operating results of certain small non-strategic businesses that we plan to discontinue. As we continue to evaluate additional opportunities to improve the overall efficiency and effectiveness of our operations, we anticipate future charges.

During the year ended December 31, 2025, we reported total costs of $749 million pre-tax ($565 million after-tax) associated with this initiative. The total costs included $616 million, pre-tax in Selling, general and administrative expenses which were primarily associated with severance ($378 million) and asset impairments ($101 million). The remainder reflects the operating results of certain non-strategic businesses. We expect substantially all of the accrued liability to be paid by the end of 2026. See Note 23 to the Consolidated Financial Statements for further details of the strategic optimization program by segment.

The following table presents a roll forward of the accrued liability recorded in Accrued expenses and other liabilities during the year ended December 31, 2025:


(In millions)



Balance, December 31, 2024	$	—
2025 charges	378
2025 payments	(238)
Balance, December 31, 2025	$	140

Pension

12 Months Ended

Dec. 31, 2025

Retirement Benefits [Abstract]

Pension

Note 17 – Pension

A.About Our Plans

The Company sponsors U.S. and non-U.S. defined benefit pension plans; future benefit accruals for the domestic plans are frozen.

Accounting Policy. The Company measures the assets and liabilities of its domestic pension plans as of December 31. Benefit obligations are measured at the present value of estimated future payments based on actuarial assumptions. The Company uses the corridor method to account for changes in the benefit obligation when actual results differ from those assumed or when assumptions change. These changes are called net unrecognized actuarial gains (losses). Under the corridor method, net unrecognized actuarial gains (losses) are initially recorded in Accumulated other comprehensive loss. When the unrecognized gain (loss) exceeds 10% of the benefit obligation, that excess is amortized to expense over the expected remaining lives of plan participants. The net plan expense is reported in Interest expense and other in the Consolidated Statements of Income.

We measure plan assets at fair value for balance sheet purposes and to measure pension benefit costs. When the actual return differs from the expected return, those differences are reflected in the net unrealized actuarial gain (loss) discussed above.

B.Funded Status and Amounts Included in Accumulated Other Comprehensive Loss

The following table summarizes the projected benefit obligations and assets related to our U.S. and non-U.S. pension plans:


	For the Years Ended December 31,
(In millions)	2025		2024
Change in benefit obligation
Benefit obligation, January 1	$	3,643	$	3,934
Service cost	—		1
Interest cost	196		194

Actuarial losses (gains), net (1)	109		(146)
Benefits paid from plan assets	(309)		(328)

Other	(9)		(12)
Benefit obligation, December 31	3,630		3,643
Change in plan assets
Fair value of plan assets, January 1	3,854		4,138
Actual return on plan assets	302		40
Benefits paid	(309)		(328)
Contributions	1		4
Fair value of plan assets, December 31	3,848		3,854
Funded status	$	218	$	211
Amounts presented in Consolidated Balance Sheets
Other assets	$	218	$	211

(1) 2025 losses reflect a decrease in the discount rate, while 2024 gains reflect an increase in the discount rate.

We fund our qualified pension plans at least at the minimum amount required by the Employee Retirement Income Security Act of 1974 and the Pension Protection Act of 2006. Contributions made by the Company to the qualified pension plan in 2025 and anticipated contributions for 2026 are immaterial. Future years' contributions will ultimately be based on a wide range of factors, including but not limited to asset returns, discount rates and funding targets. Nonqualified pension plans are generally funded on a pay-as-you-go basis as there are no plan assets for these plans.

Benefit Payments. The following benefit payments are expected to be paid in:


(In millions)
2026	$	316
2027	$	312
2028	$	310
2029	$	307
2030	$	304
2031 - 2035	$	1,409

Amounts reflected in the pension assets (liabilities) shown above that have not yet been reported in Net income and, therefore, have been included in Accumulated other comprehensive loss consisted of the following:


(In millions)	December 31, 2025		December 31, 2024
Unrecognized net losses	$	(1,230)	$	(1,228)
Unrecognized prior service cost	(4)		(4)
Postretirement benefits liability adjustment	$	(1,234)	$	(1,232)

C.Cost of Our Plans

Net pension cost (benefit) was as follows:


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Service cost	$	—	$	1	$	1
Interest cost	196		194		204
Expected long-term return on plan assets	(232)		(247)		(204)
Amortization of:
Prior actuarial losses, net	38		39		52


Curtailment loss	—		1		—
Net cost (benefit)	$	2	$	(12)	$	53

D.Assumptions Used for Pension


	For the Years Ended December 31,
	2025	2024
Discount rate:
Pension benefit obligation	5.27%	5.57%
Pension benefit cost	5.57%	5.10%
Expected long-term return on plan assets:
Pension benefit cost	6.50%	6.50%
Mortality table for pension obligations	White Collar mortality table with MP 2021 projection scale	White Collar mortality table with MP 2021 projection scale

The Company develops discount rates by applying actual annualized yields for high-quality bonds by duration to the expected pension plan liability cash flows. The bond yields represent a diverse mix of actively traded, high-quality fixed-income securities that have an above-average return at each duration, as management believes this approach is representative of the yield achieved through plan asset investment strategy. The expected long-term return on plan assets was developed considering historical long-term actual returns, expected long-term market conditions, plan asset mix and management's plan asset investment strategy.

E.Pension Plan Assets

As of December 31, 2025, pension assets included $3.8 billion invested in the separate accounts of Connecticut General Life Insurance Company, a subsidiary of the Company, and an additional $0.1 billion invested in funds of unaffiliated investment managers.

The fair values of pension assets by category are as follows:


(In millions)	December 31, 2025		December 31, 2024
Debt securities:
Federal government and agency	$	100	$	99
Corporate	2,674		2,673
Asset-backed	138		138
Fund investments	66		76
Total debt securities	2,978		2,986
Equity securities:
Domestic	23		21
International, including funds and pooled separate accounts (1)	—		6
Total equity securities	23		27
Securities partnerships, including pooled separate accounts (1)	447		402
Real estate and real estate funds, including pooled separate accounts (1)	212		228
Commercial mortgage loans	21		27

Guaranteed deposit account contract	48		47
Cash equivalents and other current assets, net	119		137
Total pension assets at fair value	$	3,848	$	3,854

(1) A pooled separate account has several participating benefit plans and each owns a share of the total pool of investments.

The Company's current target investment allocation percentages are 90% fixed income and 10% in other investments, including private equity (securities partnerships), public equity securities, and real estate, and are developed by management as guidelines, although the fair values of each asset category are expected to vary as a result of changes in market conditions. The Company will evaluate further allocation changes to equity securities, other investments and fixed-income securities as funding levels change.

See Note 12 to the Consolidated Financial Statements for further details regarding how fair value is determined, including the level within the fair value hierarchy and the procedures we use to validate fair value measurements. The Company classifies substantially all debt securities in Level 2 for pension plan assets. These assets are valued using recent trades of similar securities or are fund investments priced using their daily net asset value that is the exit price. All domestic equity securities and international equity funds within pension assets are classified in Level 3.

Securities partnerships, real estate and hedge funds are valued using net asset value as a practical expedient and are excluded from the fair value hierarchy. See Note 12 to the Consolidated Financial Statements for additional disclosures related to these assets invested in the separate accounts of the Company's subsidiary. Certain securities as described in Note 12 to the Consolidated Financial Statements, as well as commercial mortgage loans and guaranteed deposit account contracts, are classified in Level 3 because unobservable inputs used in their valuation are significant.

F.401(k) Plan

The Company sponsors a 401(k) plan. All employees are immediately eligible for the plan at hire. The Company matches a portion of employees' contributions to the plan and may increase its matching contributions if the Company's annual performance meets certain targets. Plan participants may invest in various funds that invest in the Company's common stock, several diversified stock funds, a bond fund or stable value funds. The Company common stock fund under the plan constitutes an "employee stock ownership plan" as defined in the Internal Revenue Code. Dividends from the Company common stock fund are reinvested in a participant's stock fund account unless the participant elects to receive the dividends in cash. The Company's annual expense for the plan was $280 million, $301 million and $296 million for the years ended December 31, 2025, 2024 and 2023, respectively.

The entire disclosure for retirement benefits.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480266/715-60-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480794/715-70-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/715/tableOfContent

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Share-Based Payment Arrangement [Abstract]

Employee Incentive Plans

12 Months Ended

Dec. 31, 2025

Employee Incentive Plans

Note 18 – Employee Incentive Plans

A.About Our Plans

The People Resources Committee (the "Committee") of the Board of Directors awards stock options, restricted stock grants, restricted stock units, deferred stock and strategic performance shares to certain employees. The Company issues original issue shares for these awards.

The Company records compensation expense for stock and option awards over their vesting periods primarily based on the estimated fair value at the grant date. Fair value is determined differently for each type of award as discussed below.

Shares of common stock available for award were as follows:

(In millions)

December 31, 2025

December 31, 2024

December 31, 2023

Common shares available for award

10.4

12.4

14.4

B.Stock Options

Accounting Policy. The Company awards options to purchase The Cigna Group common stock at the market price of the stock on the grant date. Options vest over periods ranging from one year to three years and expire no later than 10 years from grant date. Fair value is estimated using the Black-Scholes option pricing model by applying the assumptions presented below. That fair value is reduced by options expected to be forfeited during the vesting period. The Company estimates forfeitures at the grant date based on our experience and adjusts the expense to reflect actual forfeitures over the vesting period. The fair value of options, net of forfeitures, is recognized in Selling, general and administrative expenses on a straight-line basis over the vesting period.

Black-Scholes option pricing model assumptions and the resulting fair value of options are presented in the following table:


	2025			2024			2023
Dividend yield	2.04		%	1.74		%	1.58		%
Expected volatility	31.0		%	30.0		%	30.0		%
Risk-free interest rate	4.4		%	4.0		%	3.6		%
Expected option life	4.9 years			4.8 years			4.7 years
Weighted average fair value of options	$	86.13		$	92.36		$	79.66

The dividend yield reflects expected future dividends. The Company intends to continue to pay dividends for the foreseeable future. The expected volatility reflects the past daily stock price volatility of The Cigna Group stock. The Company does not consider volatility implied in the market prices of traded options to be a good indicator of future volatility because remaining traded options will expire within one year. The risk-free interest rate is derived using the four-year U.S. Treasury bond yield rate as of the award date for the primary annual grant. Expected option life reflects the Company's historical experience.

The following table shows the status of, and changes in, common stock options:


	For the Years Ended December 31,
	2025			2024			2023
(Options in thousands)	Options	Weighted Average Exercise Price		Options	Weighted Average Exercise Price		Options	Weighted Average Exercise Price
Outstanding - January 1	5,655	$	226.38	6,696	$	202.02	6,992	$	186.54
Granted	857	$	305.86	781	$	336.48	915	$	294.37
Exercised	(1,088)	$	192.40	(1,727)	$	178.82	(1,080)	$	174.66
Expired or canceled	(222)	$	314.78	(95)	$	278.78	(131)	$	246.95
Outstanding - December 31	5,202	$	242.81	5,655	$	226.38	6,696	$	202.02
Options exercisable at year-end	3,806	$	216.90	3,941	$	196.01	4,616	$	179.28

Compensation expense of $62 million related to unvested stock options as of December 31, 2025 will be recognized over the next two years (weighted average period).

The table below summarizes information for stock options exercised:


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Intrinsic value of options exercised	$	128	$	275	$	126
Cash received for options exercised	$	203	$	305	$	187
Tax benefit from options exercised	$	16	$	34	$	17

The following table summarizes information for outstanding common stock options:


	December 31, 2025
	Options Outstanding		Options Exercisable
Number (in thousands)	5,202		3,806
Total intrinsic value (in millions)	$	246	$	246
Weighted average exercise price	$	242.81	$	216.90
Weighted average remaining contractual life	5.7 years		4.6 years

C.Restricted Stock

The Company awards restricted stock (grants and units) to the Company's employees that vest over periods ranging from one year to three years. Recipients of restricted stock awards accumulate dividends during the vesting period but generally forfeit their awards and accumulated dividends if their employment terminates before the vesting date.

Accounting Policy. Fair value of restricted stock awards is equal to the market price of The Cigna Group common stock on the date of grant. This fair value is reduced by awards that are expected to be forfeited. At the grant date, the Company estimates forfeitures based on experience and adjusts the expense to reflect actual forfeitures over the vesting period. This fair value, net of forfeitures, is recognized in Selling, general and administrative expenses over the vesting period on a straight-line basis.

The following table shows the status of, and changes in, restricted stock awards:


	For the Years Ended December 31,
	2025			2024			2023
(Awards in thousands)	Grants/Units	Weighted Average Fair Value at Award Date		Grants/Units	Weighted Average Fair Value at Award Date		Grants/Units	Weighted Average Fair Value at Award Date
Outstanding - January 1	1,250	$	302.42	1,404	$	257.38	1,535	$	219.25
Awarded	701	$	305.67	624	$	319.39	700	$	294.60
Vested	(664)	$	284.20	(713)	$	245.35	(759)	$	214.70
Forfeited	(149)	$	316.12	(65)	$	283.62	(72)	$	256.24
Outstanding - December 31	1,138	$	313.25	1,250	$	302.42	1,404	$	257.38

The fair value of vested restricted stock at the vesting date was as follows:


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Fair value of vested restricted stock	$	203	$	238	$	220

Approximately 8,400 employees held 1.1 million restricted stock awards at the end of 2025 with $187 million of related compensation expense to be recognized over the next two years (weighted average period).

D.Strategic Performance Shares ("SPSs")

The Company awards SPSs to executives and certain other key employees generally with a performance period of three years. Half of these shares are subject to a market condition (total shareholder return relative to industry peer companies), and half are subject to a performance condition (cumulative adjusted net income). These targets are set by the Committee at the beginning of the performance period. Holders of these awards receive shares of The Cigna Group common stock at the end of the performance period ranging anywhere from 0% to 200% of the original awards.

Accounting Policy. Compensation expense for SPSs is recorded over the performance period. Fair value is determined at the grant date for "market condition" SPSs using a Monte Carlo simulation model and not subsequently adjusted regardless of the final outcome. Expense is initially accrued for "performance condition" SPSs based on the most likely outcome but evaluated for adjustment each period for updates in the expected outcome. Expense is adjusted to the actual outcome (number of shares awarded multiplied by the share price at the grant date) at the end of the performance period.

The following table shows the status of, and changes in, SPSs:


	For the Years Ended December 31,
	2025			2024			2023
(Awards in thousands)	Shares	Weighted Average Fair Value at Award Date		Shares	Weighted Average Fair Value at Award Date		Shares	Weighted Average Fair Value at Award Date
Outstanding - January 1	601	$	282.83	686	$	243.90	780	$	212.68
Awarded	217	$	305.28	195	$	336.81	219	$	293.85
Vested	(233)	$	231.75	(242)	$	214.93	(250)	$	191.78
Forfeited	(80)	$	317.01	(38)	$	289.35	(63)	$	237.50
Outstanding - December 31	505	$	310.78	601	$	282.83	686	$	243.90

The weighted average fair value per share of SPSs for expense purposes, including the Monte Carlo factor, at the award date for the years ended December 31, 2025, 2024 and 2023 was $323.60, $377.23 and $329.11, respectively.

The fair value of vested SPSs at the vesting date was as follows:


	For the Years Ended December 31,
	2025			2024			2023
(Shares in thousands; $ in millions)	Shares	Fair Value		Shares	Fair Value		Shares	Fair Value
Shares of The Cigna Group common stock distributed upon SPS vesting	301	$	92	257	$	86	257	$	76

Approximately 600 employees held 505,000 SPSs at the end of 2025, and $43 million of related compensation expense is expected to be recognized over the next two years. The amount of expense for "performance condition" SPSs will vary based on actual performance in 2026 and 2027.

E.Compensation Cost and Tax Effects of Share-Based Compensation

The Company records tax benefits in Shareholders' net income during the vesting period based on the amount of expense being recognized. The difference between tax benefits based on the expense and the actual tax benefit realized are also recorded in income tax expense when stock options are exercised, or when restricted stock and SPSs vest.


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Total compensation cost for shared-based awards	$	291	$	308	$	286
Tax benefits recognized	$	69	$	94	$	92

Goodwill, Other Intangibles and Property and Equipment

12 Months Ended

Dec. 31, 2025

Goodwill Other Intangibles And Property And Equipment [Abstract]

Goodwill, Other Intangibles, and Property and Equipment

Note 19 – Goodwill, Other Intangibles, and Property and Equipment

A.Goodwill

Accounting Policy. Goodwill represents the excess of the cost of businesses acquired over the fair value of their net assets. The resulting goodwill is assigned to those reporting units expected to realize cash flows from the acquisition, based on those reporting units' relative fair values. The Company's reporting units are aligned with its operating segments as described in Note 1.

The Company conducts its annual quantitative evaluation for goodwill impairment during the third quarter at the reporting unit level and writes it down through Shareholders' net income if impaired. On a quarterly basis, the Company performs a qualitative impairment assessment to determine if events or changes in circumstances indicate that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. The fair value of a reporting unit is generally estimated based on discounted cash flow analysis and market approach models using assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. Following a change in reporting units or held for sale determination, goodwill is allocated using relative fair value. The significant assumptions and estimates used in determining fair value primarily include the discount rate and future cash flows. A discount rate is selected to correspond with each reporting unit's weighted average cost of capital, consistent with that used for investment decisions considering the specific and detailed operating plans and strategies within each reporting unit. Projections of future cash flows differ by reporting unit and are consistent with our ongoing strategic projections. Future cash flows for Evernorth Health Services reporting units are primarily driven by the forecasted gross margins of the business, as well as operating expenses and long-term growth rates. Future cash flows for our other reporting units are primarily driven by forecasted revenues, benefit expenses, operating expenses and long-term growth rates.

Goodwill Activity. Goodwill activity was as follows:


(In millions)	Evernorth Health Services		Cigna Healthcare		Total
Balance at January 1, 2024	$	35,130	$	9,129	$	44,259
Goodwill acquired	114		—		114

Impact of foreign currency translation and other adjustments	190		(193)		(3)
Goodwill at December 31, 2024	35,434		8,936		44,370
Goodwill acquired	548		—		548


Impact of foreign currency translation and other adjustments	—		6		6
Goodwill at December 31, 2025	$	35,982	$	8,942	$	44,924

B.Other Intangible Assets

Accounting Policy. The Company's Other intangible assets primarily include purchased customer and producer relationships, trademarks, and provider networks. The fair value of purchased customer relationships and the amortization method were determined as of the dates of purchase using an income approach that relies on projected future net cash flows, including key assumptions for customer attrition and discount rates. The Company's definite-lived intangible assets are amortized on an accelerated or straight-line basis, reflecting their pattern of economic benefits, over periods from 1 year to 30 years. Management revises amortization periods if it believes there has been a change in the length of time that an intangible asset will continue to have value. Costs incurred to renew or extend the terms of these intangible assets are generally expensed as incurred.

The Company's amortized intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the total of the expected future undiscounted cash flows generated by the underlying asset group is less than the carrying amount of the asset group, the Company recognizes an impairment charge equal to the difference between the carrying value of the asset group and its estimated fair value. The Company's indefinite-lived intangible assets are reviewed for impairment at least annually by comparing their fair value with their carrying value. If the carrying value exceeds fair value, that excess is recognized as an impairment loss.

Components of Other Assets, Including Other Intangibles. Other intangible assets were comprised of the following:


(In millions)	Cost		Accumulated Amortization		Net Carrying Value
December 31, 2025
Customer relationships	$	30,624	$	10,655	$	19,969
Trade name - Express Scripts	8,400				8,400
Other	346		155		191
Total	39,370		10,810		28,560
December 31, 2024
Customer relationships	$	29,971	$	9,119	$	20,852
Trade name - Express Scripts	8,400				8,400
Other	316		131		185
Other intangible assets (1)	38,687		9,250		29,437
Value of business acquired ("VOBA") (reported in Other assets) (2)	211		142		69
Total	$	38,898	$	9,392	$	29,506

(1) Includes $20 million of Other intangible assets classified as assets of businesses held for sale as of December 31, 2024.

(2) Includes $69 million of VOBA classified as assets of businesses held for sale as of December 31, 2024.

The Company has indefinite-lived intangible assets totaling $8.4 billion as of December 31, 2025 and $8.5 billion as of December 31, 2024, largely consisting of the Express Scripts trade name.

C.Property and Equipment

Accounting Policy. Property and equipment is carried at cost less accumulated depreciation. Cost includes interest, real estate taxes and other costs incurred during construction when applicable. Internal-use software that is acquired, developed or modified solely to meet the Company's internal needs, with no plan to market externally, is also included in this category. Costs directly related to acquiring, developing or modifying internal-use software are capitalized.

The Company calculates depreciation and amortization principally using the straight-line method generally based on the estimated useful life of each asset as follows: buildings and improvements, 10 to 40 years; purchased and internally developed software, 3 to 5 years; and furniture and equipment (including computer equipment), 3 to 10 years. Improvements to leased facilities are depreciated over the lesser of the remaining lease term or the estimated life of the improvement. The Company considers events and circumstances that would indicate the carrying value of property, equipment or capitalized software might not be recoverable. An impairment charge is recorded if the Company determines the carrying value of any of these assets is not recoverable. The Company also reviews and shortens the estimated useful lives of these assets, if necessary.

Components of Property and Equipment. Property and equipment were comprised of the following:


(In millions)	Cost		Accumulated Amortization		Net Carrying Value
December 31, 2025
Internal-use software	$	11,678	$	8,904	$	2,774
Other property and equipment	2,075		1,198		877
Total property and equipment	13,753		10,102		3,651


December 31, 2024
Internal-use software	$	11,295	$	8,167	$	3,128
Other property and equipment	2,115		1,287		828
Total property and equipment (1)	13,410		9,454		3,956

(1)Includes $302 million of Property and equipment net carrying value classified as assets of businesses held for sale as of December 31, 2024.

Components of Depreciation and Amortization. Depreciation and amortization expense was comprised of the following:


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Internal-use software	$	987	$	1,021	$	1,216
Other property and equipment	239		248		260
Value of business acquired (reported in Other assets)	—		—		7
Other intangibles	1,549		1,506		1,552
Total depreciation and amortization	$	2,775	$	2,775	$	3,035

The Company estimates annual pre-tax amortization for intangible assets, including internal-use software, over the next five calendar years to be as follows:


(In millions)	Pre-tax Amortization
2026	$	2,360
2027	$	2,237
2028	$	2,062
2029	$	1,821
2030	$	1,592

Discloses the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain or loss on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. This element may be used as a single block of text to include the entire intangible asset disclosure including data and tables. Disclosure of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, building and production equipment. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures. This element may be used as a single block of text to include the entire PPE disclosure, including data and tables.

Shareholders Equity and Dividend Restrictions

12 Months Ended

Dec. 31, 2025

Shareholders' Equity And Dividend Restrictions

Note 20 – Shareholders' Equity and Dividend Restrictions

State insurance departments and foreign jurisdictions that regulate certain of the Company's subsidiaries prescribe accounting practices (differing in some respects from GAAP) to determine statutory net income and surplus. The Company's life, accident, and health insurance and Health Maintenance Organization ("HMO") subsidiaries are regulated by such statutory requirements. The statutory net income of the Company's life, accident, and health insurance and HMO subsidiaries for the years ended, and their statutory surplus as of, December 31 were as follows:


(In billions)	2025		2024		2023
Net income	$	3.7	$	3.9	$	5.3
Surplus	$	13.0	$	16.0	$	14.9

The Company's HMO and life, accident and health insurance subsidiaries are also subject to minimum statutory surplus requirements and may be required to maintain investments on deposit with state departments of insurance or other regulatory bodies. Additionally, these subsidiaries may be subject to regulatory restrictions on the amount of annual dividends or other distributions (such as loans or cash advances) that insurance companies may extend to their parent companies without prior approval. These amounts, including restricted GAAP net assets of the Company's subsidiaries, were as follows:


(In billions)	December 31, 2025
Minimum statutory surplus required by regulators (1)	$	4.5
Investments on deposit with regulatory bodies	$	0.3
Maximum dividend distributions permitted in 2026 without regulatory approval	$	2.0
Maximum loans to the parent company permitted without regulatory approval	$	1.2
Restricted GAAP net assets of subsidiaries of The Cigna Group	$	11.3

(1) Excludes amounts associated with foreign operated equity method joint ventures.

Permitted practices used by the Company's insurance subsidiaries in 2025 that differed from prescribed regulatory accounting had an immaterial impact on statutory surplus.

Undistributed earnings for equity method investments are $1.6 billion as of December 31, 2025

Income Taxes

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

Income Taxes

Note 21 – Income Taxes

Accounting Policy. Deferred income taxes are reflected in the Consolidated Balance Sheets for differences between the financial and income tax reporting bases of the Company's underlying assets and liabilities and are established based upon enacted tax rates and laws. Deferred income tax assets are recognized when available evidence indicates that realization is more likely than not, and a valuation allowance is established to the extent this standard is not met. The deferred income tax provision generally represents the net change in deferred income tax assets and liabilities during the reporting period excluding adjustments to Accumulated other comprehensive income (loss) or amounts recorded in connection with a business combination. The current income tax provision generally represents estimated amounts due on income tax returns for the year reported to various jurisdictions plus the effect of any uncertain tax positions. The Company uses the deferral method of accounting on investments that generate tax credits. Under this method, the investment tax credits are recognized as a reduction to the related asset, which are generally reported in Other assets in the Consolidated Balance Sheets. The Company recognizes a liability for uncertain tax positions if management believes the probability that the positions will be sustained is 50% or less. For uncertain positions that management believes are more likely than not to be sustained, the Company recognizes a liability based upon management's estimate of the most likely settlement outcome with the taxing authority. The liabilities for uncertain tax positions are classified as current when the position is expected to be settled within 12 months or the statute of limitation expires within 12 months.

Income taxes attributable to the Company's foreign operations are provided using the foreign jurisdictions' applicable tax rate.

The Company prospectively adopted ASU 2023-09, Improvements to Income Tax Disclosures. As a result, disclosures for 2025 reflect the requirements of ASU 2023-09, including the reconciliation of the statutory federal income tax rate and disaggregated tax payment information. Prior years (2024 and 2023) are presented under the previous disclosure requirements.

Income Tax Expense

The components of income taxes were as follows:


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Current taxes
U.S. income taxes	$	807	$	1,167	$	1,459
Foreign income taxes	191		248		161
State income taxes	169		171		180
Total current taxes	1,167		1,586		1,800
Deferred taxes (tax benefits)
U.S. income tax benefits	(69)		(142)		(533)
Foreign income taxes (tax benefits)	447		64		(1,046)
State income tax benefits	(52)		(17)		(80)
Total deferred taxes (tax benefits)	326		(95)		(1,659)
Total income taxes	$	1,493	$	1,491	$	141

Total income taxes were different from the amount computed using the statutory federal income tax rate in 2025 for the following reasons:


	For the Year Ended December 31,
	2025
(in millions)	$		%
Tax expense at statutory rate	$	1,634	21.0	%
State income tax effect, net of federal income tax effect (1)	93		1.2
Nontaxable or nondeductible items	13		0.2
Effects of cross-border tax laws:
Global intangible low-taxed income ("GILTI")	127		1.6
Other cross-border tax laws	11		0.1
Tax credits	(83)		(1.1)
Change in valuation allowance	(74)		(1.0)
Change in unrecognized tax benefits	37		0.5
Other
Impact of sale of business	(173)		(2.2)
Tax equity investments	(102)		(1.3)
Other reconciling items	3		0.2
Foreign tax effects:
Switzerland
Effect of rates different than U.S. statutory	(360)		(4.6)
Cantonal income taxes	206		2.6
Change in valuation allowance	384		4.9

Other countries	(223)		(2.9)
Total income taxes	$	1,493	19.2	%

(1) The jurisdictions that make up the majority (greater than 50 percent) of the state and local tax impact are Florida and California.

Total income taxes were different from the amount computed using the statutory federal income tax rate in 2024 and 2023 for the following reasons:


	For the Years Ended December 31,
	2024				2023
(In millions)	$		%		$		%
Tax expense at statutory rate	$	1,107	21.0	%	$	1,158	21.0	%
Change in valuation allowance	767		14.6		1,290		23.4
State income tax effect, net of federal income tax effect	62		1.2		(39)		(0.7)
Investment tax credits	(111)		(2.1)		(48)		(0.8)
Impact of businesses held for sale	(129)		(2.4)		(213)		(3.9)
Effect of foreign earnings	(252)		(4.9)		(173)		(3.1)
Other foreign tax attributes	—		—		(153)		(2.8)
Swiss tax attributes	—		—		(1,674)		(30.4)


Other	47		0.9		(7)		(0.1)
Total income taxes	$	1,491	28.3	%	$	141	2.6	%

Tax Equity Investments. Company investments in renewable energy projects provided $968 million, $1,057 million and $453 million of investment tax credits for the years ended December 31, 2025, 2024 and 2023, respectively. The Company accounted for the tax credits using the deferral method and accordingly reduced the associated carrying value of the related assets by these amounts.

Pre-tax Income Disaggregation. Consolidated pre-tax income from the Company's foreign operations was approximately 53% of the Company's pre-tax income in 2025, 62% in 2024 and 48% in 2023. The change relative to 2024 is primarily attributable to lower 2024 domestic earnings driven by the impairment of equity securities in 2024 (see Note 11 to the Consolidated Financial Statements).

Deferred Income Taxes

Deferred income tax assets and liabilities were as follows:


(In millions)	December 31, 2025		December 31, 2024
Deferred tax assets
Foreign tax attributes	$	1,615	$	1,752
Deferred loss - sale of business	—		773
Investments	587		561
Other insurance and contractholder liabilities	241		300
Loss carryforwards	492		270
Other accrued liabilities	321		207
Employee and retiree benefit plans	190		177
Unrealized depreciation on investments and foreign currency translation	10		93
Policy acquisition expenses	53		—
Other	339		256
Deferred tax assets before valuation allowance	3,848		4,389
Valuation allowance for deferred tax assets	(2,374)		(2,332)
Deferred tax assets, net of valuation allowance	1,474		2,057
Deferred tax liabilities
Acquisition-related basis differences	7,558		7,822
Depreciation and amortization	602		243
Policy acquisition expenses	—		74




Total deferred tax liabilities	8,160		8,139
Net deferred income tax liabilities (1)	$	(6,686)	$	(6,082)

(1)Deferred tax liabilities, net in the Consolidated Balance Sheets excludes $459 million and $954 million reported in Other assets as of December 31, 2025 and December 31, 2024, respectively, and $61 million reported in liabilities of businesses held for sale as of December 31, 2024.

Management believes that it is more likely than not that future results will be sufficient to realize the Company's gross deferred tax assets ("DTAs") that remain after valuation allowance. Valuation allowances have been established against certain federal, state and foreign tax attributes. There are multiple expiration dates associated with these tax attributes.

Foreign Jurisdiction Tax Attributes. As of December 31, 2025 and 2024, the Company had DTAs of approximately $1.6 billion and $1.8 billion, respectively, and had a related $1.2 billion and $0.8 billion valuation allowance, respectively, against these deferred tax assets based on projections of future earnings and requirements to utilize the assets within certain time periods. In 2025, the Company recorded an increase to the valuation allowance as a result of management's reassessment of the composition of future foreign and domestic earnings. It is possible that the Company may revalue these net deferred tax assets in future periods due to modifications in certain assumptions, such as forecasted future earnings.

Capital DTAs: Impairments, Unrealized Investment Losses and Sale of Medicare Advantage and Related Businesses. As of December 31, 2025 and 2024, the Company had approximately $819 million and $880 million, respectively, in DTAs associated with the impairment of equity securities and other unrealized investment losses (see Note 11 to the Consolidated Financial Statements), as well as $237 million and $773 million, respectively, of DTAs in connection with the HCSC transaction, reflecting total capital DTAs of approximately $1,056 million and $1,653 million, respectively. A valuation allowance of $1,025 million and $1,351 million, respectively, has been established against these DTAs as of December 31, 2025 and 2024 due to the uncertainty relative to the recovery of the deferred tax benefits as the Company does not anticipate having sufficient sources of capital income to support these capital losses. We have determined that a valuation allowance against the remaining capital DTAs is not currently required based on the Company's loss carryback capacity and ability and intent to hold certain investment securities until recovery. We continue to monitor and evaluate the need for any additional valuation allowance.

During 2025, the reallocation of the HCSC transaction purchase price by legal entity resulted in an equal write-off of the DTAs and valuation allowance associated with the tax-deductible capital loss on the sale, resulting in zero net impact to the Company's total tax provision. Additionally, a reallocation of available sources of capital income generated a substantial portion of the after-tax gain on sale presented in Note 5 to the Consolidated Financial Statements. There was no material change to the realizability assessment of the Company's consolidated DTAs and no material net impact to the Company's consolidated tax expense as a result of this reallocation.

Uncertain Tax Positions

Reconciliations of unrecognized tax benefits were as follows:


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Balance at January 1,	$	1,477	$	1,399	$	1,343
Decrease due to prior year positions	(50)		(7)		(26)

Increase due to current year positions	187		165		107
Reduction related to settlements with taxing authorities	(62)		(22)		(13)
Reduction related to lapse of applicable statute of limitations	(14)		(58)		(12)
Balance at December 31,	$	1,538	$	1,477	$	1,399

Substantially all unrecognized tax benefits would increase Shareholders' net income if recognized.

The Company classifies net interest expense on uncertain tax positions as a component of income tax expense and in Other non-current liabilities in the Consolidated Balance Sheets. In addition to the amounts in the table above, the liability for net interest expense on uncertain tax positions was approximately $223 million, $228 million and $220 million as of December 31, 2025, 2024 and 2023, respectively.

Other Tax Matters

The statutes of limitations for the Company's consolidated federal income tax returns through 2016 have closed. The statute of limitations for the Company's 2020 and 2021 tax returns have also closed. However, The Cigna Group filed amended returns for both the 2015 and 2016 tax years, which are under review by the Internal Revenue Service ("IRS"). Additionally, the IRS is examining the Company's returns for 2017, 2018, 2019, 2022 and 2023. The IRS has examined Express Scripts' tax returns for 2010 through 2017, for which there remain significant disputed matters. In addition, the Company has pending refund claims for various years. The Company has established adequate reserves for these matters.

The Company conducts business in a number of state and foreign jurisdictions and may be engaged in multiple audit proceedings at any given time. Generally, no further state or foreign audit activity is expected for tax years prior to 2013 for Express Scripts entities and 2014 for all other entities of The Cigna Group.

Pillar Two. The Organization for Economic Co-operation and Development ("OECD") Pillar Two Framework defines a minimum effective tax rate of 15%. The Company is within the scope of the OECD Pillar Two model rules, which did not have a significant impact on our 2025 results. We will continue to monitor the potential impact on future periods but do not currently expect Pillar Two to significantly impact future periods.

Income Taxes Paid

For the year ended December 31, 2025, the Company made tax payments, net of refunds, in the amount of $399 million to the following jurisdictions: U.S. federal refund ($4 million), U.S. state payment ($140 million), and foreign payments ($263 million), primarily Switzerland. The Company’s federal tax payments reflect the benefit of $968 million of renewable energy tax credits, which have been applied against the Company’s federal tax liability under existing tax rules.

For the years ended December 31, 2024 and 2023, the company made tax payments, net of refunds in the amount of $898 million and $1,471 million, respectively. For the years ended December 31, 2024 and 2023, the Company’s federal tax payments reflect the benefit of $1,057 million and $453 million, respectively, of renewable energy tax credits, which were applied against the Company’s federal tax liability under existing tax rules.

The entire disclosure for income tax.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

Contingencies and Other Matters	12 Months Ended
Contingencies and Other Matters	Dec. 31, 2025
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Other Matters	Note 22 – Contingencies and Other Matters The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business. A.Financial Guarantees: Retiree and Life Insurance Benefits The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments. As of December 31, 2025, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $400 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of December 31, 2025. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy. The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition. B.Certain Other Guarantees The Company had indemnification obligations as of December 31, 2025 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations, or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no recorded liabilities for these indemnification obligations as of December 31, 2025. C.Guaranty Fund Assessments The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions. There were no material charges or credits resulting from existing or new guaranty fund assessments for the year ended December 31, 2025. Legal and Regulatory Matters The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a qui tam relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health company. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the IRS or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions, as described in Note 21. Accounting Policy. The Company accrues for legal and regulatory matters when a loss contingency is both probable and estimable. The estimated loss is generally recorded in Selling, general and administrative expenses and represents the Company's best estimate of the loss contingency. If the loss estimate is a range, the Company accrues the minimum amount in the range if no amount is better than any other estimated amount in the range. Legal costs to defend the Company's litigation and arbitration matters are expensed as incurred in cases that the Company cannot reasonably estimate the ultimate cost to defend. If the Company can reasonably estimate the cost to defend, a liability for these costs is accrued when the claim is reported.

Segment Information

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Segment Information

Note 23 – Segment Information

See Note 1 to the Consolidated Financial Statements for a description of our segments. A description of our basis for reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The Chairman and Chief Executive Officer is the chief operating decision maker ("CODM") responsible for making decisions about resources to be allocated to each segment and assessing its performance.

The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management, including the CODM, believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability to enable resource allocation decisions. We define pre-tax adjusted income (loss) from operations as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results.

The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management, including the CODM, believes they are not indicative of past or future underlying performance of the business.

The Company does not report total assets by segment because this is not a metric used by the CODM to allocate resources or evaluate segment performance.

The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted:


	For the Years Ended December 31,
		2025	2024				2023
(In millions)			Pre-tax		After-tax		Pre-tax		After-tax		Pre-tax		After-tax
Strategic optimization program (primarily Selling, general and administrative expenses)			$	749	$	565	$	—	$	—	$	—	$	—
Deferred tax expenses (benefits), net (Income taxes, less amount attributable to noncontrolling interests)			—		427		—		84		—		(1,071)
Integration and transaction-related costs (Selling, general and administrative expenses)			327		247		275		211		45		35
(Benefits) charges associated with litigation matters (Selling, general and administrative expenses)			(17)		(13)		—		—		201		171
Net (gain) loss on sale of businesses			(13)		(404)		(24)		(2)		1,499		1,429
Impairment of dividend receivable (Net investment income)			—		—		182		138		—		—
Charge for organizational efficiency plan (Selling, general and administrative expenses)			—		—		—		—		252		193


Total impact from special items			$	1,046	$	822	$	433	$	431	$	1,997	$	757

Summarized segment financial information was as follows:


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2025
Revenues from external customers	$	232,098	$	41,426	$	325	$	5	$	273,854
Intersegment revenues	2,713		5,405		51		(8,169)
Net investment income	142		581		298		25		1,046
Total revenues	234,953		47,412		674		(8,139)		274,900
Net investment results from certain equity method investments	—		(249)		—		—		(249)


Adjusted revenues	$	234,953	$	47,163	$	674	$	(8,139)	$	274,651
Pharmacy and other service costs	223,086		—
Medical costs	—		33,474
Selling, general and administrative expenses	4,170		9,545
Other segment items (1)
Interest (expense) and other	(1)		9
Less: Income attributable to noncontrolling interests	475		—
Pre-tax adjusted income (loss) from operations	7,221		4,153		89		(1,593)		9,870

Income (loss) before income taxes	$	5,826	$	4,344	$	(46)	$	(2,343)	$	7,781
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(475)		—		—		—		(475)
Net investment (gains) losses (2)	(20)		(210)		2		3		(225)
Amortization of acquired intangible assets	1,720		23		—		—		1,743
Special items
Strategic optimization program	174		22		133		420		749
Integration and transaction-related costs	—		—		—		327		327




Net (gain) on sale of businesses	(4)		(9)		—		—		(13)
(Benefits) associated with litigation matters	—		(17)		—		—		(17)

Pre-tax adjusted income (loss) from operations	$	7,221	$	4,153	$	89	$	(1,593)	$	9,870

Other segment information
Depreciation and amortization	$	2,400	$	339	$	16	$	20	$	2,775

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2024
Revenues from external customers	$	198,177	$	47,528	$	440	$	3	$	246,148
Intersegment revenues	3,775		4,972		79		(8,826)
Net investment income	21		618		309		25		973
Total revenues	201,973		53,118		828		(8,798)		247,121
Net investment results from certain equity method investments	—		(204)		—		—		(204)
Special item related to impairment of dividend receivable	182		—		—		—		182
Adjusted revenues	$	202,155	$	52,914	$	828	$	(8,798)	$	247,099
Pharmacy and other service costs	190,968		—
Medical costs	—		37,887
Selling, general and administrative expenses	3,779		10,805
Other segment items (1)
Interest (expense) and other	(2)		7
Less: Income attributable to noncontrolling interests	405		—
Pre-tax adjusted income (loss) from operations	7,001		4,229		(9)		(1,688)		9,533

Income (loss) before income taxes	$	3,929	$	3,315	$	(12)	$	(1,963)	$	5,269
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(405)		—		—		—		(405)
Net investment losses (2)	2,129		401		3		—		2,533
Amortization of acquired intangible assets	1,662		41		—		—		1,703
Special items
Integration and transaction-related costs	—		—		—		275		275
Impairment of dividend receivable	182		—		—		—		182





Net (gain) loss on sale of businesses	(496)		472		—		—		(24)

Pre-tax adjusted income (loss) from operations	$	7,001	$	4,229	$	(9)	$	(1,688)	$	9,533

Other segment information
Depreciation and amortization	$	2,319	$	417	$	9	$	30	$	2,775

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2023
Revenues from external customers	$	147,588	$	46,219	$	291	$	1	$	194,099
Intersegment revenues	5,670		4,332		—		(10,002)
Net investment income	241		597		305		23		1,166
Total revenues	153,499		51,148		596		(9,978)		195,265
Net investment results from certain equity method investments	—		57		—		—		57

Adjusted revenues	$	153,499	$	51,205	$	596	$	(9,978)	$	195,322
Pharmacy and other service costs	143,571		—
Medical costs	—		35,678
Selling, general and administrative expenses	3,340		11,055
Other segment items (1)
Interest (expense) and other	(2)		8
Less income attributable to noncontrolling interests	144		2
Pre-tax adjusted income (loss) from operations	6,442		4,478		96		(1,698)		9,318

Income (loss) before income taxes	$	4,768	$	2,664	$	76	$	(1,995)	$	5,513
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(144)		(2)		—		—		(146)
Net investment losses (2)	—		133		2		—		135
Amortization of acquired intangible assets	1,774		45		—		—		1,819
Special items
Net loss on sale of businesses	—		1,481		18		—		1,499
Charge for organizational efficiency plan	—		—		—		252		252
Charges associated with litigation matters	44		157		—		—		201
Integration and transaction-related costs	—		—		—		45		45





Pre-tax adjusted income (loss) from operations	$	6,442	$	4,478	$	96	$	(1,698)	$	9,318

Other segment information
Depreciation and amortization	$	2,438	$	569	$	3	$	25	$	3,035

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type:


	For the Years Ended December 31,
(In millions)		2025		2024		2023
Products (Pharmacy revenues) (ASC 606)
Network revenues		$	125,573	$	105,340	$	67,514
Home delivery and specialty revenues		80,492		72,476		65,732
Other revenues		13,329		11,545		9,047
Total Evernorth Health Services		219,394		189,361		142,293
Other Operations		54		60		—
Corporate and eliminations		(2,776)		(4,059)		(5,050)
Total Pharmacy revenues		216,672		185,362		137,243
Insurance premiums (ASC 944)
Cigna Healthcare
U.S. Healthcare
Employer insured		18,852		17,576		16,490
Medicare Advantage		2,363		8,679		8,771
Stop loss		7,599		6,744		6,143
Individual and Family Plans		3,371		3,951		5,088
Other		3,366		4,938		4,095
U.S. Healthcare		35,551		41,888		40,587
International Health		4,126		3,624		3,295
Total Cigna Healthcare		39,677		45,512		43,882
Other Operations		288		380		281
Corporate and eliminations		296		104		74
Total Premiums		40,261		45,996		44,237
Services (Fees) (ASC 606) and Other revenues (1)
Evernorth Health Services		15,417		12,591		10,965
Cigna Healthcare		7,154		6,988		6,669
Other Operations		34		79		10
Corporate and eliminations		(5,684)		(4,868)		(5,025)
Total Fees and other revenues (1)		16,921		14,790		12,619
Total revenues from external customers		$	273,854	$	246,148	$	194,099

(1)Other revenues for the years ended December 31, 2025, 2024 and 2023 were $696 million, $584 million and $210 million, respectively.

Major Customers. Revenues from a single pharmacy benefit client were approximately 19% and 16% of total revenues from external customers for the years ended December 31, 2025 and 2024, respectively. These amounts were reported in the Evernorth Health Services segment.

Additionally, revenues from U.S. Federal Government agencies, under a number of contracts, were 11% and 15% of total revenues from external customers for the years ended December 31, 2024 and 2023, respectively. These amounts were reported in the Evernorth Health Services and Cigna Healthcare segments. For the year ended December 31, 2025, revenues from U.S. Federal Government agencies were less than 10%.

U.S. and Foreign Revenues. Revenues from U.S. external customers as a percentage of total revenues from external customers were 98% for the years ended December 31, 2025, 2024 and 2023

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Condensed Financial Information Disclosure [Abstract]

Schedule I - Condensed Financial Information of The Cigna Group

12 Months Ended

Dec. 31, 2025

Schedule I - Condensed Financial Information of The Cigna Group

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE I

CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP

(REGISTRANT)

STATEMENTS OF INCOME


	For the Years Ended December 31,

(In millions)	2025		2024		2023
Revenues
Net investment income and other revenue	$	21	$	26	$	22
Intercompany interest income	469		469		516
Total revenues	490		495		538
Operating expenses
Selling, general and administrative expenses	5		14		2
Total operating expenses	5		14		2
lncome from operations	485		481		536
Interest expense and other	(1,365)		(1,388)		(1,332)
Gain on sale of businesses	4,890		—		—
Intercompany interest expense	—		(2)		(118)


lncome (loss) before income taxes	4,010		(909)		(914)
Income tax benefits	(201)		(189)		(192)
lncome (loss) of parent company	4,211		(720)		(722)
Equity in income of subsidiaries	1,746		4,154		5,886
Shareholders' net income	5,957		3,434		5,164
Shareholders' other comprehensive (loss) income, net of tax
Net unrealized (depreciation) appreciation on securities and derivatives	(238)		661		503
Net long-duration insurance and contractholder liabilities measurement adjustments	(291)		(1,067)		(715)
Net translation gains (losses) of foreign currencies	71		(49)		5
Postretirement benefits liability adjustment	(7)		(22)		1
Shareholders' other comprehensive loss, net of tax	(465)		(477)		(206)
Shareholders' comprehensive income	$	5,492	$	2,957	$	4,958

See Notes to Financial Statements on the following pages.

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE I

CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP

(REGISTRANT)

BALANCE SHEETS


	As of December 31,
(In millions)	2025		2024
Assets
Cash and cash equivalents	$	118	$	164

Other current assets	29		103
Total current assets	147		267
Investments in subsidiaries	61,382		62,887
Intercompany receivable	14,146		10,546
Other non-current assets	48		71
TOTAL ASSETS	$	75,723	$	73,771
Liabilities
Short-term debt	$	550	$	2,848
Other current liabilities	1,983		1,528
Total current liabilities	2,533		4,376
Long-term debt	30,268		28,134
Intercompany payable	1,134		195
Other non-current liabilities	75		33
TOTAL LIABILITIES	34,010		32,738
Shareholders' equity
Common stock (shares issued, 405 and 403; authorized, 600)	4		4
Additional paid-in capital	31,790		31,288
Accumulated other comprehensive loss	(2,806)		(2,341)
Retained earnings	47,865		43,519
Less treasury stock, at cost	(35,140)		(31,437)
TOTAL SHAREHOLDERS' EQUITY	41,713		41,033
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	75,723	$	73,771

See Notes to Financial Statements on the following pages.

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE I

CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP

(REGISTRANT)

STATEMENTS OF CASH FLOWS


	For the Years Ended December 31,

(In millions)	2025		2024		2023
Cash Flows from Operating Activities
Shareholders' net income	$	5,957	$	3,434	$	5,164
Adjustments to reconcile Shareholders' net income to net cash provided by operating activities
Equity in income from subsidiaries	(1,746)		(4,154)		(5,886)

Dividends received from subsidiaries	1,171		2,916		1,381
Gain on sale of businesses	(4,890)		—		—
Other liabilities	496		(306)		540
Other, net	592		243		640
NET CASH PROVIDED BY OPERATING ACTIVITIES	1,580		2,133		1,839
Cash Flows from Investing Activities
Net change in amounts due from affiliates	—		—		622
Proceeds from divestiture of businesses	4,891		—		—


NET CASH PROVIDED BY INVESTING ACTIVITIES	4,891		—		622
Cash Flows from Financing Activities
Net change in amounts due to/from affiliates	(1,101)		4,761		1,473
Net change in commercial paper	(880)		(357)		1,237

Repayment of term loan	(2,000)		—		—
Net proceeds on issuance of term loan	1,999		—		—
Repayment of long-term debt	(3,861)		(2,731)		(2,822)
Net proceeds on issuance of long-term debt	4,458		4,462		1,491
Issuance of common stock	203		305		187
Common stock dividend paid	(1,611)		(1,567)		(1,450)
Repurchase of common stock	(3,621)		(7,034)		(2,284)

Other, net	(108)		(117)		(110)
NET CASH USED IN FINANCING ACTIVITIES	(6,522)		(2,278)		(2,278)
Net (decrease) increase in cash, cash equivalents and restricted cash	(51)		(145)		183
Cash, cash equivalents and restricted cash, beginning of year	190		335		152
Cash, cash equivalents and restricted cash, end of year (1)	$	139	$	190	$	335
Noncash Investing and Financing Activities:
Net amounts due from affiliates settled through capital transactions	$	(1,617)	$	(7,565)	$	(5,221)

(1) Includes restricted cash reported in Other non-current assets.

See Notes to Financial Statements on the following pages.

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE I

CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP

(REGISTRANT)

NOTES TO CONDENSED FINANCIAL STATEMENTS

The accompanying condensed financial statements should be read in conjunction with the Consolidated Financial Statements and the accompanying notes thereto contained in this Annual Report on Form 10-K ("Form 10-K").

Note 1 - For purposes of these condensed financial statements, The Cigna Group (the "Company") accounts for investments in wholly owned and majority-owned subsidiaries using the equity method of accounting. The Cigna Group, through its predecessor companies, was incorporated in Delaware in 1981. Cigna Corporation was renamed The Cigna Group in February 2023.

Note 2 - See Note 7 – Debt included in Part II, Item 8 of this Form 10-K for a description of the short-term and long-term debt obligations of The Cigna Group and its subsidiaries.

Short-term and Credit Facilities Debt

Term Loan. In August 2025, the Company entered into a new 364-day term loan facility (the "Term Loan Facility") and borrowed $2.0 billion to partially fund an investment in Shields Health Solutions ("Shields"), a leading specialty pharmacy management company. The full outstanding balance was repaid and the Term Loan Facility was terminated in September 2025, using proceeds from the debt issuance described below.

Revolving Credit Agreement. Our Credit Agreement (defined below) provides us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. As of December 31, 2025, there were no outstanding balances under the Credit Agreement.

In April 2025, The Cigna Group replaced its previous revolving credit agreements and entered into a $6.5 billion, five-year revolving credit and letter of credit agreement that will mature in April 2030, with an option to extend the maturity date for an additional one-year period, subject to consent of the banks (the "Credit Agreement"). The Company can borrow up to $6.5 billion under the Credit Agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit.

The Credit Agreement includes an option to increase commitments up to $1.5 billion for a maximum total commitment of $8.0 billion. The Credit Agreement allows for borrowings at either a base rate, term Secured Overnight Financing Rate ("SOFR") or daily simple SOFR, plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.

The Credit Agreement also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreement, may not exceed 60%, subject to certain exceptions upon the consummation of an acquisition.

Commercial Paper. Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $6.5 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. There was no commercial paper balance as of December 31, 2025.

Long-Term Debt

Debt Issuance. In September 2025, we issued $4.5 billion of new senior notes, as detailed in the table below. The proceeds from this debt issuance were used to repay the $2.0 billion of loans outstanding under the Term Loan Facility as described above. We used the remaining net proceeds for general corporate purposes, including investments and repayment of indebtedness. Interest on this debt is paid semiannually.

Principal

Maturity Date

Interest Rate

Net Proceeds

Redeemable Date(1)

"Make Whole" Premium (2)

$1,000 million

September 15, 2030

4.500%

$994 million

August 15, 2030

15

$1,250 million

September 15, 2032

4.875%

$1,245 million

July 15, 2032

15

$1,500 million

January 15, 2036

5.250%

$1,490 million

October 15, 2035

15

$750 million

January 15, 2056

6.000%

$736 million

July 15, 2055

20

(1) Redeemable at any time prior to this date at a "make whole" premium, defined below. Redeemable at par on or after this date.

(2) "Make whole" premium calculated using the most directly comparable U.S. Treasury rate plus the amount of basis points set forth in this column.

Debt Maturities. Maturities of the Company's long-term debt as of December 31, 2025 are as follows:


(In millions)
2026	$	550
2027	$	2,055
2028	$	3,800
2029	$	1,000
2030	$	2,400
Maturities after 2030	$	21,255

Debt Covenants. The Company was in compliance with its debt covenants as of December 31, 2025.

Note 3 - The Company's intercompany receivables consist primarily of net intercompany loan amounts due from Evernorth Health, Inc. of $8.5 billion as of both December 31, 2025 and December 31, 2024. Interest income on the loan receivable was accrued at an average rate of 5.50% in 2025.

The Company's intercompany payables primarily reflect intercompany balances due to affiliates as of December 31, 2025. During the year ended December 31, 2025, the Company settled a portion of the outstanding intercompany payables via non-cash capital transactions.

Note 4 - The Company guaranteed approximately $8.5 billion primarily related to intercompany indebtedness and financial obligations of certain direct and indirect wholly-owned subsidiaries. There were immaterial liabilities required for these guarantees as of December 31, 2025.

Note 5 - The Company completed the sale of our Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies® businesses on March 19, 2025. The Company received cash proceeds of $4.9 billion and recorded the related gain on sale of businesses.

Schedule II - Valuation and Qualifying Accounts and Reserves

12 Months Ended

Dec. 31, 2025

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Schedule II - Valuation and Qualifying Accounts and Reserves

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE II

VALUATION AND QUALIFYING ACCOUNTS AND RESERVES


(In millions)	Balance at Beginning of Year		Charged (Credited) to Costs and Expenses		Charged (Credited) to Other Accounts		Other Deductions		Balance at End of Year
Description
2025
Investment asset valuation reserves
Available-for-sale debt securities	$	111	$	58	$	—	$	(32)	$	137
Commercial mortgage loans	$	30	$	6	$	—	$	—	$	36
Accounts receivable, net	$	186	$	245	$	2	$	(175)	$	258
Deferred tax asset valuation allowance	$	2,332	$	317	$	(275)	$	—	$	2,374
Reinsurance recoverables	$	30	$	(7)	$	—	$	—	$	23
2024
Investment asset valuation reserves
Available-for-sale debt securities	$	33	$	87	$	—	$	(9)	$	111
Commercial mortgage loans	$	31	$	(1)	$	—	$	—	$	30
Accounts receivable, net	$	163	$	176	$	(1)	$	(152)	$	186
Deferred tax asset valuation allowance	$	1,498	$	866	$	(32)	$	—	$	2,332
Reinsurance recoverables	$	35	$	(5)	$	—	$	—	$	30
2023
Investment asset valuation reserves
Available-for-sale debt securities	$	44	$	11	$	—	$	(22)	$	33
Commercial mortgage loans	$	21	$	10	$	—	$	—	$	31
Accounts receivable, net	$	160	$	90	$	1	$	(88)	$	163
Deferred tax asset valuation allowance	$	208	$	1,286	$	4	$	—	$	1,498
Reinsurance recoverables	$	35	$	—	$	—	$	—	$	35

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2025 shares
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Terminated	false
David Cordani [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On November 5, 2025, David Cordani, Chairman and Chief Executive Officer of The Cigna Group, terminated a 10b5-1 plan that was adopted on May 6, 2025. Mr. Cordani's plan provided for (i) the sale of shares of The Cigna Group common stock issuable upon vesting of a performance award (the actual number of shares depends on actual performance achieved and may range from 0% to 200% of the 32,586 shares subject to the award at the target level of performance) and (ii) the combined exercise of 212,543 vested stock options and sale of up to 50% of the after-tax shares of The Cigna Group common stock acquired from the option exercise, in each case through May 5, 2026.
Name	David Cordani
Title	Chairman and Chief Executive Officer of The Cigna Group
Adoption Date	May 6, 2025
Rule 10b5-1 Arrangement Terminated	true
Termination Date	November 5, 2025
Expiration Date	May 5, 2026
Arrangement Duration	183 days
Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At Zero PercentTarget Level [Member] \| David Cordani [Member]
Trading Arrangements, by Individual
Aggregate Available	0
Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At 200 Percent Target Level [Member] \| David Cordani [Member]
Trading Arrangements, by Individual
Aggregate Available	65,172
Trading Arrangement, Common Stock Issuable Upon Vesting Of Performance Award At Target Level [Member] \| David Cordani [Member]
Trading Arrangements, by Individual
Aggregate Available	32,586
Trading Arrangement, Stock Options [Member] \| David Cordani [Member]
Trading Arrangements, by Individual
Aggregate Available	212,543

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	Cybersecurity Strategy and Risk Management Cybersecurity is a core element of our enterprise risk management strategy. Safeguarding business information, intellectual property, and the data of customers, patients, employees and business partners is vital for operational continuity, regulatory compliance and sustaining stakeholder trust. Our comprehensive cybersecurity program is supported by policies and procedures designed to protect our systems and operations, as well as sensitive personal information and data, from foreseeable cybersecurity threats. Core to our security model is our defense-in-depth framework, comprising multiple layers of processes and technologies that help prevent, detect and respond to threats. Our approach to safeguarding against external threats incorporates a suite of preventive technologies, including malicious email blocking, defenses against automated attacks and multifactor authentication. Event monitoring technologies run continuously, detecting suspected intrusion attempts and alerting our Cybersecurity Incident Response Team. We undertake a number of critical security processes to mitigate and protect against cybersecurity risks, which include but are not limited to (i) identity and access management; (ii) security awareness and training; (iii) security operations and monitoring; (iv) change management; (v) disaster recovery/business continuity; (vi) intelligence feeds; (vii) physical security; (viii) third-party vendor security reviews; (ix) vulnerability management/patching; and (x) cybersecurity incident reporting. We routinely manage cybersecurity risks through a defined framework that includes activities aimed at the identification, assessment, treatment and monitoring of risks. Cybersecurity risk assessment results are used by senior management to make informed decisions about where to allocate resources to reduce cybersecurity risks and improve overall security posture. We examine our entire program annually with third parties and measure the program against generally accepted industry standards and frameworks, such as an internationally recognized security control framework established by the NIST and used by companies to assess and improve their ability to prevent, detect and respond to cyberattacks. Our cybersecurity policies and standards are reviewed annually and are mainly guided by the NIST 800-53 Cybersecurity Framework. In addition to the NIST framework, we leverage the International Organization for Standardization 27001 and 27002 standards. To enhance our preparedness and practice our collective cybersecurity response capabilities, we conduct tabletop exercises with leaders, stakeholders, subject matter experts and certain executives. These events are developed in partnership with external security experts and designed to exercise and engage some of the most critical areas of cybersecurity incident response and preparedness through an interactive and evolving simulated scenario. In addition to these internal measures, the effectiveness of components of our overall cybersecurity program is frequently evaluated by external third parties, which includes work performed over various levels of control assessments for specific business lines and core processes. These include Health Information Trust Alliance ("HITRUST") for health care data security, PCI DSS for payment security, and System Organization Controls 2 ("SOC 2") for information security and related controls for specific business lines and core processes. We also perform an annual maturity assessment and benchmark our security controls to identify opportunities to strengthen our cybersecurity program. As part of our Global Threat Management Program, a dedicated Incident Handling Team, comprising both technical and management personnel, determines the severity of a validated cybersecurity event across the enterprise and is responsible for the development and ongoing maintenance of our comprehensive Global Incident Response Plan ("GIRP"). The GIRP is reviewed quarterly at a minimum but may be updated as needed based on lessons learned, changes in key teams or processes, or other circumstances as warranted, and the procedures therein are tested annually. The GIRP's incident handling procedures dictate our actions during each phase of an incident, including the assembly of a broad, cross-functional Computer Security Incident Response Team, the formulation of a response, and post-incident reviews and corrective actions. Our information protection department maintains a risk register that is used to manage cybersecurity risks associated with its business activities, technology assets, and its interaction with internal and external business, information technology and security parties. Cybersecurity risks are also periodically reviewed by Enterprise Risk Management to ensure appropriate oversight of cybersecurity risk management activities. Suppliers that access, host or transmit our data are contractually required to comply with our Security Policies and Standards. Additionally, suppliers may be subject to periodic security audits or risk assessments, which include security questionnaires, security capabilities and maturity assessments, controls evidence reviews, application vulnerability assessments, public internet presence monitoring, and alignment reviews with service-specific industry standards. Follow-up activities are performed as needed. Contracts with suppliers also include critical security requirements, such as right to audit, technology requirements and hiring practices, including background checks for those who have access to our network. To further ensure supplier resilience and continuity, we regularly evaluate and assess our critical supplier relationships and business continuity plans, enabling us to quickly adapt and maintain operations in the event of prolonged disruption. As of the date of this report, we do not believe that any risks from any cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations or financial condition. However, future cybersecurity threats or incidents could materially affect us, including our business strategy, results of operations or financial condition. For more information on our cybersecurity-related risks, see Part I, Item 1A "Risk Factors – Operational Risks – As a large global health company, we and our vendors are subject to cyberattacks or other privacy or data security incidents. If we are unable to prevent or contain the effects of any such attacks, or fail to ensure vendors do the same, we may suffer exposure to substantial liability, reputational harm, loss of revenue or other damages."
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	Our comprehensive cybersecurity program is supported by policies and procedures designed to protect our systems and operations, as well as sensitive personal information and data, from foreseeable cybersecurity threats.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Cybersecurity Governance Our Board of Directors (the "Board") has ultimate oversight over our privacy and cybersecurity programs and strategy and is responsible for ensuring that we have risk management policies and processes in place to meet and mitigate evolving risks and threats. Certain members of our Board have cybersecurity certifications. Throughout 2025, the Board executed this oversight directly and through both the Audit Committee, for cybersecurity purposes, and the Compliance Committee, for privacy purposes. In these capacities, these committees were regularly briefed by the Global Chief Information Security Officer ("GCISO") and Chief Privacy Officer on cybersecurity and privacy matters. These briefings were designed to provide visibility about the identification, assessment and management of critical risks, audit findings, and management's risk mitigation strategies. Additionally, these briefings included information about current trends in the environment, incident preparedness, AI, and various components of our cybersecurity and privacy programs. On an annual basis, the Board reviews our cybersecurity program, including the threat landscape and related controls, and periodically conducts cybersecurity tabletop exercises. Our dedicated cybersecurity team is led by our GCISO. Our current GCISO joined the Company in October 2023 and works closely with senior management to develop and innovate the cybersecurity and risk management strategies. Prior to joining the team, our GCISO held senior information security roles at other global organizations, where this individual defined information security strategies; built global information security programs; implemented cybersecurity capabilities that protect consumers, wholesale partners and brands; and oversaw the security of a global payment network, a corporate network and digital assets. Beginning in 2026, oversight of cybersecurity matters has transitioned to the Board's Finance & Technology Committee. The Finance & Technology Committee now receives similar updates on cybersecurity and information protection programs from the GCISO as described above. Throughout 2025, the Compliance Committee, now the Audit & Compliance Committee, oversaw privacy risks and related matters, including through regular updates from our Chief Compliance and Risk Officer.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Board of Directors (the "Board") has ultimate oversight over our privacy and cybersecurity programs and strategy and is responsible for ensuring that we have risk management policies and processes in place to meet and mitigate evolving risks and threats. Certain members of our Board have cybersecurity certifications. Throughout 2025, the Board executed this oversight directly and through both the Audit Committee, for cybersecurity purposes, and the Compliance Committee, for privacy purposes. Beginning in 2026, oversight of cybersecurity matters has transitioned to the Board's Finance & Technology Committee. The Finance & Technology Committee now receives similar updates on cybersecurity and information protection programs from the GCISO as described above. Throughout 2025, the Compliance Committee, now the Audit & Compliance Committee, oversaw privacy risks and related matters, including through regular updates from our Chief Compliance and Risk Officer.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	Throughout 2025, the Board executed this oversight directly and through both the Audit Committee, for cybersecurity purposes, and the Compliance Committee, for privacy purposes. In these capacities, these committees were regularly briefed by the Global Chief Information Security Officer ("GCISO") and Chief Privacy Officer on cybersecurity and privacy matters. These briefings were designed to provide visibility about the identification, assessment and management of critical risks, audit findings, and management's risk mitigation strategies. Additionally, these briefings included information about current trends in the environment, incident preparedness, AI, and various components of our cybersecurity and privacy programs. On an annual basis, the Board reviews our cybersecurity program, including the threat landscape and related controls, and periodically conducts cybersecurity tabletop exercises. Beginning in 2026, oversight of cybersecurity matters has transitioned to the Board's Finance & Technology Committee. The Finance & Technology Committee now receives similar updates on cybersecurity and information protection programs from the GCISO as described above. Throughout 2025, the Compliance Committee, now the Audit & Compliance Committee, oversaw privacy risks and related matters, including through regular updates from our Chief Compliance and Risk Officer.
Cybersecurity Risk Role of Management [Text Block]	Our dedicated cybersecurity team is led by our GCISO. Our current GCISO joined the Company in October 2023 and works closely with senior management to develop and innovate the cybersecurity and risk management strategies. Prior to joining the team, our GCISO held senior information security roles at other global organizations, where this individual defined information security strategies; built global information security programs; implemented cybersecurity capabilities that protect consumers, wholesale partners and brands; and oversaw the security of a global payment network, a corporate network and digital assets.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our Board of Directors (the "Board") has ultimate oversight over our privacy and cybersecurity programs and strategy and is responsible for ensuring that we have risk management policies and processes in place to meet and mitigate evolving risks and threats. Certain members of our Board have cybersecurity certifications. Throughout 2025, the Board executed this oversight directly and through both the Audit Committee, for cybersecurity purposes, and the Compliance Committee, for privacy purposes. In these capacities, these committees were regularly briefed by the Global Chief Information Security Officer ("GCISO") and Chief Privacy Officer on cybersecurity and privacy matters
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Prior to joining the team, our GCISO held senior information security roles at other global organizations, where this individual defined information security strategies; built global information security programs; implemented cybersecurity capabilities that protect consumers, wholesale partners and brands; and oversaw the security of a global payment network, a corporate network and digital assets.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	Throughout 2025, the Board executed this oversight directly and through both the Audit Committee, for cybersecurity purposes, and the Compliance Committee, for privacy purposes. In these capacities, these committees were regularly briefed by the Global Chief Information Security Officer ("GCISO") and Chief Privacy Officer on cybersecurity and privacy matters. These briefings were designed to provide visibility about the identification, assessment and management of critical risks, audit findings, and management's risk mitigation strategies. Additionally, these briefings included information about current trends in the environment, incident preparedness, AI, and various components of our cybersecurity and privacy programs. On an annual basis, the Board reviews our cybersecurity program, including the threat landscape and related controls, and periodically conducts cybersecurity tabletop exercises. Our dedicated cybersecurity team is led by our GCISO. Our current GCISO joined the Company in October 2023 and works closely with senior management to develop and innovate the cybersecurity and risk management strategies. Prior to joining the team, our GCISO held senior information security roles at other global organizations, where this individual defined information security strategies; built global information security programs; implemented cybersecurity capabilities that protect consumers, wholesale partners and brands; and oversaw the security of a global payment network, a corporate network and digital assets. Beginning in 2026, oversight of cybersecurity matters has transitioned to the Board's Finance & Technology Committee. The Finance & Technology Committee now receives similar updates on cybersecurity and information protection programs from the GCISO as described above. Throughout 2025, the Compliance Committee, now the Audit & Compliance Committee, oversaw privacy risks and related matters, including through regular updates from our Chief Compliance and Risk Officer.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2025
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment, tax and receivable valuations, interest rates, and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.
Recent Accounting Pronouncements, Recently Adopted Accounting Guidance and Accounting Guidance Not Yet Adopted	Recent Accounting Pronouncements There were no new accounting standards adopted during the year ended December 31, 2025 that had a material impact on our Consolidated Financial Statements. Accounting Guidance Not Yet Adopted Accounting Standards Update ("ASU") 2025-06, Targeted Improvements to the Accounting for Internal-Use Software (Subtopic 350-40). Required to be adopted January 1, 2028, with early adoption permitted and requires the following: •Seeks to improve the operability of the recognition guidance considering different methods of software development, mainly more iterative methods, by: ◦Aligning internal-use software capitalization requirements to probable completion and required funding and authorization. ◦Clarifying certain criteria for probable completion, including that the significant performance requirements of the software be identified and no longer subject to substantial revision. •Transition options include prospective from the date of adoption as well as retrospective and modified retrospective adoption. The Company is currently evaluating the impact of this guidance on our results of operations and financial position, as well as potential impacts to information systems and controls. ASU 2024-03, Disaggregation of Income Statement Expenses (Subtopic 220-40). Required to be adopted for the annual reporting period ending December 31, 2027 and for interim reporting periods beginning January 1, 2028 and requires: •Additional expense detail in the footnotes disaggregating income statement captions including any of the following: inventory purchases; employee compensation; depreciation; and intangible asset amortization, as well as a qualitative description of remaining expenses to reconcile to the total expense within those income statement captions; •Disclosure of the definition and total amount of selling expenses; and •Transition options include prospective from the date of adoption as well as retrospective adoption. The only financial statement impact resulting from adoption will be increased disclosure. The Company continues to evaluate the effects the adoption requirements on information systems and controls.
Cash and Cash Equivalents	Cash and cash equivalents are carried at cost that approximates fair value. Cash equivalents consist of short-term investments with maturities of three months or less from the time of purchase. The Company reclassifies cash overdraft positions to liabilities when the legal right of offset does not exist.
Inventories	Inventories consist of prescription drugs and medical supplies and are stated at the lower of first-in-first-out cost or net realizable value.
Translation of Foreign Currencies	The Company generally conducts its international business through foreign operating entities that maintain assets and liabilities in local currencies that are their functional currencies. The Company uses exchange rates as of the balance sheet date to translate assets and liabilities into U.S. dollars. Translation gains or losses on functional currencies, net of applicable taxes, are recorded in Accumulated other comprehensive loss. The Company uses average monthly exchange rates during the year to translate revenues and expenses into U.S. dollars.
Revenue Recognition	. Pharmacy revenues are primarily derived from providing pharmacy benefit management services to clients and customers. Pharmacy revenues are recognized when control of the promised goods or services is transferred to clients and customers in an amount that reflects the consideration the Company expects to receive for those goods or services. The Company provides or makes available various services supporting benefit management and claims administration and is generally obligated to provide prescription drugs to clients' members using multiple distribution methods, including retail networks, home delivery and specialty pharmacies. These goods and services are integrated into a single performance obligation to process claims, dispense prescription drugs and provide other services over the contract period (generally three years). This performance obligation is satisfied as the business stands ready to fulfill its obligation. Revenues for dispensing prescription drugs through retail pharmacies are reported gross and consist of the prescription price (ingredient cost and dispensing fee) contracted with clients, including the customer copayment, and any associated fees for services, because the Company acts as the principal in these arrangements. When a prescription is presented to a retail network pharmacy, the Company is solely responsible for customer eligibility, drug utilization review, drug-to-drug interaction review, any required clinical intervention, plan provision information, payment to the pharmacy and client billing. These revenues are recognized based on the full prescription price when the pharmacy claim is processed and approved for payment. The Company also provides benefit design and formulary consultation services to clients and negotiates separate contractual relationships with clients and network pharmacies. These factors indicate that the Company has control over these transactions until the prescription is processed. Revenues are billed, due and recognized at contract rates either on a periodic basis or as services are provided (such as based on volume of claims processed). This recognition pattern aligns with the benefits from services provided. Home delivery and specialty pharmacy revenues are due and recognized as each prescription is shipped, net of reserves for discounts and contractual allowances estimated based on historical experience. Any differences between estimates and actual collections are reflected in Pharmacy revenues when payments are received. Historically, adjustments to original estimates and returns have not been material. The Company has elected the practical expedient to account for shipping and handling as a fulfillment activity. We may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid at the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. The liability for these financial and performance guarantees was $1.8 billion as of December 31, 2025 and $1.9 billion as of December 31, 2024. The Company administers programs through which we may receive rebates and other vendor consideration from pharmaceutical manufacturers. The amounts of such rebates or other vendor consideration shared with pharmacy benefit management services clients vary based on the contractual arrangement with the client and in some cases the type of consideration received from the pharmaceutical manufacturer. Rebates and other vendor consideration payable to pharmacy benefit management services clients are recorded as a reduction of Pharmacy revenues. Estimated amounts payable to clients are based on contractual sharing arrangements between the Company and the client and these amounts are adjusted when amounts are collected from pharmaceutical manufacturers in accordance with the contractual arrangement between the Company and the client. Historically, these adjustments have not been material. Other pharmacy service revenues are earned by distributing specialty pharmaceuticals and medical supplies to providers, clinics and hospitals. These revenues are billed, due and recognized at contracted rates as prescriptions and supplies are shipped and services are provided. Pharmacy Costs. Pharmacy costs include the cost of prescriptions sold, network pharmacy claim costs and copayments. Also included are direct costs of dispensing prescriptions including supplies, shipping and handling, and direct costs associated with clinical programs, such as drug utilization management and medication adherence counseling. Home delivery and specialty pharmacy costs are recognized when the drug is shipped, and retail network costs are recognized when the drug is processed and approved for payment. Rebates and other vendor consideration received when providing pharmacy benefit management services are recorded as a reduction of pharmacy costs. Rebates are recognized as prescriptions are shipped or processed and approved for payment. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected, net of contractual allowances, has not been material. The Company maintains reimbursement guarantees with certain retail network pharmacies. For each such guarantee, the Company records a pharmacy and other service costs payable or prepaid asset for applicable retail network claims based on our actual performance throughout the period against the contractual reimbursement rate. The Company's contracts with certain retail pharmacies give the Company the right to adjust reimbursement rates during the annual guarantee period. E.Premiums and Related Expenses Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses are recognized when incurred and, for our Cigna Healthcare business, are presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for experience-rated refunds based on contract terms and calculated using the customer's experience (including estimates of incurred but not reported claims). The Patient Protection and Affordable Care Act ("ACA") established a risk adjustment program that transfers funds among insurers based on the relative risk of their covered populations of individuals who purchased insurance on a public exchange. We recognize receivables or payables from the Centers for Medicare and Medicaid Services ("CMS") for the Company's Individual and Family Plans as adjustments to premium revenue when amounts are reasonably estimable and collection is reasonably assured, using year-to-date experience and industry data. Final settlements are determined by the United States Department of Health and Human Services ("HHS") in the subsequent year. Premium revenue may also include an adjustment to reflect the estimated effect of rebates due to customers under medical loss ratio provisions of the ACA. These rebate liabilities are settled in the subsequent year. Liabilities related to experience-rated refunds, risk adjustment programs and the minimum medical loss ratio are included in Accrued expenses and other liabilities (current). Premiums for supplemental health, accident and individual life insurance and annuity long-duration products are recognized as revenue when due. Cigna Healthcare long-duration premium revenues are associated with contracts that provide coverage greater than one year or are guaranteed to be renewed at the option of the policyholder beyond one year. Benefits and expenses are matched with premiums. Revenue for universal life products is recognized as follows: •Investment income on assets supporting universal life products is recognized in Net investment income/losses as earned. •Charges for mortality, administration and policy surrender are recognized in Premiums as earned. Administrative fees are considered earned when services are provided. Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by policyholders. Expenses are recognized when claims are incurred and income is credited to policyholders in accordance with contract provisions. The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current). See Note 9 to the Consolidated Financial Statements for further information. F.Fees and Related Expenses The majority of the Company's service fee revenues are derived from the following programs: •Administrative Services Only ("ASO") arrangements allow plan sponsors to self-fund claims and assume the risk of medical or other benefit costs. In return for fees from these clients, the Company provides access to our participating provider networks and other services supporting benefit management. •Fee-for-service clinical solutions offered to clients, such as drug utilization management and medication adherence counseling help clients to drive better health outcomes at a lower cost by identifying and addressing potentially unsafe or wasteful prescribing, dispensing and utilization of prescription drugs, and communicating with, or supporting communications with, physicians, pharmacies and patients. •Wholesale Marketplace Drug Formulary Management services include either our drug formulary administrative service arrangements or our formulary processing arrangements. Drug formulary administrative services may include formulary consultation, administration of rebate contracts, rebate submission, collection from drug manufacturers and the distribution of rebates to clients. Services may also include facilitating audits of data submissions and reporting of rebates to clients. •Health benefit management solutions are offered primarily to sponsors of health benefit plans to drive cost reductions and improve quality outcomes for clients as well as provide behavioral health services to third-party health plans, employers and administrators. In certain arrangements, the Company assumes the financial obligation for third-party provider costs for medical services provided to the health plan's customers. Arrangements are generally short-term (one year or less) except for certain three-year health benefit management solutions contracts, and each consists of a single performance obligation. Performance obligations are satisfied as services are provided to clients, either on a stand-ready or utilization basis. Fees are billed, due and recognized at contracted rates on a periodic basis, generally monthly or agreed-upon arrangements terms. Fee revenues for services are generally recorded on a gross basis with the associated direct and indirect costs presented in Pharmacy and other service costs, or Selling, general and administrative expenses. Retained rebates reported in Fees and other revenues in our formulary processing arrangements are either recognized gross as services are provided to clients, consistent with the related service fee, or net as rebates are processed. The latter applies in arrangements in which the Company is permitted to retain a portion of rebates collected in exchange for services, but the Company does not obtain control of the retained rebate until rebates are transferred to the client. Fees for services may include variable consideration as a component of the transaction price, which is estimated at contract inception, recognized and adjusted through the contract period through Accrued expenses and other liabilities. Variable consideration includes certain health benefit management contracts requiring the Company to share the results of medical cost experience that differ from specified targets and ASO performance guarantees that compensate clients if certain service standards, clinical outcomes or financial metrics are not met.
Cost of Goods and Service	. Pharmacy revenues are primarily derived from providing pharmacy benefit management services to clients and customers. Pharmacy revenues are recognized when control of the promised goods or services is transferred to clients and customers in an amount that reflects the consideration the Company expects to receive for those goods or services. The Company provides or makes available various services supporting benefit management and claims administration and is generally obligated to provide prescription drugs to clients' members using multiple distribution methods, including retail networks, home delivery and specialty pharmacies. These goods and services are integrated into a single performance obligation to process claims, dispense prescription drugs and provide other services over the contract period (generally three years). This performance obligation is satisfied as the business stands ready to fulfill its obligation. Revenues for dispensing prescription drugs through retail pharmacies are reported gross and consist of the prescription price (ingredient cost and dispensing fee) contracted with clients, including the customer copayment, and any associated fees for services, because the Company acts as the principal in these arrangements. When a prescription is presented to a retail network pharmacy, the Company is solely responsible for customer eligibility, drug utilization review, drug-to-drug interaction review, any required clinical intervention, plan provision information, payment to the pharmacy and client billing. These revenues are recognized based on the full prescription price when the pharmacy claim is processed and approved for payment. The Company also provides benefit design and formulary consultation services to clients and negotiates separate contractual relationships with clients and network pharmacies. These factors indicate that the Company has control over these transactions until the prescription is processed. Revenues are billed, due and recognized at contract rates either on a periodic basis or as services are provided (such as based on volume of claims processed). This recognition pattern aligns with the benefits from services provided. Home delivery and specialty pharmacy revenues are due and recognized as each prescription is shipped, net of reserves for discounts and contractual allowances estimated based on historical experience. Any differences between estimates and actual collections are reflected in Pharmacy revenues when payments are received. Historically, adjustments to original estimates and returns have not been material. The Company has elected the practical expedient to account for shipping and handling as a fulfillment activity. We may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid at the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. The liability for these financial and performance guarantees was $1.8 billion as of December 31, 2025 and $1.9 billion as of December 31, 2024. The Company administers programs through which we may receive rebates and other vendor consideration from pharmaceutical manufacturers. The amounts of such rebates or other vendor consideration shared with pharmacy benefit management services clients vary based on the contractual arrangement with the client and in some cases the type of consideration received from the pharmaceutical manufacturer. Rebates and other vendor consideration payable to pharmacy benefit management services clients are recorded as a reduction of Pharmacy revenues. Estimated amounts payable to clients are based on contractual sharing arrangements between the Company and the client and these amounts are adjusted when amounts are collected from pharmaceutical manufacturers in accordance with the contractual arrangement between the Company and the client. Historically, these adjustments have not been material. Other pharmacy service revenues are earned by distributing specialty pharmaceuticals and medical supplies to providers, clinics and hospitals. These revenues are billed, due and recognized at contracted rates as prescriptions and supplies are shipped and services are provided. Pharmacy Costs. Pharmacy costs include the cost of prescriptions sold, network pharmacy claim costs and copayments. Also included are direct costs of dispensing prescriptions including supplies, shipping and handling, and direct costs associated with clinical programs, such as drug utilization management and medication adherence counseling. Home delivery and specialty pharmacy costs are recognized when the drug is shipped, and retail network costs are recognized when the drug is processed and approved for payment. Rebates and other vendor consideration received when providing pharmacy benefit management services are recorded as a reduction of pharmacy costs. Rebates are recognized as prescriptions are shipped or processed and approved for payment. Historically, the effect of adjustments resulting from the reconciliation of rebates recognized to the amounts billed and collected, net of contractual allowances, has not been material. The Company maintains reimbursement guarantees with certain retail network pharmacies. For each such guarantee, the Company records a pharmacy and other service costs payable or prepaid asset for applicable retail network claims based on our actual performance throughout the period against the contractual reimbursement rate. The Company's contracts with certain retail pharmacies give the Company the right to adjust reimbursement rates during the annual guarantee period. E.Premiums and Related Expenses Premiums for short-duration group health, accident and life insurance and managed care coverages are recognized as revenue on a pro rata basis over the contract period. Benefits and expenses are recognized when incurred and, for our Cigna Healthcare business, are presented net of pharmaceutical manufacturer rebates. For experience-rated contracts, premium revenue includes an adjustment for experience-rated refunds based on contract terms and calculated using the customer's experience (including estimates of incurred but not reported claims). The Patient Protection and Affordable Care Act ("ACA") established a risk adjustment program that transfers funds among insurers based on the relative risk of their covered populations of individuals who purchased insurance on a public exchange. We recognize receivables or payables from the Centers for Medicare and Medicaid Services ("CMS") for the Company's Individual and Family Plans as adjustments to premium revenue when amounts are reasonably estimable and collection is reasonably assured, using year-to-date experience and industry data. Final settlements are determined by the United States Department of Health and Human Services ("HHS") in the subsequent year. Premium revenue may also include an adjustment to reflect the estimated effect of rebates due to customers under medical loss ratio provisions of the ACA. These rebate liabilities are settled in the subsequent year. Liabilities related to experience-rated refunds, risk adjustment programs and the minimum medical loss ratio are included in Accrued expenses and other liabilities (current). Premiums for supplemental health, accident and individual life insurance and annuity long-duration products are recognized as revenue when due. Cigna Healthcare long-duration premium revenues are associated with contracts that provide coverage greater than one year or are guaranteed to be renewed at the option of the policyholder beyond one year. Benefits and expenses are matched with premiums. Revenue for universal life products is recognized as follows: •Investment income on assets supporting universal life products is recognized in Net investment income/losses as earned. •Charges for mortality, administration and policy surrender are recognized in Premiums as earned. Administrative fees are considered earned when services are provided. Benefits and expenses for universal life products consist of benefit claims in excess of policyholder account balances and income earned by policyholders. Expenses are recognized when claims are incurred and income is credited to policyholders in accordance with contract provisions. The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current). See Note 9 to the Consolidated Financial Statements for further information. F.Fees and Related Expenses The majority of the Company's service fee revenues are derived from the following programs: •Administrative Services Only ("ASO") arrangements allow plan sponsors to self-fund claims and assume the risk of medical or other benefit costs. In return for fees from these clients, the Company provides access to our participating provider networks and other services supporting benefit management. •Fee-for-service clinical solutions offered to clients, such as drug utilization management and medication adherence counseling help clients to drive better health outcomes at a lower cost by identifying and addressing potentially unsafe or wasteful prescribing, dispensing and utilization of prescription drugs, and communicating with, or supporting communications with, physicians, pharmacies and patients. •Wholesale Marketplace Drug Formulary Management services include either our drug formulary administrative service arrangements or our formulary processing arrangements. Drug formulary administrative services may include formulary consultation, administration of rebate contracts, rebate submission, collection from drug manufacturers and the distribution of rebates to clients. Services may also include facilitating audits of data submissions and reporting of rebates to clients. •Health benefit management solutions are offered primarily to sponsors of health benefit plans to drive cost reductions and improve quality outcomes for clients as well as provide behavioral health services to third-party health plans, employers and administrators. In certain arrangements, the Company assumes the financial obligation for third-party provider costs for medical services provided to the health plan's customers. Arrangements are generally short-term (one year or less) except for certain three-year health benefit management solutions contracts, and each consists of a single performance obligation. Performance obligations are satisfied as services are provided to clients, either on a stand-ready or utilization basis. Fees are billed, due and recognized at contracted rates on a periodic basis, generally monthly or agreed-upon arrangements terms. Fee revenues for services are generally recorded on a gross basis with the associated direct and indirect costs presented in Pharmacy and other service costs, or Selling, general and administrative expenses. Retained rebates reported in Fees and other revenues in our formulary processing arrangements are either recognized gross as services are provided to clients, consistent with the related service fee, or net as rebates are processed. The latter applies in arrangements in which the Company is permitted to retain a portion of rebates collected in exchange for services, but the Company does not obtain control of the retained rebate until rebates are transferred to the client. Fees for services may include variable consideration as a component of the transaction price, which is estimated at contract inception, recognized and adjusted through the contract period through Accrued expenses and other liabilities. Variable consideration includes certain health benefit management contracts requiring the Company to share the results of medical cost experience that differ from specified targets and ASO performance guarantees that compensate clients if certain service standards, clinical outcomes or financial metrics are not met.

Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.

Accounts Receivable, Net (Policies)	12 Months Ended
Accounts Receivable, Net (Policies)	Dec. 31, 2025
Receivables [Abstract]
Accounts Receivable	Accounting Policy. We bill pharmaceutical manufacturers based on management's interpretation of contractual terms and estimate a contractual allowance based on the best information available at the time a claim is processed. Contractual allowances for certain rebates receivable from pharmaceutical manufacturers are determined by reviewing payment experience and specific known items that could be adjusted under contract terms. The Company's estimation process for contractual allowances for pharmaceutical manufacturer receivables generally results in an allowance for balances outstanding greater than 90 days. Contractual allowances for certain receivables from third-party payors are based on their contractual terms and are estimated based on the Company's best information available at the time revenue is recognized. The allowance for expected credit losses for current accounts receivable is based primarily on past collections experience relative to the length of time receivables are past due; however, when available evidence reasonably supports an assumption that counterparty credit risk over the expected payment period will differ from current and historical payment collections, a forecasting adjustment is reflected in the allowance for expected credit losses. Discounts and claims adjustments issued to customers in the form of client credits and other non-credit adjustments are based on the current status of each customer's receivable balance, current economic and market conditions and a variety of other factors, including the length of time the receivables are past due, the financial health of customers and our past experience. Receivables and any associated allowance are written off only when all collection attempts have failed and such amounts are determined unrecoverable. We regularly review the adequacy of these allowances based on a variety of factors, including age of the outstanding receivable and collection history. When circumstances related to specific collection patterns change, estimates of the recoverability of receivables are adjusted. The Company's accounts receivable include amounts due from clients, third-party payors, customers and pharmaceutical manufacturers, and are presented net of allowances. These balances include the following: •Noninsurance customer receivables - amounts due from customers for noninsurance services, primarily pharmacy benefit management and ASO contracts. •Pharmaceutical manufacturers receivables - amounts due from pharmaceutical manufacturers. •Insurance customer receivables - amounts due from customers under insurance and managed care contracts, primarily premiums receivable and amounts due from CMS. •Other receivables - all other accounts receivable not included in the categories above. The transactions under the Facility are accounted for as a sale and recorded as a reduction to accounts receivable in the Consolidated Balance Sheets because control of, and risk related to, the accounts receivable are transferred to the financial institution. Although the sale is made without recourse, we provide collection services related to the transferred assets. Amounts associated with this Facility are reflected within Net cash provided by operating activities in the Consolidated Statements of Cash Flows. Factoring fees paid under this Facility are reflected in Interest expense and other in the Consolidated Statements of Income.

Divestiture (Policies)	12 Months Ended
Divestiture (Policies)	Dec. 31, 2025
Discontinued Operations and Disposal Groups [Abstract]
Divestiture	Accounting Policy. The Company classifies assets and liabilities as held for sale ("disposal group") when management commits to a plan to sell the disposal group, the sale is probable within one year and the disposal group is available for immediate sale in its present condition. The Company considers various factors, particularly whether actions required to complete the plan indicate it is unlikely that significant changes to the plan will be made or the plan will be withdrawn. Assets held for sale are measured at the lower of carrying value or fair value less costs to sell. Any loss resulting from the measurement is recognized in the period the held for sale criteria are met. Conversely, gains are not recognized until the date of the sale. When the disposal group is classified as held for sale, depreciation and amortization for most long-lived assets ceases, and the Company tests the assets for impairment. Deferred policy acquisition costs continue to be amortized.

Earnings Per Share (Policies)	12 Months Ended
Earnings Per Share (Policies)	Dec. 31, 2025
Earnings Per Share [Abstract]
Earnings Per Share	Accounting Policy. The Company computes basic earnings per share using the weighted-average number of unrestricted common and deferred shares outstanding. Diluted earnings per share also includes the dilutive effect of outstanding employee stock options and restricted stock using the treasury stock method and the effect of strategic performance shares.

Insurance and Contractholder Liabilities (Policies)	12 Months Ended
Insurance and Contractholder Liabilities (Policies)	Dec. 31, 2025
Insurance Loss Reserves [Abstract]
Unearned Premium	Accounting Policy - Unearned Premium. The unrecognized portion of premiums received is recorded as unearned premiums included in Insurance and contractholder liabilities (current and non-current). The Company evaluates certain insurance contracts subject to premium deficiency testing and recognizes a premium deficiency loss and corresponding reserve when expected claims costs, claims adjustment expenses, maintenance costs, and unamortized acquisition costs exceed unearned premium. Anticipated investment income is considered in the calculation of premium deficiency.
Unpaid Claims and Claims Expenses	This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities. Accounting Policy. The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. The Company compares key assumptions used to establish the medical costs payable to actual experience for each reporting period. The unpaid claims liability is adjusted through current period Shareholders' net income when actual experience differs from these assumptions. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trend. The liability is primarily calculated using "completion factors" developed by comparing the claim incurral date to the date claims were paid. Completion factors are impacted by several key items including changes in: (i) electronic (auto-adjudication) versus manual claim processing; (ii) frequency and timeliness of provider claims submissions; (iii) number of customers; and (iv) the mix of products. The Company uses historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. The Company relies more heavily on medical cost trend analysis that reflects expected claim payment patterns and other relevant operational considerations for more recent months. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of health benefits offered, including inpatient, outpatient and pharmacy; the impact of copays and deductibles; changes in provider practices; and changes in consumer demographics and consumption behavior. There is no single or common claim frequency metric used in the health care industry. The Company believes a relevant metric for its health insurance business is the number of customers for whom an insured medical claim was paid. Customers for whom no insured medical claim was paid are excluded from the calculation. Claims that did not result in a liability are not included in the frequency metric.
Future Policy Benefits	Accounting Policy. Future policy benefits represent the present value of estimated future obligations, estimated using actuarial methods, for long-duration insurance policies and annuity products currently in force, consisting primarily of reserves for annuity contracts, life insurance benefits and certain supplemental health products that are guaranteed renewable beyond one year. Contracts are grouped at a level no higher than issue year, based on the original contract issue date, and at lower levels of disaggregation within each issue year for certain businesses to reflect factors including product type, plan type and currency. Management estimates these obligations based on assumptions for premiums, interest rates, mortality or morbidity, future claim adjudication expenses, and surrenders. Mortality, morbidity and surrender assumptions are based on the Company's own experience and published actuarial tables and are updated at least annually, to the extent changes in circumstances require. Interest rate assumptions are based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed income instruments"). For interest accretion purposes, interest rates are fixed at the year of the cohort's inception; however, for purposes of liability measurement, they are updated to the current rate quarterly, with all changes in the interest rate from inception to current period reported through Accumulated other comprehensive loss. For contracts issued domestically, we use observable inputs from a published spot rate curve for terms up to 30 years and extrapolate for longer terms using a constant forward rate approach. For contracts issued by foreign operating entities with functional currencies other than the U.S. dollar, we use observable inputs to approximate a risk-free rate and add a credit spread adjustment to align with a low credit risk fixed income instrument. For terms beyond the last observable risk-free rates, which vary by international market, we extrapolate to the ultimate forward rate assuming a constant credit spread. For the annuity business, the premium paying period is shorter than the benefit coverage period, and a deferred profit liability is reported in future policy benefits representing gross premium received in excess of net premiums. Deferred profit liability is amortized based on expected future benefit payments. Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations' traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.
Contractholder Deposit Funds	Accounting Policy. Liabilities for contractholder deposit funds primarily include deposits received from customers for investment-related and universal life products as well as investment earnings on their fund balances in Other Operations. These liabilities are adjusted to reflect administrative charges and, for universal life fund balances, mortality charges. Interest credited on these funds is accrued ratably over the contract period.
Market Risk Benefits	Accounting Policy. Variable annuity reinsurance liabilities are measured as MRBs at fair value, net of nonperformance risk, with fluctuations in value gross of reinsurer nonperformance risk reported in benefit expenses, while fluctuations in the Company's own nonperformance risk (own credit risk) are reported in Accumulated other comprehensive loss. Nonperformance risk reflects risk that a party might default and therefore not fulfill its obligations (i.e., nonpayment risk). The nonperformance risk adjustment reflects a market participant's view of nonpayment risk by adding an additional spread to the discount rate in the calculation of both (a) the variable annuity reinsurance liabilities to be paid by the Company and (b) the variable annuity reinsurance assets to be paid by the reinsurers, after considering collateral. The Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy described in Note 12 to the Consolidated Financial Statements because assumptions related to future annuitant behavior are largely unobservable. As discussed further in Note 10 to the Consolidated Financial Statements, due to the reinsurance agreements covering these liabilities, the liabilities do not generally impact net income except for the change in nonperformance risk on the reinsurance recoverable, which is reported in benefit expenses and does not offset the nonperformance risk valuation on the liability. Variable annuity liabilities are established using capital market assumptions and assumptions related to future annuitant behavior (including mortality, lapse and annuity election rates).

Reinsurance (Policies)	12 Months Ended
Reinsurance (Policies)	Dec. 31, 2025
Reinsurance Disclosures [Abstract]
Reinsurance	Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 to the Consolidated Financial Statements for additional information on reinsurance. Accounting Policy. Reinsurance recoverables represent amounts due from reinsurers for both paid and unpaid claims of the Company's insurance businesses. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. Most reinsurance recoverables are classified as non-current assets. The current portion of reinsurance recoverables is reported in Other current assets and consists primarily of recoverables on paid claims expected to be settled within one year. Reinsurance recoverables are presented net of allowances, consisting primarily of an allowance for expected credit losses, which is recognized on reinsurance recoverable balances each period and adjusted through Medical costs and other benefit expenses. Estimates of the allowance for expected credit losses are based on internal and external data used to develop expected loss rates over the anticipated duration of the recoverable asset that vary by external credit rating and collateral level. Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value. Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 9 to the Consolidated Financial Statements.

Investments (Policies)	12 Months Ended
Investments (Policies)	Dec. 31, 2025
Investments [Abstract]
Investments	Accounting Policy. Debt securities, commercial mortgage loans, derivative financial instruments and short-term investments with contractual maturities during the next 12 months are classified on the balance sheet as current investments unless they are held as statutory deposits or restricted for other purposes, in which case they are classified as Long-term investments. All other investments are classified as Long-term investments, with the exception of equity security funds that are used in our cash management strategy and are classified as current investments. See Note 12 to the Consolidated Financial Statements for information about the valuation of the Company's investment portfolio. Accounting Policy. Debt securities (including bonds, mortgage and other asset-backed securities, and preferred stocks redeemable by the investor) are classified as available for sale and are carried at fair value with changes in fair value recorded either in Accumulated other comprehensive loss within Shareholders' equity or in credit loss expense based on fluctuations in the allowance for credit losses, as further discussed below. When the Company intends to sell or determines that it is more likely than not to be required to sell an impaired debt security, the excess of amortized cost over fair value is directly written down with a charge to Net investment gains/losses. Certain asset-backed securities are considered variable interest entities. See Note 13 to the Consolidated Financial Statements for additional information. The Company reviews declines in fair value from a debt security's amortized cost basis to determine whether a credit loss exists and, when appropriate, recognizes a credit loss allowance with a corresponding charge to credit loss expense, presented in Net investment gains/losses in the Company's Consolidated Statements of Income. The allowance for credit loss represents the excess of amortized cost over the greater of its fair value or the net present value of the debt security's projected future cash flows (based on qualitative and quantitative factors, including the probability of default and the estimated timing and amount of recovery). Each period, the allowance for credit loss is adjusted as needed through credit loss expense. The Company does not measure an allowance for credit losses for accrued interest receivables. When interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured, accrued interest, reported in Other current assets, is written off through a charge to Net investment income/losses and interest income is recognized on a cash basis. Review of Declines in Fair Value. Management reviews debt securities in an unrealized loss position to determine whether a credit loss allowance is needed based on criteria that include severity of decline; financial health and specific prospects of the issuer; and changes in the regulatory, economic or general market environment of the issuer's industry or geographic region. Accounting Policy. Equity securities with a readily determinable fair value consist primarily of public equity investments in the health care sector and mutual funds that invest in fixed income debt securities while those without a readily determinable fair value consist of private equity investments. Changes in the fair values of equity securities that have a readily determinable fair value are reported in Net investment gains/losses. Equity securities without a readily determinable fair value are carried at cost minus impairment plus or minus changes resulting from observable price changes. Accounting Policy. Commercial mortgage loans are carried at unpaid principal balances, net of an allowance for expected credit losses, and classified as either current or long-term investments based on their contractual maturities. Changes in the allowance for expected credit losses are recognized as credit loss expense and presented in Net investment gains/losses in the Company's Consolidated Statements of Income. Each period, the Company establishes (or adjusts) its allowance for expected credit losses for commercial mortgage loans. The allowance for expected credit losses is based on a credit risk category that is assigned to each loan at origination using key credit quality indicators, including debt service coverage and loan-to-value ratios. Credit risk categories are updated as key credit quality indicators change. An expected loss rate, assigned based on the credit risk category, is applied to each loan's unpaid principal balance to develop the aggregate allowance for expected credit losses. Commercial mortgage loans are considered impaired and written off against the allowance when it is probable that the Company will not collect all amounts due per the terms of the promissory note. In situations involving foreclosure or the use of real estate operations to recover value, the allowance for credit losses is determined by the extent to which the mortgage loan’s carrying value exceeds the fair value of its underlying collateral. Credit Quality. The Company regularly evaluates and monitors credit risk. Mortgage origination professionals employ an internal credit quality rating system designed to evaluate the relative risk of the transaction at origination that is then updated each year as part of the annual portfolio loan review. The Company evaluates and monitors credit quality on a consistent and ongoing basis. The annual portfolio review performed in the second quarter of 2025 confirmed ongoing strong overall credit quality in line with the previous year's results. Quality ratings are based on our evaluation of a number of key inputs related to the loan. The two most significant contributors to the credit quality rating are the debt service coverage and loan-to-value ratios. The debt service coverage ratio measures the amount of property cash flow available to meet annual interest and principal payments on debt, with a ratio below 1.0 indicating that there is not enough cash flow to cover the required loan payments. The loan-to-value ratio, commonly expressed as a percentage, compares the amount of the loan to the fair value of the underlying property collateralizing the loan. Accounting Policy. Policy loans, primarily associated with our corporate-owned life insurance business, are carried at unpaid principal balances plus accumulated interest, the total of which approximates fair value. These loans are collateralized by life insurance policy cash values and therefore have minimal exposure to credit loss. Interest rates are reset annually based on a rolling average of benchmark interest rates. Accounting Policy. Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans, and health care-related investments. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one-quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Depreciation is generally recorded using the straight-line method based on the estimated useful life of each asset. Investment real estate as of December 31, 2025 and 2024 is expected to be held longer than one year and may include real estate acquired through the foreclosure of commercial mortgage loans. Additionally, foreign currency swaps carried at fair value and certain restricted deposits are reported in the table below as "Other." See discussion below for information on the Company's accounting policies for derivative financial instruments. Other long-term investments and related commitments are diversified by issuer, property type and geographic region. These investments are primarily unconsolidated variable interest entities (see Note 13 to the Consolidated Financial Statements for additional information).Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income/losses. Accounting Policy. Security investments with maturities of greater than three months to one year from time of purchase are classified as short-term, available for sale and carried at fair value that approximates cost. Accounting Policy. When interest and principal payments on investments are current, the Company recognizes interest income when it is earned. The Company recognizes interest income on a cash basis when interest payments are delinquent based on contractual terms or when certain terms (interest rate or maturity date) of the investment have been restructured. For unconsolidated entities that are included in other long-term investments, investment income is generally recognized according to the Company's share of the reported income or loss on the underlying investments. Investment income attributed to the Company's separate accounts is excluded from our earnings because associated gains and losses generally accrue directly to separate account policyholders. Accounting Policy. Investment gains and losses are based on specifically identified assets and result from sales, investment asset write-downs, changes in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments.
Derivative Financial Instruments	Accounting Policy. Derivatives are recorded in our Consolidated Balance Sheets at fair value and are classified as current or non-current according to their contractual maturities. Further information on our policies for determining fair value are discussed in Note 12. The Company applies hedge accounting when derivatives are designated, qualified and highly effective as hedges. Under hedge accounting, the changes in fair value of the derivative and the hedged risk are generally recognized together and offset each other when reported in Shareholders' net income. Various qualitative or quantitative methods appropriate for each hedge are used to formally assess and document hedge effectiveness at inception and each period throughout the life of a hedge. Fair Value Hedges of the Foreign Exchange-Related Changes in Fair Values of Certain Foreign-Denominated Bonds: This program hedges the foreign exchange-related changes in fair values of certain foreign-denominated bonds. The notional value of these derivatives matches the amortized cost of the hedged bonds. A majority of these instruments are denominated in Euros, with the remaining instruments denominated in British Pounds Sterling and Australian Dollars. Swap fair values are reported in Long-term investments or Other non-current liabilities. Offsetting changes in fair values attributable to the foreign exchange risk of the swap contracts and the hedged bonds are reported in Net investment gains/losses. The portion of the swap contracts' changes in fair value excluded from the assessment of hedge effectiveness is recorded in Other comprehensive loss and recognized in Net investment income/losses as swap coupon payments are accrued, offsetting the foreign-denominated coupons received on the designated bonds. Net cash flows are reported in Operating activities, while exchanges of notional principal amounts are reported in Investing activities. Fair Value Hedges of the Interest Rate Exposure on the Company's Long-Term Debt: This program converts a portion of the interest rate exposure on the Company's long-term debt from fixed to variable rates. This more closely aligns the Company's interest expense with the interest income received on its cash equivalent and short-term investment balances. The variable rates are benchmarked to SOFR. Using fair value hedge accounting, the fair values of the swap contracts are reported in other assets or other liabilities. The critical terms of these swaps match those of the long-term debt being hedged. As a result, the carrying value of the hedged debt is adjusted to reflect changes in its fair value driven by SOFR. The effects of those adjustments on interest expense are offset by the effects of corresponding changes in the swaps' fair value. The net impact from the hedge reported in Interest expense and other reflects interest expense on the hedged debt at the variable interest rate. Cash flows relating to these contracts are reported in Operating activities. Net Investment Hedges of Certain Foreign Subsidiaries Operating Principally in Currencies Other than the U.S. Dollar: This program reduces the risk of changes in net assets due to changes in foreign currency spot exchange rates for certain foreign subsidiaries that conduct their business principally in currencies other than the U.S. Dollar. The notional value of hedging instruments matches the hedged amount of subsidiary net assets. Foreign currency swap contracts are denominated in Euros. The fair values of the foreign currency swap and forward contracts are reported in other assets or other liabilities. The changes in fair values of these instruments are reported in Other comprehensive loss, specifically in translation of foreign currencies. The portion of the change in fair values relating to foreign exchange spot rates will be recognized in earnings upon deconsolidation of the hedged foreign subsidiaries. Cash flows relating to these contracts are reported in Investing activities.

Disclosure of accounting policy for its derivative instruments and hedging activities.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-7

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/815/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(n))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Disclosure of accounting policy for investment in financial asset.

Fair Value Measures and Disclosures (Policies)	12 Months Ended
Fair Value Measures and Disclosures (Policies)	Dec. 31, 2025
Fair Value Disclosures [Abstract]
Fair Value Measurements	Accounting Policy. The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value. Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor. The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument's fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3). The Company estimates fair values using prices from third parties or internal pricing methods. Fair value estimates received from third-party pricing services are based on reported trade activity and quoted market prices when available and other market information that a market participant would use to estimate fair value. The internal pricing methods are performed by the Company's investment professionals and generally involve using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality as well as other qualitative factors. In instances where there is little or no market activity for the same or similar instruments, fair value is estimated using methods, models and assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. These valuation techniques involve some level of estimation and judgment that becomes significant with increasingly complex instruments or pricing models. The Company is responsible for determining fair value and for assigning the appropriate level within the fair value hierarchy based on the significance of unobservable inputs. The Company reviews methodologies, processes and controls of third-party pricing services and compares prices on a test basis to those obtained from other external pricing sources or internal estimates. The Company performs ongoing analyses of both prices received from third-party pricing services and those developed internally to determine that they represent appropriate estimates of fair value. The controls executed by the Company include evaluating changes in prices and monitoring for potentially stale valuations. The Company also performs sample testing of sales values to confirm the accuracy of prior fair value estimates. The minimal exceptions identified during these processes indicate that adjustments to prices are infrequent and do not significantly impact valuations. An annual due diligence review of the most significant pricing service is conducted to review their processes, methodologies and controls. This review includes a walk-through of inputs for a sample of securities held across various asset types to validate the documented pricing process. Level 1 Financial Assets Inputs for instruments classified in Level 1 include unadjusted quoted prices for identical assets in active markets accessible at the measurement date. Active markets provide pricing data for trades occurring at least weekly and include exchanges and dealer markets. Assets in Level 1 include actively traded U.S. government bonds and exchange-listed equity securities. Level 2 Financial Assets and Financial Liabilities Inputs for instruments classified in Level 2 include quoted prices for similar assets or liabilities in active markets, quoted prices from those willing to trade in markets that are not active, or other inputs that are market-observable or can be corroborated by market data for the term of the instrument. Such other inputs include market interest rates and volatilities, spreads, and yield curves. An instrument is classified in Level 2 if the Company determines that unobservable inputs are insignificant. Debt and Equity Securities. Third-party pricing services and internal methods often use recent trades of securities with similar features and characteristics because many debt securities do not trade daily. Pricing models are used to determine these prices when recent trades are not available. These models calculate fair values by discounting future cash flows at estimated market interest rates. Such market rates are derived by calculating the appropriate spreads over comparable U.S. Treasury securities based on the credit quality, industry and structure of the asset. Typical inputs and assumptions to pricing models include, but are not limited to, a combination of benchmark yields, reported trades, issuer spreads, liquidity, benchmark securities, bids, offers, reference data, and industry and economic events. For mortgage-backed securities, inputs and assumptions may also include characteristics of the issuer, collateral attributes, prepayment speeds and credit rating. Nearly all of these instruments are valued using recent trades or pricing models. Short-term Investments are carried at fair value that approximates cost. The Company compares market prices for these securities to recorded amounts on a regular basis to validate that current carrying amounts approximate exit prices. The short-term nature of the investments and corroboration of the reported amounts over the holding period support their classification in Level 2. Derivative Assets and Liabilities classified in Level 2 represent over-the-counter instruments, such as foreign currency forward and swap contracts. Fair values for these instruments are determined using market-observable inputs, including forward currency and interest rate curves and widely published market-observable indices. Credit risk related to the counterparty and the Company is considered when estimating the fair values of these derivatives. The nature and use of these derivative financial instruments are described in Note 11. Level 3 Financial Assets and Financial Liabilities Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9E, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy. The Company classifies certain newly issued, privately placed, complex or illiquid securities in Level 3. Approximately 4% of debt securities are priced using significant unobservable inputs and classified in this category. Fair values of mortgage and other asset-backed securities, as well as corporate and government debt securities, are primarily determined using pricing models that incorporate the specific characteristics of each asset and related assumptions, including the investment type and structure, credit quality, industry and maturity date in comparison to current market indices, spreads, and liquidity of assets with similar characteristics. Inputs and assumptions for pricing may also include characteristics of the issuer, collateral attributes, and prepayment speeds for mortgage and other asset-backed securities. Recent trades in the subject security or similar securities are assessed when available, and the Company may also review published research in its evaluation, as well as the issuer's financial statements. Information about Debt Securities. The significant unobservable input used to value our corporate and government debt securities, and mortgage and other asset-backed securities, is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security. Total gains and losses included in Shareholders' net income in the table above are reflected in the Consolidated Statements of Income as Net investment gains/losses and as Net investment income/losses. Gains and losses included in Other comprehensive loss, net of tax, in the table above are reflected in Net unrealized (depreciation) appreciation on securities and derivatives in the Consolidated Statements of Comprehensive Income. Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads.Assets and Liabilities Measured at Fair Value under Certain Conditions Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.
Separate Accounts	Accounting Policy. Separate account assets and liabilities are contractholder funds maintained in accounts with specific investment objectives. Our subsidiaries or external advisors manage invested assets of separate accounts on behalf of contractholders, including The Cigna Group Pension Plan, variable universal life products sold through our corporate-owned life insurance products and the run-off businesses. The assets of these accounts are legally segregated and are not subject to claims that arise out of any of the Company's other businesses. These separate account assets are carried at fair value with equal amounts recorded for related separate account liabilities. The investment income and fair value gains and losses of separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. Fees and charges earned for mortality risks, asset management or administrative services are reported in either Premiums or Fees and other revenues. Investments that are measured using the practical expedient of net asset value are excluded from the fair value hierarchy. The separate account activity for the years ended December 31, 2025 and 2024 was primarily driven by changes in the market values of the underlying separate account investments. Separate account assets classified in Level 1 primarily include exchange-listed equity securities. Level 2 assets primarily include corporate and structured bonds valued using recent trades of similar securities or pricing models that discount future cash flows at estimated market interest rates, as described above, and actively traded institutional and retail mutual fund investments. Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly issued, privately placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans.

Variable Interest Entities (Policies)	12 Months Ended
Variable Interest Entities (Policies)	Dec. 31, 2025
Variable Interest Entities [Abstract]
Variable Interest Entities	When the Company becomes involved with a variable interest entity and when there is a change in the Company's involvement with an entity, the Company must determine if it is the primary beneficiary and must consolidate the entity. The Company is considered the primary beneficiary if it has the power to direct the entity's most significant economic activities and has the right to receive benefits or obligation to absorb losses that could be significant to the entity. The Company evaluates the following criteria: the structure and purpose of the entity; the risks and rewards created by and shared through the entity; and the Company's ability to direct its activities, receive its benefits and absorb its losses relative to the other parties involved with the entity, including its sponsors, equity holders, guarantors, creditors and servicers. Securities Limited Partnerships and Real Estate Limited Partnerships. The Company owns interests in securities limited partnerships and real estate limited partnerships that are defined as unconsolidated variable interest entities. These partnerships invest in the equity or mezzanine debt of privately held companies and real estate properties. General partners unaffiliated with the Company control decisions that most significantly impact the partnership's operations, and the limited partners do not have substantive kick-out or participating rights. We perform ongoing qualitative analyses of our involvement with these variable interest entities to determine if consolidation is required.

Collectively Significant Operating Unconsolidated Subsidiaries (Policies)	12 Months Ended
	Dec. 31, 2025
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Operating Joint Ventures	Accounting Policy. We record in our Consolidated Statements of Income our proportionate share of net income or loss generated by operating joint ventures within Fees and other revenues. In certain instances, income or loss is reported on a one-month lag due to the timing of when financial information is received.

Accumulated Other Comprehensive Income (Loss) (Policies)	12 Months Ended
	Dec. 31, 2025
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
AOCI	Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.

Pension (Policies)	12 Months Ended
Pension (Policies)	Dec. 31, 2025
Retirement Benefits [Abstract]
Pension Plans	Accounting Policy. The Company measures the assets and liabilities of its domestic pension plans as of December 31. Benefit obligations are measured at the present value of estimated future payments based on actuarial assumptions. The Company uses the corridor method to account for changes in the benefit obligation when actual results differ from those assumed or when assumptions change. These changes are called net unrecognized actuarial gains (losses). Under the corridor method, net unrecognized actuarial gains (losses) are initially recorded in Accumulated other comprehensive loss. When the unrecognized gain (loss) exceeds 10% of the benefit obligation, that excess is amortized to expense over the expected remaining lives of plan participants. The net plan expense is reported in Interest expense and other in the Consolidated Statements of Income. We measure plan assets at fair value for balance sheet purposes and to measure pension benefit costs. When the actual return differs from the expected return, those differences are reflected in the net unrealized actuarial gain (loss) discussed above. The Company develops discount rates by applying actual annualized yields for high-quality bonds by duration to the expected pension plan liability cash flows. The bond yields represent a diverse mix of actively traded, high-quality fixed-income securities that have an above-average return at each duration, as management believes this approach is representative of the yield achieved through plan asset investment strategy. The expected long-term return on plan assets was developed considering historical long-term actual returns, expected long-term market conditions, plan asset mix and management's plan asset investment strategy. See Note 12 to the Consolidated Financial Statements for further details regarding how fair value is determined, including the level within the fair value hierarchy and the procedures we use to validate fair value measurements. The Company classifies substantially all debt securities in Level 2 for pension plan assets. These assets are valued using recent trades of similar securities or are fund investments priced using their daily net asset value that is the exit price. All domestic equity securities and international equity funds within pension assets are classified in Level 3. Securities partnerships, real estate and hedge funds are valued using net asset value as a practical expedient and are excluded from the fair value hierarchy. See Note 12 to the Consolidated Financial Statements for additional disclosures related to these assets invested in the separate accounts of the Company's subsidiary. Certain securities as described in Note 12 to the Consolidated Financial Statements, as well as commercial mortgage loans and guaranteed deposit account contracts, are classified in Level 3 because unobservable inputs used in their valuation are significant.

Employee Incentive Plans (Policies)	12 Months Ended
Employee Incentive Plans (Policies)	Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]
Employee Incentive Plans	The Company records compensation expense for stock and option awards over their vesting periods primarily based on the estimated fair value at the grant date. Fair value is determined differently for each type of award as discussed below. Accounting Policy. The Company awards options to purchase The Cigna Group common stock at the market price of the stock on the grant date. Options vest over periods ranging from one year to three years and expire no later than 10 years from grant date. Fair value is estimated using the Black-Scholes option pricing model by applying the assumptions presented below. That fair value is reduced by options expected to be forfeited during the vesting period. The Company estimates forfeitures at the grant date based on our experience and adjusts the expense to reflect actual forfeitures over the vesting period. The fair value of options, net of forfeitures, is recognized in Selling, general and administrative expenses on a straight-line basis over the vesting period. Accounting Policy. Fair value of restricted stock awards is equal to the market price of The Cigna Group common stock on the date of grant. This fair value is reduced by awards that are expected to be forfeited. At the grant date, the Company estimates forfeitures based on experience and adjusts the expense to reflect actual forfeitures over the vesting period. This fair value, net of forfeitures, is recognized in Selling, general and administrative expenses over the vesting period on a straight-line basis. Accounting Policy. Compensation expense for SPSs is recorded over the performance period. Fair value is determined at the grant date for "market condition" SPSs using a Monte Carlo simulation model and not subsequently adjusted regardless of the final outcome. Expense is initially accrued for "performance condition" SPSs based on the most likely outcome but evaluated for adjustment each period for updates in the expected outcome. Expense is adjusted to the actual outcome (number of shares awarded multiplied by the share price at the grant date) at the end of the performance period.

Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.C.Q3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.1.Q5)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.3.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2.Q6)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/718/tableOfContent

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Goodwill, Other Intangibles and Property and Equipment (Policies)	12 Months Ended
	Dec. 31, 2025
Goodwill Other Intangibles And Property And Equipment [Abstract]
Goodwill	Accounting Policy. Goodwill represents the excess of the cost of businesses acquired over the fair value of their net assets. The resulting goodwill is assigned to those reporting units expected to realize cash flows from the acquisition, based on those reporting units' relative fair values. The Company's reporting units are aligned with its operating segments as described in Note 1. The Company conducts its annual quantitative evaluation for goodwill impairment during the third quarter at the reporting unit level and writes it down through Shareholders' net income if impaired. On a quarterly basis, the Company performs a qualitative impairment assessment to determine if events or changes in circumstances indicate that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. The fair value of a reporting unit is generally estimated based on discounted cash flow analysis and market approach models using assumptions that the Company believes a hypothetical market participant would use to determine a current transaction price. Following a change in reporting units or held for sale determination, goodwill is allocated using relative fair value. The significant assumptions and estimates used in determining fair value primarily include the discount rate and future cash flows. A discount rate is selected to correspond with each reporting unit's weighted average cost of capital, consistent with that used for investment decisions considering the specific and detailed operating plans and strategies within each reporting unit. Projections of future cash flows differ by reporting unit and are consistent with our ongoing strategic projections. Future cash flows for Evernorth Health Services reporting units are primarily driven by the forecasted gross margins of the business, as well as operating expenses and long-term growth rates. Future cash flows for our other reporting units are primarily driven by forecasted revenues, benefit expenses, operating expenses and long-term growth rates.
Other Intangible Assets	Accounting Policy. The Company's Other intangible assets primarily include purchased customer and producer relationships, trademarks, and provider networks. The fair value of purchased customer relationships and the amortization method were determined as of the dates of purchase using an income approach that relies on projected future net cash flows, including key assumptions for customer attrition and discount rates. The Company's definite-lived intangible assets are amortized on an accelerated or straight-line basis, reflecting their pattern of economic benefits, over periods from 1 year to 30 years. Management revises amortization periods if it believes there has been a change in the length of time that an intangible asset will continue to have value. Costs incurred to renew or extend the terms of these intangible assets are generally expensed as incurred. The Company's amortized intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. If the total of the expected future undiscounted cash flows generated by the underlying asset group is less than the carrying amount of the asset group, the Company recognizes an impairment charge equal to the difference between the carrying value of the asset group and its estimated fair value. The Company's indefinite-lived intangible assets are reviewed for impairment at least annually by comparing their fair value with their carrying value. If the carrying value exceeds fair value, that excess is recognized as an impairment loss.
Property and Equipment	Accounting Policy. Property and equipment is carried at cost less accumulated depreciation. Cost includes interest, real estate taxes and other costs incurred during construction when applicable. Internal-use software that is acquired, developed or modified solely to meet the Company's internal needs, with no plan to market externally, is also included in this category. Costs directly related to acquiring, developing or modifying internal-use software are capitalized. The Company calculates depreciation and amortization principally using the straight-line method generally based on the estimated useful life of each asset as follows: buildings and improvements, 10 to 40 years; purchased and internally developed software, 3 to 5 years; and furniture and equipment (including computer equipment), 3 to 10 years. Improvements to leased facilities are depreciated over the lesser of the remaining lease term or the estimated life of the improvement. The Company considers events and circumstances that would indicate the carrying value of property, equipment or capitalized software might not be recoverable. An impairment charge is recorded if the Company determines the carrying value of any of these assets is not recoverable. The Company also reviews and shortens the estimated useful lives of these assets, if necessary.

Income Taxes (Policies)	12 Months Ended
Income Taxes (Policies)	Dec. 31, 2025
Income Tax Disclosure [Abstract]
Income Taxes	Accounting Policy. Deferred income taxes are reflected in the Consolidated Balance Sheets for differences between the financial and income tax reporting bases of the Company's underlying assets and liabilities and are established based upon enacted tax rates and laws. Deferred income tax assets are recognized when available evidence indicates that realization is more likely than not, and a valuation allowance is established to the extent this standard is not met. The deferred income tax provision generally represents the net change in deferred income tax assets and liabilities during the reporting period excluding adjustments to Accumulated other comprehensive income (loss) or amounts recorded in connection with a business combination. The current income tax provision generally represents estimated amounts due on income tax returns for the year reported to various jurisdictions plus the effect of any uncertain tax positions. The Company uses the deferral method of accounting on investments that generate tax credits. Under this method, the investment tax credits are recognized as a reduction to the related asset, which are generally reported in Other assets in the Consolidated Balance Sheets. The Company recognizes a liability for uncertain tax positions if management believes the probability that the positions will be sustained is 50% or less. For uncertain positions that management believes are more likely than not to be sustained, the Company recognizes a liability based upon management's estimate of the most likely settlement outcome with the taxing authority. The liabilities for uncertain tax positions are classified as current when the position is expected to be settled within 12 months or the statute of limitation expires within 12 months. Income taxes attributable to the Company's foreign operations are provided using the foreign jurisdictions' applicable tax rate. The Company prospectively adopted ASU 2023-09, Improvements to Income Tax Disclosures. As a result, disclosures for 2025 reflect the requirements of ASU 2023-09, including the reconciliation of the statutory federal income tax rate and disaggregated tax payment information. Prior years (2024 and 2023) are presented under the previous disclosure requirements. The Company classifies net interest expense on uncertain tax positions as a component of income tax expense and in Other non-current liabilities in the Consolidated Balance Sheets.

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

Commitment and Contingencies (Policies)	12 Months Ended
Commitment and Contingencies (Policies)	Dec. 31, 2025
Commitments and Contingencies Disclosure [Abstract]
Guarantees	Financial Guarantees: Retiree and Life Insurance BenefitsThe Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments.An additional liability is established if management believes that the Company will be required to make payments under the guarantees;Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.Certain Other GuaranteesThe Company had indemnification obligations as of December 31, 2025 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations, or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.
Commitment and Contingencies	Accounting Policy. The Company accrues for legal and regulatory matters when a loss contingency is both probable and estimable. The estimated loss is generally recorded in Selling, general and administrative expenses and represents the Company's best estimate of the loss contingency. If the loss estimate is a range, the Company accrues the minimum amount in the range if no amount is better than any other estimated amount in the range. Legal costs to defend the Company's litigation and arbitration matters are expensed as incurred in cases that the Company cannot reasonably estimate the ultimate cost to defend. If the Company can reasonably estimate the cost to defend, a liability for these costs is accrued when the claim is reported.

Segment Reporting (Policies)	12 Months Ended
Segment Reporting (Policies)	Dec. 31, 2025
Segment Reporting [Abstract]
Segment Information	Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The Chairman and Chief Executive Officer is the chief operating decision maker ("CODM") responsible for making decisions about resources to be allocated to each segment and assessing its performance. The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management, including the CODM, believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability to enable resource allocation decisions. We define pre-tax adjusted income (loss) from operations as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management, including the CODM, believes they are not indicative of past or future underlying performance of the business.

Disclosure of accounting policy for segment reporting.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 36
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-36

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 29
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-29

Discontinued Operations and Disposal Groups [Abstract]

Accounts Receivable, Net (Tables)

12 Months Ended

Dec. 31, 2025

Receivables [Abstract]

Accounts Receivable, Net

The following amounts were included within Accounts receivable, net:


(In millions)	December 31, 2025		December 31, 2024
Noninsurance customer receivables	$	14,707	$	11,879
Pharmaceutical manufacturers receivables	12,437		10,914
Insurance customer receivables	1,385		3,199
Other receivables	239		162
Total			$	26,154
Accounts receivable, net classified as assets of businesses held for sale			(1,927)
Total	$	28,768	$	24,227

Supplier Finance Program (Tables)

12 Months Ended

Dec. 31, 2025

Payables and Accruals [Abstract]

Supplier Finance Program

The obligations confirmed as valid within the Program by the financial institutions were as follows and are reflected in Accounts payable in the Consolidated Balance Sheets:


	For the Years Ended December 31,
(in millions)	2025		2024
Confirmed obligations outstanding at the beginning of the year	$	1,637	$	1,536
Invoices confirmed during the year	39,108		39,091
Less: confirmed invoices paid during the year	39,143		38,990
Confirmed obligations outstanding at the end of the year	$	1,602	$	1,637

Divestiture (Tables)

12 Months Ended

Dec. 31, 2025

Divestiture


(In millions)	December 31, 2024
Cash and cash equivalents	$	1,339
Investments	1,444
Accounts receivable, net	1,927
Other assets, including Goodwill (1)	2,294
Total assets of businesses held for sale	7,004
Insurance and contractholder liabilities	1,579
All other liabilities	831
Total liabilities of businesses held for sale	$	2,410

(1) Included Goodwill of $94 million.

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 20
-Topic 205
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3

Computation of Basic and Diluted Earnings Per Share

Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2025

Earnings Per Share [Abstract]

Basic and diluted earnings per share were computed as follows:




	For the Years Ended December 31,
	2025						2024						2023
(Shares in thousands, dollars in millions, except per share amounts)	Basic		Effect of Dilution		Diluted		Basic		Effect of Dilution		Diluted		Basic		Effect of Dilution		Diluted
Shareholders' net income	$	5,957			$	5,957	$	3,434			$	3,434	$	5,164			$	5,164
Shares:
Weighted average	266,744				266,744		280,294				280,294		293,892				293,892
Common stock equivalents			1,819		1,819				2,924		2,924				2,990		2,990
Total shares	266,744		1,819		268,563		280,294		2,924		283,218		293,892		2,990		296,882
Earnings per share	$	22.33	$	(0.15)	$	22.18	$	12.25	$	(0.13)	$	12.12	$	17.57	$	(0.18)	$	17.39

Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share

The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:



	For the Years Ended December 31,
(In millions)	2025	2024	2023
Anti-dilutive options	2.0	1.1	0.9

Debt (Tables)

12 Months Ended

Dec. 31, 2025

Debt Disclosure [Abstract]

Outstanding amounts of debt and finance leases

The outstanding amounts of debt (net of issuance costs, discounts or premiums) and finance leases were as follows:


(In millions)	December 31, 2025		December 31, 2024
Short-term debt
Commercial paper	$	—	$	880
$900 million, 3.250% Notes due April 2025	—		897
$1,216 million, 4.125% Notes due November 2025	—		1,215

$550 million, 1.250% Notes due March 2026	549		—
Other, including finance leases	43		43
Total short-term debt	$	592	$	3,035
Long-term debt
$1,284 million, 4.500% Notes due February 2026	$	—	$	1,285
$700 million, 5.685% Notes due March 2026	—		699
$550 million, 1.250% Notes due March 2026	—		549
$1,500 million, 3.400% Notes due March 2027	1,481		1,466
$259 million, 7.875% Debentures due May 2027	260		259
$600 million, 3.050% Notes due October 2027	599		598
$3,800 million, 4.375% Notes due October 2028	3,792		3,790
$1,000 million, 5.000% Notes due May 2029	996		995
$1,400 million, 2.400% Notes due March 2030 (1)	1,406		1,386
$1,000 million, 4.500% Notes due September 2030	993		—
$1,500 million, 2.375% Notes due March 2031 (1)	1,420		1,384
$750 million, 5.125% Notes due May 2031 (1)	750		745
$1,250 million, 4.875% Notes due September 2032	1,243		—
$45 million, 8.080% Step Down Notes due January 2033	45		45
$800 million, 5.400% Notes due March 2033 (1)	796		795
$1,250 million, 5.250% Notes due February 2034 (1)	1,250		1,226
$1,500 million, 5.250% Notes due January 2036	1,488		—
$190 million, 6.150% Notes due November 2036	190		190
$2,200 million, 4.800% Notes due August 2038 (1)	2,194		2,193
$750 million, 3.200% Notes due March 2040	748		744
$121 million, 5.875% Notes due March 2041	119		119
$448 million, 6.125% Notes due November 2041	484		485
$317 million, 5.375% Notes due February 2042	315		315
$1,500 million, 4.800% Notes due July 2046	1,469		1,469
$1,000 million, 3.875% Notes due October 2047	990		990
$3,000 million, 4.900% Notes due December 2048	2,972		2,971
$1,184 million, 3.400% Notes due March 2050	1,172		1,237
$1,429 million, 3.400% Notes due March 2051	1,410		1,479
$1,500 million, 5.600% Notes due February 2054	1,486		1,482
$750 million, 6.000% Notes due January 2056	735		—
Other, including finance leases	68		41
Total long-term debt	$	30,871	$	28,937

(1)The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments as of December 31, 2025. See Note 11 to the Consolidated Financial Statements for further information about the Company's interest rate risk management and these derivative instruments.

Debt Issuance. In September 2025, we issued $4.5 billion of new senior notes, as detailed in the table below. The proceeds from this debt issuance were used to repay the $2.0 billion of loans outstanding under the Term Loan Facility as described below. We used the remaining net proceeds for general corporate purposes, including investments and repayment of indebtedness. Interest on this debt is paid semiannually.

Principal

Maturity Date

Interest Rate

Net Proceeds

Redeemable Date(1)

"Make Whole" Premium (2)

$1,000 million

September 15, 2030

4.500%

$994 million

August 15, 2030

15

$1,250 million

September 15, 2032

4.875%

$1,245 million

July 15, 2032

15

$1,500 million

January 15, 2036

5.250%

$1,490 million

October 15, 2035

15

$750 million

January 15, 2056

6.000%

$736 million

July 15, 2055

20

(1) Redeemable at any time prior to this date at a "make whole" premium, defined below. Redeemable at par on or after this date.

(2) "Make whole" premium calculated using a comparable U.S. Treasury rate plus the amount of basis points set forth in this column.

Maturities of Outstanding Long-Term Debt

Maturities of outstanding long-term debt as of December 31, 2025 are as follows:


(In millions)	Scheduled Maturities (1)
2026	$	550
2027	$	2,359
2028	$	3,800
2029	$	1,000
2030	$	2,400
Maturities after 2030	$	21,485

(1) Long-term debt maturity amounts include current maturities of long-term debt. Finance leases are excluded from this table.

Common and Preferred Stock (Tables)

12 Months Ended

Dec. 31, 2025

Share Activity

The following table presents the share activity of The Cigna Group:


	For the Years Ended December 31,
(Shares in thousands)	2025	2024	2023
Common: Par value $0.01; 600,000 shares authorized
Outstanding- January 1,	273,789	292,504	298,676
Net issued for stock option exercises and other benefit plans	1,569	2,198	1,619
Repurchased common stock	(11,894)	(20,913)	(7,791)
Outstanding- December 31,	263,464	273,789	292,504
Treasury stock	141,136	128,723	107,390
Issued- December 31,	404,600	402,512	399,894

Dividend Payments

The following table provides details of the Company's dividend payments:


Record Date	Payment Date	Amount per Share	Total Amount Paid (in millions)
2025
March 5, 2025	March 20, 2025	$1.51	$412
June 3, 2025	June 18, 2025	$1.51	$401
September 4, 2025	September 18, 2025	$1.51	$402
December 4, 2025	December 18, 2025	$1.51	$396
2024
March 6, 2024	March 21, 2024	$1.40	$401
June 4, 2024	June 20, 2024	$1.40	$392
September 4, 2024	September 19, 2024	$1.40	$390
December 4, 2024	December 19, 2024	$1.40	$384
2023
March 8, 2023	March 23, 2023	$1.23	$368
June 7, 2023	June 22, 2023	$1.23	$362
September 6, 2023	September 21, 2023	$1.23	$362
December 6, 2023	December 21, 2023	$1.23	$358

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-4

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-5

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481142/505-10-45-2

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-10

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

Insurance and Contractholder Liabilities

Insurance and Contractholder Liabilities (Tables)

12 Months Ended

Dec. 31, 2025

Insurance Loss Reserves [Abstract]

The Company's insurance and contractholder liabilities were comprised of the following:


	December 31, 2025						December 31, 2024
(In millions)	Current		Non-current		Total		Current		Non-current		Total
Unpaid claims and claim expenses
Cigna Healthcare	$	4,180	$	61	$	4,241	$	4,932	$	86	$	5,018
Other	167		176		343		147		144		291
Future policy benefits
Cigna Healthcare	38		153		191		91		507		598
Other Operations	142		3,081		3,223		157		3,140		3,297
Contractholder deposit funds
Cigna Healthcare	—		—		—		9		115		124
Other Operations	336		5,778		6,114		366		5,958		6,324
Market risk benefits	25		649		674		25		760		785
Unearned premiums	822		40		862		753		31		784
Total							6,480		10,741		17,221
Insurance and contractholder liabilities classified as liabilities of businesses held for sale (1)							(1,092)		(487)		(1,579)
Total insurance and contractholder liabilities	$	5,710	$	9,938	$	15,648	$	5,388	$	10,254	$	15,642

(1) Amounts classified as liabilities of businesses held for sale include $983 million of Unpaid claims, $408 million of Future policy benefits, $85 million of Unearned premiums and $103 million of Contractholder deposit funds as of December 31, 2024.

Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:


	For the Years Ended December 31,
(In millions)	2025 (1)		2024 (1)		2023 (1)
Beginning balance	$	5,018	$	5,092	$	4,176
Less: Reinsurance and other amounts recoverable	159		236		221
Beginning balance, net	4,859		4,856		3,955

Incurred costs related to:
Current year	33,816		38,347		35,953
Prior years	(342)		(456)		(279)
Total incurred	33,474		37,891		35,674
Paid costs related to:
Current year	28,769		33,718		31,322
Prior years	4,147		4,170		3,451
Total paid	32,916		37,888		34,773
Less: Divestiture and other	1,323		—		—
Ending balance, net	4,094		4,859		4,856
Add: Reinsurance and other amounts recoverable	147		159		236
Ending balance	$	4,241	$	5,018	$	5,092

(1) Includes unpaid claims amounts classified as liabilities of businesses held for sale prior to the completion of the HCSC transaction. As of December 31, 2024 and December 31, 2023, includes $983 million and $823 million, respectively, classified as liabilities of businesses held for sale.

Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses

Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:


	For the Years Ended December 31,
	2025				2024
(Dollars in millions)	$		% (1)		$		% (2)
Actual completion factors and other	$	200	0.5	%	$	223	0.6	%
Medical cost trend	142		0.4		233		0.7

Total favorable variance	$	342	0.9	%	$	456	1.3	%

(1)Percentage of current year incurred costs as reported for the year ended December 31, 2024.

(2)Percentage of current year incurred costs as reported for the year ended December 31, 2023.

Incurred and Paid Claims Development

The following table depicts the incurred and paid claims development and unpaid claims liability as of December 31, 2025 (net of reinsurance) reported in the Cigna Healthcare segment. The information about incurred and paid claims development for the year ended December 31, 2024 is presented as supplementary information and is unaudited.


	Incurred Costs
Incurral Year	2024 (Unaudited)		2025		Unpaid Claims and Claim Expenses
(In millions)
2024	$	37,179	$	36,853	88
2025			33,530		4,006
Cumulative incurred costs for the periods presented			$	70,383

	Cumulative Costs Paid
Incurral Year	2024 (Unaudited)		2025
(In millions)
2024	$	32,719	$	36,544
2025			28,635
Cumulative paid costs for the periods presented			$	65,179

Outstanding liabilities for the periods presented, net of reinsurance			$	5,204
Divestiture and other			(1,110)
Net unpaid claims and claims expenses - Cigna Healthcare			4,094
Reinsurance and other amounts recoverable			147
Unpaid claims and claim expenses - Cigna Healthcare			$	4,241

Future Policy Benefit Activity

The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:


	As of
	December 31, 2025		December 31, 2024
Interest accretion rate	5.64	%	5.64	%
Current discount rate	5.18	%	5.42	%
Weighted average duration	10.6 years		10.8 years

Summary of Market Risk Benefit

Market risk benefits activity was as follows:


	For the Years Ended December 31,
(In millions)	2025		2024
Balance, beginning of year	$	785	$	1,003
Balance, beginning of year, before the effect of nonperformance risk (own credit risk)	838		1,085
Changes due to expected run-off	(20)		(12)
Changes due to capital markets versus expected	(63)		(233)
Changes due to policyholder behavior versus expected	(24)		(39)
Assumption changes	(17)		37
Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)	714		838
Nonperformance risk (own credit risk), end of period	(40)		(53)
Balance, end of period	$	674	$	785
Reinsured market risk benefit, end of period	$	712	$	836

Account Value, Net Amount at Risk and the Number of Contractholders for Guarantees Assumed in the Event of Death

The following table presents the account value, net amount at risk, average attained age of contractholders (weighted by exposure) and the number of contractholders for guarantees assumed by the Company. The net amount at risk is the amount that the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. As of December 31, 2025, the account value and net amount at risk decreased, reflecting a reduction in contractholders and favorable equity market performance. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded.


(Dollars in millions, excludes impact of reinsurance ceded)	December 31, 2025		December 31, 2024
Account value	$	7,281	$	7,777
Net amount at risk	$	1,115	$	1,283
Average attained age of contractholders (weighted by exposure)	78.3 years		77.7 years
Number of contractholders (estimated)	110,000		130,000

Reinsurance (Tables)

12 Months Ended

Dec. 31, 2025

Reinsurance Disclosures [Abstract]

Reinsurance Recoverables

The Company's reinsurance recoverables as of December 31, 2025 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:


(In millions)	Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable		Collateral Provisions Exist That May Mitigate Risk of Credit Loss (1)		No Collateral		Total
Ongoing operations
A- equivalent and higher current ratings (2)	$	—	$	5	$	211	$	216
BBB- to BBB+ equivalent current credit ratings (2)	—		—		64		64
Not rated	85		1		4		90
Acquisition, disposition or run-off activities
BBB+ equivalent and higher current ratings (2)(3)	288		2,838		32		3,158

Not rated	—		5		1		6
Total reinsurance recoverables before market risk benefits	$	373	$	2,849	$	312	$	3,534
Allowance for uncollectible reinsurance							(23)
Market risk benefits							712
Total reinsurance recoverables (4)							$	4,223

(1)Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.

(2)Certified by a nationally recognized statistical ratings organization ("NRSRO").

(3)Comprised of six reinsurers, of which 76% is held by two reinsurers, Lincoln National Life Insurance Company and Lincoln Life and Annuity Company of New York.

(4)Includes $120 million of current reinsurance recoverables that are reported in Other current assets.

Investments (Tables)

12 Months Ended

Dec. 31, 2025

Investments [Abstract]

Investments by category and current or long-term classification

The following table summarizes the Company's investments by category and current or long-term classification:


	December 31, 2025						December 31, 2024
(In millions)	Current		Long-Term		Total		Current		Long-Term		Total
Debt securities	$	691	$	7,671	$	8,362	$	463	$	8,960	$	9,423
Equity securities	22		3,534		3,556		7		554		561
Commercial mortgage loans	86		1,147		1,233		108		1,243		1,351
Policy loans	—		1,082		1,082		—		1,156		1,156
Other long-term investments	—		5,037		5,037		—		4,576		4,576
Short-term investments	257		—		257		170		—		170
Total							$	748	$	16,489	$	17,237
Investments classified as assets of businesses held for sale (1)							(83)		(1,361)		(1,444)
Investments per Consolidated Balance Sheets	$	1,056	$	18,471	$	19,527	$	665	$	15,128	$	15,793

(1) Investments related to the HCSC transaction that were held for sale as of December 31, 2024. These investments were primarily comprised of debt securities.

Debt Securities by Contractual Maturity

The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of December 31, 2025:



(In millions)	Amortized Cost		Fair Value
Due in one year or less	$	695	$	598
Due after one year through five years	3,700		3,703
Due after five years through ten years	2,030		1,995
Due after ten years	1,968		1,822
Mortgage and other asset-backed securities	267		244
Total	$	8,660	$	8,362

Gross Unrealized Appreciation (Depreciation) on Debt Securities

Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:


(In millions)	Amortized Cost		Allowance for Credit Loss		Unrealized Appreciation		Unrealized Depreciation		Fair Value
December 31, 2025
Federal government and agency	$	215	$	—	$	15	$	(3)	$	227
State and local government	24		—		1		—		25
Foreign government	450		—		12		(6)		456
Corporate	7,704		(137)		175		(332)		7,410
Mortgage and other asset-backed	267		—		3		(26)		244
Total	$	8,660	$	(137)	$	206	$	(367)	$	8,362


December 31, 2024
Federal government and agency	$	276	$	—	$	14	$	(9)	$	281
State and local government	37		—		1		(1)		37
Foreign government	350		—		5		(11)		344
Corporate	9,091		(111)		102		(659)		8,423
Mortgage and other asset-backed	371		—		1		(34)		338
Total	$	10,125	$	(111)	$	123	$	(714)	$	9,423

Summary of Debt Securities with a Decline in Fair Value

The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded (by investment grade and the length of time these securities have been in an unrealized loss position). Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased.


	December 31, 2025							December 31, 2024
(Dollars in millions)	Fair Value		Amortized Cost		Unrealized Depreciation		Number of Issues	Fair Value		Amortized Cost		Unrealized Depreciation		Number of Issues
One year or less
Investment grade	$	384	$	386	$	(2)	149	$	1,203	$	1,227	$	(24)	545
Below investment grade	120		125		(5)		239	245		250		(5)		739
More than one year
Investment grade	3,044		3,382		(338)		799	4,687		5,319		(632)		1,297
Below investment grade	185		207		(22)		86	416		469		(53)		123
Total	$	3,733	$	4,100	$	(367)	1,273	$	6,551	$	7,265	$	(714)	2,704

Equity Security Investments

The following table provides the values of the Company's equity security investments:


	December 31, 2025				December 31, 2024
(In millions)	Cost		Carrying Value		Cost		Carrying Value
Equity securities with readily determinable fair values	$	78	$	92	$	635	$	37
Equity securities with no readily determinable fair value	6,792		3,464		3,215		524
Total	$	6,870	$	3,556	$	3,850	$	561

Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio

The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:


(Dollars in millions)	December 31, 2025					December 31, 2024
Loan-to-Value Ratio	Carrying Value		Average Debt Service Coverage Ratio	Average Loan-to-Value Ratio		Carrying Value		Average Debt Service Coverage Ratio	Average Loan-to-Value Ratio
Below 60%	$	355	2.13			$	547	2.07
60% to 79%	694		1.81			595		1.83
80% to 100%	184		0.79			209		0.51



Total	$	1,233	1.72	71	%	$	1,351	1.70	69	%

Carrying Value Information for Other Long-Term Investments

The following table provides unfunded commitment and carrying value information for these investments. The Company expects to disburse approximately 30% of the committed amounts in 2026.

Our limited partnership investments are reduced as the Company receives cash distributions for returns on its investment that were previously recognized in Net investment income/losses. The amount of these cash distributions was $314 million in 2025, $344 million in 2024 and $253 million in 2023.



					Unfunded Commitments as of
	Carrying Value as of December 31,
(In millions)	2025		2024		December 31, 2025
Real estate investments	$	1,895	$	1,763	$	1,106
Securities partnerships	2,948		2,587		2,058
Other	194		226		—
Total	$	5,037	$	4,576	$	3,164

Summary of Derivative Instruments Held

The following table summarizes the types and notional quantity of derivative instruments held by the Company:


	Notional Value as of
(In millions)	December 31, 2025		December 31, 2024
Type of Instrument
Fair value hedge - Foreign currency swap contracts	$	908	$	975
Fair value hedge - Interest rate swap contracts	$	3,150	$	2,700
Net investment hedge - Foreign currency swap contracts	$	415	$	415

Components of Net Investment Income

The components of Net investment income were as follows:


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Debt securities	$	454	$	492	$	500
Equity securities (1)	6		(114)		123
Commercial mortgage loans	52		61		65
Policy loans	51		56		60
Other long-term investments	232		75		123
Short-term investments and cash	294		447		339
Total investment income	1,089		1,017		1,210
Less investment expenses	43		44		44
Net investment income	$	1,046	$	973	$	1,166

(1)Includes a $182 million impairment of dividend receivable for the year ended December 31, 2024.

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2025

Fair Value Disclosures [Abstract]

Financial Assets and Financial Liabilities Carried at Fair Value

The following table provides information about the Company's investment and derivative financial assets and liabilities carried at fair value on a recurring basis. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders.


(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)				Total
	December 31, 2025		December 31, 2024		December 31, 2025		December 31, 2024		December 31, 2025		December 31, 2024		December 31, 2025		December 31, 2024
Financial assets at fair value
Debt securities
Federal government and agency	$	105	$	165	$	122	$	116	$	—	$	—	$	227	$	281
State and local government	—		—		25		37		—		—		25		37
Foreign government	—		—		446		344		10		—		456		344
Corporate	—		—		7,133		8,049		277		374		7,410		8,423
Mortgage and other asset-backed	—		—		206		295		38		43		244		338
Total debt securities	105		165		7,932		8,841		325		417		8,362		9,423
Equity securities (1)	54		1		36		36		2		—		92		37
Short-term investments	—		—		257		170		—		—		257		170
Derivative assets	—		—		68		168		923		—		991		168
Financial liabilities at fair value
Derivative liabilities	$	—	$	—	$	22	$	1	$	354	$	—	$	376	$	1

(1)Excludes certain equity securities that have no readily determinable fair value.

Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities

The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.


	Fair Value as of					Unobservable Adjustment Range (Weighted Average by Quantity) as of
(Fair value in millions)	December 31, 2025		December 31, 2024		Unobservable Input December 31, 2025	December 31, 2025		December 31, 2024
Debt securities
Corporate	$	286	$	373	Liquidity	60 - 920 (175)	bps	60 - 1520 (370)	bps
Mortgage and other asset-backed securities	38		43		Liquidity	105 - 350 (160)	bps	100 - 550 (280)	bps
Other debt securities	1		1
Total Level 3 debt securities	$	325	$	417

Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value

The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.



	Years Ended December 31,
(In millions)		2025		2024

Beginning balance		$	417	$	447
Losses included in Shareholders' net income		(90)		(69)
Gains (losses) included in Other comprehensive loss		33		(9)

Purchases, sales and settlements
Purchases		655		17
Sales		(8)		(2)
Settlements		(105)		(21)
Total purchases, sales and settlements		542		(6)
Transfers into / (out of) Level 3
Transfers into Level 3		59		72
Transfers out of Level 3		(65)		(18)
Total transfers into / (out of) Level 3		(6)		54
Ending balance		$	896	$	417
Total losses included in Shareholders' net income attributable to instruments held at the reporting date		$	(94)	$	(69)
Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period		$	19	$	(9)

Fair Values of Separate Account Assets

Fair values of Separate account assets were as follows:


	Quoted Prices in Active Markets for Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)				Total
(In millions)	December 31, 2025		December 31, 2024		December 31, 2025		December 31, 2024		December 31, 2025		December 31, 2024		December 31, 2025		December 31, 2024
Guaranteed separate accounts (see Note 22)	$	247	$	231	$	330	$	345	$	—	$	—	$	577	$	576
Non-guaranteed separate accounts (1)	271		267		5,769		5,575		209		228		6,249		6,070
Subtotal	$	518	$	498	$	6,099	$	5,920	$	209	$	228	6,826		6,646
Non-guaranteed separate accounts priced at net asset value as a practical expedient (1)													661		632
Total													$	7,487	$	7,278

(1)Non-guaranteed separate accounts include $3.8 billion as of both December 31, 2025 and December 31, 2024 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of both December 31, 2025 and December 31, 2024. Non-guaranteed separate accounts are primarily comprised of securities partnerships, real estate and real estate funds.

Fair Value Disclosures for Financial Instruments Not Carried at Fair Value

The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.


	Classification in Fair Value Hierarchy	December 31, 2025				December 31, 2024
(In millions)		Fair Value		Carrying Value		Fair Value		Carrying Value
Commercial mortgage loans	Level 3	$	1,195	$	1,233	$	1,256	$	1,351
Long-term debt, including current maturities, excluding finance leases	Level 2	$	29,907	$	31,352	$	28,392	$	31,008

Collectively Significant Operating Unconsolidated Subsidiaries (Tables)

12 Months Ended

Dec. 31, 2025

Equity Method Investments and Joint Ventures [Abstract]

Operating Joint Venture Investments

The below summarized results of operations and financial position of the operating joint ventures reflects the latest available financial information and does not represent the Company's proportionate share of the assets, liabilities or earnings of such entities.


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Revenues	$	7,747	$	7,309	$	5,962
Net income	$	755	$	607	$	98


(In millions)	December 31, 2025		December 31, 2024
Total assets	$	39,547	$	34,395
Total liabilities	$	40,009	$	33,892

Accumulated Other Comprehensive Income (Loss) (Tables)

12 Months Ended

Dec. 31, 2025

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Changes in the Components of AOCI

Changes in the components of AOCI were as follows:


	For The Years Ended December 31,
(In millions)		2025		2024		2023
Securities and derivatives


Beginning balance		$	832	$	171	$	(332)
Unrealized (depreciation) appreciation on securities and derivatives, before reclassification, net of tax benefit (expense) of $118, $(207) and $(146), respectively		(309)		601		474
Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(20), $(16) and $(8), respectively		71		60		29
Shareholders' other comprehensive (loss) income, net of tax		(238)		661		503
Ending balance		$	594	$	832	$	171
Net long-duration insurance and contractholder liabilities measurement adjustments


Beginning balance		$	(2,038)	$	(971)	$	(256)
Net current period change in discount rate for certain long-duration liabilities, before reclassification, net of tax benefit of $71, $357 and $222, respectively		(225)		(1,044)		(691)
Amounts reclassified to Shareholders' net income, net of tax expense of $16, $— and $— respectively		(56)		—		—
Net current period change in discount rate for certain long-duration liabilities, net of tax benefit of $87, $357 and $222, respectively		(281)		(1,044)		(691)
Net current period change in instrument-specific credit risk for market risk benefits, net of tax benefit of $3, $6 and $5, respectively		(10)		(23)		(24)
Shareholders' other comprehensive (loss), net of tax		(291)		(1,067)		(715)
Ending balance		$	(2,329)	$	(2,038)	$	(971)
Translation of foreign currencies


Beginning balance		$	(198)	$	(149)	$	(154)
Net translation of foreign currencies, before reclassification, net of tax (expense) benefit of $(9), $2 and $5, respectively		71		(60)		5
Amounts reclassified to Shareholders' net income, net of tax expense of $—, $— and $—, respectively		—		11		—
Shareholders' other comprehensive income (loss), net of tax		71		(49)		5
Ending balance		$	(127)	$	(198)	$	(149)
Postretirement benefits liability
Beginning balance		$	(937)	$	(915)	$	(916)
Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(8), $(7) and $(11), respectively		25		22		35
Net change due to valuation update, before reclassification, net of tax benefit of $9, $14 and $12, respectively		(32)		(44)		(34)
Shareholders' other comprehensive (loss) income, net of tax		(7)		(22)		1
Ending balance		$	(944)	$	(937)	$	(915)
Total Accumulated other comprehensive loss


Beginning balance		$	(2,341)	$	(1,864)	$	(1,658)
Shareholders' other comprehensive (loss), net of tax benefit of $180, $149 and $79, respectively		(465)		(477)		(206)
Ending balance		$	(2,806)	$	(2,341)	$	(1,864)

Strategic Optimization Program (Tables)

12 Months Ended

Dec. 31, 2025

Restructuring and Related Activities [Abstract]

Roll forward of Accrued Liability

The following table presents a roll forward of the accrued liability recorded in Accrued expenses and other liabilities during the year ended December 31, 2025:


(In millions)



Balance, December 31, 2024	$	—
2025 charges	378
2025 payments	(238)
Balance, December 31, 2025	$	140

Pension (Tables)

12 Months Ended

Dec. 31, 2025

Retirement Benefits [Abstract]

Summary of the Projected Benefit Obligations and Assets Related to Pension Plans

The following table summarizes the projected benefit obligations and assets related to our U.S. and non-U.S. pension plans:


	For the Years Ended December 31,
(In millions)	2025		2024
Change in benefit obligation
Benefit obligation, January 1	$	3,643	$	3,934
Service cost	—		1
Interest cost	196		194

Actuarial losses (gains), net (1)	109		(146)
Benefits paid from plan assets	(309)		(328)

Other	(9)		(12)
Benefit obligation, December 31	3,630		3,643
Change in plan assets
Fair value of plan assets, January 1	3,854		4,138
Actual return on plan assets	302		40
Benefits paid	(309)		(328)
Contributions	1		4
Fair value of plan assets, December 31	3,848		3,854
Funded status	$	218	$	211
Amounts presented in Consolidated Balance Sheets
Other assets	$	218	$	211

(1) 2025 losses reflect a decrease in the discount rate, while 2024 gains reflect an increase in the discount rate.

Benefit Payments

The following benefit payments are expected to be paid in:


(In millions)
2026	$	316
2027	$	312
2028	$	310
2029	$	307
2030	$	304
2031 - 2035	$	1,409

Postretirement Benefits Liability Adjustment Included in AOCI

Amounts reflected in the pension assets (liabilities) shown above that have not yet been reported in Net income and, therefore, have been included in Accumulated other comprehensive loss consisted of the following:


(In millions)	December 31, 2025		December 31, 2024
Unrecognized net losses	$	(1,230)	$	(1,228)
Unrecognized prior service cost	(4)		(4)
Postretirement benefits liability adjustment	$	(1,234)	$	(1,232)

Components of Net Pension Cost

Net pension cost (benefit) was as follows:


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Service cost	$	—	$	1	$	1
Interest cost	196		194		204
Expected long-term return on plan assets	(232)		(247)		(204)
Amortization of:
Prior actuarial losses, net	38		39		52


Curtailment loss	—		1		—
Net cost (benefit)	$	2	$	(12)	$	53

Assumptions Used for Pension


	For the Years Ended December 31,
	2025	2024
Discount rate:
Pension benefit obligation	5.27%	5.57%
Pension benefit cost	5.57%	5.10%
Expected long-term return on plan assets:
Pension benefit cost	6.50%	6.50%
Mortality table for pension obligations	White Collar mortality table with MP 2021 projection scale	White Collar mortality table with MP 2021 projection scale

Fair Value of Pension Assets by Category

The fair values of pension assets by category are as follows:


(In millions)	December 31, 2025		December 31, 2024
Debt securities:
Federal government and agency	$	100	$	99
Corporate	2,674		2,673
Asset-backed	138		138
Fund investments	66		76
Total debt securities	2,978		2,986
Equity securities:
Domestic	23		21
International, including funds and pooled separate accounts (1)	—		6
Total equity securities	23		27
Securities partnerships, including pooled separate accounts (1)	447		402
Real estate and real estate funds, including pooled separate accounts (1)	212		228
Commercial mortgage loans	21		27

Guaranteed deposit account contract	48		47
Cash equivalents and other current assets, net	119		137
Total pension assets at fair value	$	3,848	$	3,854

(1) A pooled separate account has several participating benefit plans and each owns a share of the total pool of investments.

Employee Incentive Plans (Tables)

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Abstract]

Shares of Common Stock Available for Award

Shares of common stock available for award were as follows:

(In millions)

December 31, 2025

December 31, 2024

December 31, 2023

Common shares available for award

10.4

12.4

14.4

Black-Sholes Option-Pricing Model Assumptions

Black-Scholes option pricing model assumptions and the resulting fair value of options are presented in the following table:


	2025			2024			2023
Dividend yield	2.04		%	1.74		%	1.58		%
Expected volatility	31.0		%	30.0		%	30.0		%
Risk-free interest rate	4.4		%	4.0		%	3.6		%
Expected option life	4.9 years			4.8 years			4.7 years
Weighted average fair value of options	$	86.13		$	92.36		$	79.66

Status of and Changes in Common Stock Options

The following table shows the status of, and changes in, common stock options:


	For the Years Ended December 31,
	2025			2024			2023
(Options in thousands)	Options	Weighted Average Exercise Price		Options	Weighted Average Exercise Price		Options	Weighted Average Exercise Price
Outstanding - January 1	5,655	$	226.38	6,696	$	202.02	6,992	$	186.54
Granted	857	$	305.86	781	$	336.48	915	$	294.37
Exercised	(1,088)	$	192.40	(1,727)	$	178.82	(1,080)	$	174.66
Expired or canceled	(222)	$	314.78	(95)	$	278.78	(131)	$	246.95
Outstanding - December 31	5,202	$	242.81	5,655	$	226.38	6,696	$	202.02
Options exercisable at year-end	3,806	$	216.90	3,941	$	196.01	4,616	$	179.28

Summary of Information for Stock Options Exercised and Outstanding

The table below summarizes information for stock options exercised:


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Intrinsic value of options exercised	$	128	$	275	$	126
Cash received for options exercised	$	203	$	305	$	187
Tax benefit from options exercised	$	16	$	34	$	17

The following table summarizes information for outstanding common stock options:


	December 31, 2025
	Options Outstanding		Options Exercisable
Number (in thousands)	5,202		3,806
Total intrinsic value (in millions)	$	246	$	246
Weighted average exercise price	$	242.81	$	216.90
Weighted average remaining contractual life	5.7 years		4.6 years

Status of and Changes in Restricted Stock Awards and the Fair Value of Vested Restricted Stock

The following table shows the status of, and changes in, restricted stock awards:


	For the Years Ended December 31,
	2025			2024			2023
(Awards in thousands)	Grants/Units	Weighted Average Fair Value at Award Date		Grants/Units	Weighted Average Fair Value at Award Date		Grants/Units	Weighted Average Fair Value at Award Date
Outstanding - January 1	1,250	$	302.42	1,404	$	257.38	1,535	$	219.25
Awarded	701	$	305.67	624	$	319.39	700	$	294.60
Vested	(664)	$	284.20	(713)	$	245.35	(759)	$	214.70
Forfeited	(149)	$	316.12	(65)	$	283.62	(72)	$	256.24
Outstanding - December 31	1,138	$	313.25	1,250	$	302.42	1,404	$	257.38

The fair value of vested restricted stock at the vesting date was as follows:


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Fair value of vested restricted stock	$	203	$	238	$	220

Status of and Changes in SPSs

The following table shows the status of, and changes in, SPSs:


	For the Years Ended December 31,
	2025			2024			2023
(Awards in thousands)	Shares	Weighted Average Fair Value at Award Date		Shares	Weighted Average Fair Value at Award Date		Shares	Weighted Average Fair Value at Award Date
Outstanding - January 1	601	$	282.83	686	$	243.90	780	$	212.68
Awarded	217	$	305.28	195	$	336.81	219	$	293.85
Vested	(233)	$	231.75	(242)	$	214.93	(250)	$	191.78
Forfeited	(80)	$	317.01	(38)	$	289.35	(63)	$	237.50
Outstanding - December 31	505	$	310.78	601	$	282.83	686	$	243.90

The fair value of vested SPSs at the vesting date was as follows:


	For the Years Ended December 31,
	2025			2024			2023
(Shares in thousands; $ in millions)	Shares	Fair Value		Shares	Fair Value		Shares	Fair Value
Shares of The Cigna Group common stock distributed upon SPS vesting	301	$	92	257	$	86	257	$	76

Compensation Cost and Tax Effects of Share-based Compensation

Compensation Cost and Tax Effects of Share-Based Compensation

The Company records tax benefits in Shareholders' net income during the vesting period based on the amount of expense being recognized. The difference between tax benefits based on the expense and the actual tax benefit realized are also recorded in income tax expense when stock options are exercised, or when restricted stock and SPSs vest.


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Total compensation cost for shared-based awards	$	291	$	308	$	286
Tax benefits recognized	$	69	$	94	$	92

Goodwill, Other Intangibles and Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2025

Goodwill Other Intangibles And Property And Equipment [Abstract]

Goodwill Activity

Goodwill Activity. Goodwill activity was as follows:


(In millions)	Evernorth Health Services		Cigna Healthcare		Total
Balance at January 1, 2024	$	35,130	$	9,129	$	44,259
Goodwill acquired	114		—		114

Impact of foreign currency translation and other adjustments	190		(193)		(3)
Goodwill at December 31, 2024	35,434		8,936		44,370
Goodwill acquired	548		—		548


Impact of foreign currency translation and other adjustments	—		6		6
Goodwill at December 31, 2025	$	35,982	$	8,942	$	44,924

Other Indefinite-Lived Intangible Assets

Components of Other Assets, Including Other Intangibles. Other intangible assets were comprised of the following:


(In millions)	Cost		Accumulated Amortization		Net Carrying Value
December 31, 2025
Customer relationships	$	30,624	$	10,655	$	19,969
Trade name - Express Scripts	8,400				8,400
Other	346		155		191
Total	39,370		10,810		28,560
December 31, 2024
Customer relationships	$	29,971	$	9,119	$	20,852
Trade name - Express Scripts	8,400				8,400
Other	316		131		185
Other intangible assets (1)	38,687		9,250		29,437
Value of business acquired ("VOBA") (reported in Other assets) (2)	211		142		69
Total	$	38,898	$	9,392	$	29,506

(1) Includes $20 million of Other intangible assets classified as assets of businesses held for sale as of December 31, 2024.

(2) Includes $69 million of VOBA classified as assets of businesses held for sale as of December 31, 2024.

Other Finite-Lived Intangible Assets

Components of Other Assets, Including Other Intangibles. Other intangible assets were comprised of the following:


(In millions)	Cost		Accumulated Amortization		Net Carrying Value
December 31, 2025
Customer relationships	$	30,624	$	10,655	$	19,969
Trade name - Express Scripts	8,400				8,400
Other	346		155		191
Total	39,370		10,810		28,560
December 31, 2024
Customer relationships	$	29,971	$	9,119	$	20,852
Trade name - Express Scripts	8,400				8,400
Other	316		131		185
Other intangible assets (1)	38,687		9,250		29,437
Value of business acquired ("VOBA") (reported in Other assets) (2)	211		142		69
Total	$	38,898	$	9,392	$	29,506

(1) Includes $20 million of Other intangible assets classified as assets of businesses held for sale as of December 31, 2024.

(2) Includes $69 million of VOBA classified as assets of businesses held for sale as of December 31, 2024.

Property and Equipment

Components of Property and Equipment. Property and equipment were comprised of the following:


(In millions)	Cost		Accumulated Amortization		Net Carrying Value
December 31, 2025
Internal-use software	$	11,678	$	8,904	$	2,774
Other property and equipment	2,075		1,198		877
Total property and equipment	13,753		10,102		3,651


December 31, 2024
Internal-use software	$	11,295	$	8,167	$	3,128
Other property and equipment	2,115		1,287		828
Total property and equipment (1)	13,410		9,454		3,956

(1)Includes $302 million of Property and equipment net carrying value classified as assets of businesses held for sale as of December 31, 2024.

Components of Depreciation and Amortization Expense

Components of Depreciation and Amortization. Depreciation and amortization expense was comprised of the following:


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Internal-use software	$	987	$	1,021	$	1,216
Other property and equipment	239		248		260
Value of business acquired (reported in Other assets)	—		—		7
Other intangibles	1,549		1,506		1,552
Total depreciation and amortization	$	2,775	$	2,775	$	3,035

Estimated Annual Pre-Tax Amortization for Intangible Assets

The Company estimates annual pre-tax amortization for intangible assets, including internal-use software, over the next five calendar years to be as follows:


(In millions)	Pre-tax Amortization
2026	$	2,360
2027	$	2,237
2028	$	2,062
2029	$	1,821
2030	$	1,592

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Shareholders Equity and Dividend Restrictions (Tables)

12 Months Ended

Dec. 31, 2025

Statutory Net Income and Net Assets of the Company's Subsidiaries

The statutory net income of the Company's life, accident, and health insurance and HMO subsidiaries for the years ended, and their statutory surplus as of, December 31 were as follows:


(In billions)	2025		2024		2023
Net income	$	3.7	$	3.9	$	5.3
Surplus	$	13.0	$	16.0	$	14.9

The Company's HMO and life, accident and health insurance subsidiaries are also subject to minimum statutory surplus requirements and may be required to maintain investments on deposit with state departments of insurance or other regulatory bodies. Additionally, these subsidiaries may be subject to regulatory restrictions on the amount of annual dividends or other distributions (such as loans or cash advances) that insurance companies may extend to their parent companies without prior approval. These amounts, including restricted GAAP net assets of the Company's subsidiaries, were as follows:


(In billions)	December 31, 2025
Minimum statutory surplus required by regulators (1)	$	4.5
Investments on deposit with regulatory bodies	$	0.3
Maximum dividend distributions permitted in 2026 without regulatory approval	$	2.0
Maximum loans to the parent company permitted without regulatory approval	$	1.2
Restricted GAAP net assets of subsidiaries of The Cigna Group	$	11.3

(1) Excludes amounts associated with foreign operated equity method joint ventures.

Tabular disclosure of how the entity's reporting under GAAP as of the balance sheet date differs from the results based on prescribed and permitted accounting practices of the state or country of domicile in which a relevant statutory filing is made, or differences in results based on the National Association of Insurance Commissioners (NAIC) prescribed practices, or a combination thereof. Describes the accounting practices used and the related monetary effect on statutory surplus, net income, and risk-based capital. If an insurance enterprise's risk-based capital would have triggered a regulatory event had it not used a permitted practice, that fact is disclosed in the financial statements. Permitted statutory accounting practices include practices not prescribed but allowed by the domiciliary state insurance department regulatory authority.

Components of Income Tax Expense

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Abstract]

The components of income taxes were as follows:


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Current taxes
U.S. income taxes	$	807	$	1,167	$	1,459
Foreign income taxes	191		248		161
State income taxes	169		171		180
Total current taxes	1,167		1,586		1,800
Deferred taxes (tax benefits)
U.S. income tax benefits	(69)		(142)		(533)
Foreign income taxes (tax benefits)	447		64		(1,046)
State income tax benefits	(52)		(17)		(80)
Total deferred taxes (tax benefits)	326		(95)		(1,659)
Total income taxes	$	1,493	$	1,491	$	141

Reconciliation of Total Income Taxes to the Amount Computed Using the Nominal Federal Income Tax Rate

Total income taxes were different from the amount computed using the statutory federal income tax rate in 2025 for the following reasons:


	For the Year Ended December 31,
	2025
(in millions)	$		%
Tax expense at statutory rate	$	1,634	21.0	%
State income tax effect, net of federal income tax effect (1)	93		1.2
Nontaxable or nondeductible items	13		0.2
Effects of cross-border tax laws:
Global intangible low-taxed income ("GILTI")	127		1.6
Other cross-border tax laws	11		0.1
Tax credits	(83)		(1.1)
Change in valuation allowance	(74)		(1.0)
Change in unrecognized tax benefits	37		0.5
Other
Impact of sale of business	(173)		(2.2)
Tax equity investments	(102)		(1.3)
Other reconciling items	3		0.2
Foreign tax effects:
Switzerland
Effect of rates different than U.S. statutory	(360)		(4.6)
Cantonal income taxes	206		2.6
Change in valuation allowance	384		4.9

Other countries	(223)		(2.9)
Total income taxes	$	1,493	19.2	%

(1) The jurisdictions that make up the majority (greater than 50 percent) of the state and local tax impact are Florida and California.

Total income taxes were different from the amount computed using the statutory federal income tax rate in 2024 and 2023 for the following reasons:


	For the Years Ended December 31,
	2024				2023
(In millions)	$		%		$		%
Tax expense at statutory rate	$	1,107	21.0	%	$	1,158	21.0	%
Change in valuation allowance	767		14.6		1,290		23.4
State income tax effect, net of federal income tax effect	62		1.2		(39)		(0.7)
Investment tax credits	(111)		(2.1)		(48)		(0.8)
Impact of businesses held for sale	(129)		(2.4)		(213)		(3.9)
Effect of foreign earnings	(252)		(4.9)		(173)		(3.1)
Other foreign tax attributes	—		—		(153)		(2.8)
Swiss tax attributes	—		—		(1,674)		(30.4)


Other	47		0.9		(7)		(0.1)
Total income taxes	$	1,491	28.3	%	$	141	2.6	%

Deferred Income Tax Assets and Liabilities

Deferred income tax assets and liabilities were as follows:


(In millions)	December 31, 2025		December 31, 2024
Deferred tax assets
Foreign tax attributes	$	1,615	$	1,752
Deferred loss - sale of business	—		773
Investments	587		561
Other insurance and contractholder liabilities	241		300
Loss carryforwards	492		270
Other accrued liabilities	321		207
Employee and retiree benefit plans	190		177
Unrealized depreciation on investments and foreign currency translation	10		93
Policy acquisition expenses	53		—
Other	339		256
Deferred tax assets before valuation allowance	3,848		4,389
Valuation allowance for deferred tax assets	(2,374)		(2,332)
Deferred tax assets, net of valuation allowance	1,474		2,057
Deferred tax liabilities
Acquisition-related basis differences	7,558		7,822
Depreciation and amortization	602		243
Policy acquisition expenses	—		74




Total deferred tax liabilities	8,160		8,139
Net deferred income tax liabilities (1)	$	(6,686)	$	(6,082)

(1)Deferred tax liabilities, net in the Consolidated Balance Sheets excludes $459 million and $954 million reported in Other assets as of December 31, 2025 and December 31, 2024, respectively, and $61 million reported in liabilities of businesses held for sale as of December 31, 2024.

Reconciliations of Unrecognized Tax Benefits

Reconciliations of unrecognized tax benefits were as follows:


	For the Years Ended December 31,
(In millions)	2025		2024		2023
Balance at January 1,	$	1,477	$	1,399	$	1,343
Decrease due to prior year positions	(50)		(7)		(26)

Increase due to current year positions	187		165		107
Reduction related to settlements with taxing authorities	(62)		(22)		(13)
Reduction related to lapse of applicable statute of limitations	(14)		(58)		(12)
Balance at December 31,	$	1,538	$	1,477	$	1,399

Segment Information (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Summary of Special Items

The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted:


	For the Years Ended December 31,
		2025	2024				2023
(In millions)			Pre-tax		After-tax		Pre-tax		After-tax		Pre-tax		After-tax
Strategic optimization program (primarily Selling, general and administrative expenses)			$	749	$	565	$	—	$	—	$	—	$	—
Deferred tax expenses (benefits), net (Income taxes, less amount attributable to noncontrolling interests)			—		427		—		84		—		(1,071)
Integration and transaction-related costs (Selling, general and administrative expenses)			327		247		275		211		45		35
(Benefits) charges associated with litigation matters (Selling, general and administrative expenses)			(17)		(13)		—		—		201		171
Net (gain) loss on sale of businesses			(13)		(404)		(24)		(2)		1,499		1,429
Impairment of dividend receivable (Net investment income)			—		—		182		138		—		—
Charge for organizational efficiency plan (Selling, general and administrative expenses)			—		—		—		—		252		193


Total impact from special items			$	1,046	$	822	$	433	$	431	$	1,997	$	757

Summarized Segment Financial Information

Summarized segment financial information was as follows:


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2025
Revenues from external customers	$	232,098	$	41,426	$	325	$	5	$	273,854
Intersegment revenues	2,713		5,405		51		(8,169)
Net investment income	142		581		298		25		1,046
Total revenues	234,953		47,412		674		(8,139)		274,900
Net investment results from certain equity method investments	—		(249)		—		—		(249)


Adjusted revenues	$	234,953	$	47,163	$	674	$	(8,139)	$	274,651
Pharmacy and other service costs	223,086		—
Medical costs	—		33,474
Selling, general and administrative expenses	4,170		9,545
Other segment items (1)
Interest (expense) and other	(1)		9
Less: Income attributable to noncontrolling interests	475		—
Pre-tax adjusted income (loss) from operations	7,221		4,153		89		(1,593)		9,870

Income (loss) before income taxes	$	5,826	$	4,344	$	(46)	$	(2,343)	$	7,781
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(475)		—		—		—		(475)
Net investment (gains) losses (2)	(20)		(210)		2		3		(225)
Amortization of acquired intangible assets	1,720		23		—		—		1,743
Special items
Strategic optimization program	174		22		133		420		749
Integration and transaction-related costs	—		—		—		327		327




Net (gain) on sale of businesses	(4)		(9)		—		—		(13)
(Benefits) associated with litigation matters	—		(17)		—		—		(17)

Pre-tax adjusted income (loss) from operations	$	7,221	$	4,153	$	89	$	(1,593)	$	9,870

Other segment information
Depreciation and amortization	$	2,400	$	339	$	16	$	20	$	2,775

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2024
Revenues from external customers	$	198,177	$	47,528	$	440	$	3	$	246,148
Intersegment revenues	3,775		4,972		79		(8,826)
Net investment income	21		618		309		25		973
Total revenues	201,973		53,118		828		(8,798)		247,121
Net investment results from certain equity method investments	—		(204)		—		—		(204)
Special item related to impairment of dividend receivable	182		—		—		—		182
Adjusted revenues	$	202,155	$	52,914	$	828	$	(8,798)	$	247,099
Pharmacy and other service costs	190,968		—
Medical costs	—		37,887
Selling, general and administrative expenses	3,779		10,805
Other segment items (1)
Interest (expense) and other	(2)		7
Less: Income attributable to noncontrolling interests	405		—
Pre-tax adjusted income (loss) from operations	7,001		4,229		(9)		(1,688)		9,533

Income (loss) before income taxes	$	3,929	$	3,315	$	(12)	$	(1,963)	$	5,269
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(405)		—		—		—		(405)
Net investment losses (2)	2,129		401		3		—		2,533
Amortization of acquired intangible assets	1,662		41		—		—		1,703
Special items
Integration and transaction-related costs	—		—		—		275		275
Impairment of dividend receivable	182		—		—		—		182





Net (gain) loss on sale of businesses	(496)		472		—		—		(24)

Pre-tax adjusted income (loss) from operations	$	7,001	$	4,229	$	(9)	$	(1,688)	$	9,533

Other segment information
Depreciation and amortization	$	2,319	$	417	$	9	$	30	$	2,775

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2023
Revenues from external customers	$	147,588	$	46,219	$	291	$	1	$	194,099
Intersegment revenues	5,670		4,332		—		(10,002)
Net investment income	241		597		305		23		1,166
Total revenues	153,499		51,148		596		(9,978)		195,265
Net investment results from certain equity method investments	—		57		—		—		57

Adjusted revenues	$	153,499	$	51,205	$	596	$	(9,978)	$	195,322
Pharmacy and other service costs	143,571		—
Medical costs	—		35,678
Selling, general and administrative expenses	3,340		11,055
Other segment items (1)
Interest (expense) and other	(2)		8
Less income attributable to noncontrolling interests	144		2
Pre-tax adjusted income (loss) from operations	6,442		4,478		96		(1,698)		9,318

Income (loss) before income taxes	$	4,768	$	2,664	$	76	$	(1,995)	$	5,513
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(144)		(2)		—		—		(146)
Net investment losses (2)	—		133		2		—		135
Amortization of acquired intangible assets	1,774		45		—		—		1,819
Special items
Net loss on sale of businesses	—		1,481		18		—		1,499
Charge for organizational efficiency plan	—		—		—		252		252
Charges associated with litigation matters	44		157		—		—		201
Integration and transaction-related costs	—		—		—		45		45





Pre-tax adjusted income (loss) from operations	$	6,442	$	4,478	$	96	$	(1,698)	$	9,318

Other segment information
Depreciation and amortization	$	2,438	$	569	$	3	$	25	$	3,035

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

Reconciliation of Operating Profit (Loss) from Segments to Consolidated


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2025
Revenues from external customers	$	232,098	$	41,426	$	325	$	5	$	273,854
Intersegment revenues	2,713		5,405		51		(8,169)
Net investment income	142		581		298		25		1,046
Total revenues	234,953		47,412		674		(8,139)		274,900
Net investment results from certain equity method investments	—		(249)		—		—		(249)


Adjusted revenues	$	234,953	$	47,163	$	674	$	(8,139)	$	274,651
Pharmacy and other service costs	223,086		—
Medical costs	—		33,474
Selling, general and administrative expenses	4,170		9,545
Other segment items (1)
Interest (expense) and other	(1)		9
Less: Income attributable to noncontrolling interests	475		—
Pre-tax adjusted income (loss) from operations	7,221		4,153		89		(1,593)		9,870

Income (loss) before income taxes	$	5,826	$	4,344	$	(46)	$	(2,343)	$	7,781
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(475)		—		—		—		(475)
Net investment (gains) losses (2)	(20)		(210)		2		3		(225)
Amortization of acquired intangible assets	1,720		23		—		—		1,743
Special items
Strategic optimization program	174		22		133		420		749
Integration and transaction-related costs	—		—		—		327		327




Net (gain) on sale of businesses	(4)		(9)		—		—		(13)
(Benefits) associated with litigation matters	—		(17)		—		—		(17)

Pre-tax adjusted income (loss) from operations	$	7,221	$	4,153	$	89	$	(1,593)	$	9,870

Other segment information
Depreciation and amortization	$	2,400	$	339	$	16	$	20	$	2,775

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2024
Revenues from external customers	$	198,177	$	47,528	$	440	$	3	$	246,148
Intersegment revenues	3,775		4,972		79		(8,826)
Net investment income	21		618		309		25		973
Total revenues	201,973		53,118		828		(8,798)		247,121
Net investment results from certain equity method investments	—		(204)		—		—		(204)
Special item related to impairment of dividend receivable	182		—		—		—		182
Adjusted revenues	$	202,155	$	52,914	$	828	$	(8,798)	$	247,099
Pharmacy and other service costs	190,968		—
Medical costs	—		37,887
Selling, general and administrative expenses	3,779		10,805
Other segment items (1)
Interest (expense) and other	(2)		7
Less: Income attributable to noncontrolling interests	405		—
Pre-tax adjusted income (loss) from operations	7,001		4,229		(9)		(1,688)		9,533

Income (loss) before income taxes	$	3,929	$	3,315	$	(12)	$	(1,963)	$	5,269
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(405)		—		—		—		(405)
Net investment losses (2)	2,129		401		3		—		2,533
Amortization of acquired intangible assets	1,662		41		—		—		1,703
Special items
Integration and transaction-related costs	—		—		—		275		275
Impairment of dividend receivable	182		—		—		—		182





Net (gain) loss on sale of businesses	(496)		472		—		—		(24)

Pre-tax adjusted income (loss) from operations	$	7,001	$	4,229	$	(9)	$	(1,688)	$	9,533

Other segment information
Depreciation and amortization	$	2,319	$	417	$	9	$	30	$	2,775

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
2023
Revenues from external customers	$	147,588	$	46,219	$	291	$	1	$	194,099
Intersegment revenues	5,670		4,332		—		(10,002)
Net investment income	241		597		305		23		1,166
Total revenues	153,499		51,148		596		(9,978)		195,265
Net investment results from certain equity method investments	—		57		—		—		57

Adjusted revenues	$	153,499	$	51,205	$	596	$	(9,978)	$	195,322
Pharmacy and other service costs	143,571		—
Medical costs	—		35,678
Selling, general and administrative expenses	3,340		11,055
Other segment items (1)
Interest (expense) and other	(2)		8
Less income attributable to noncontrolling interests	144		2
Pre-tax adjusted income (loss) from operations	6,442		4,478		96		(1,698)		9,318

Income (loss) before income taxes	$	4,768	$	2,664	$	76	$	(1,995)	$	5,513
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(144)		(2)		—		—		(146)
Net investment losses (2)	—		133		2		—		135
Amortization of acquired intangible assets	1,774		45		—		—		1,819
Special items
Net loss on sale of businesses	—		1,481		18		—		1,499
Charge for organizational efficiency plan	—		—		—		252		252
Charges associated with litigation matters	44		157		—		—		201
Integration and transaction-related costs	—		—		—		45		45





Pre-tax adjusted income (loss) from operations	$	6,442	$	4,478	$	96	$	(1,698)	$	9,318

Other segment information
Depreciation and amortization	$	2,438	$	569	$	3	$	25	$	3,035

(1)Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2)Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.

Revenue from External Customers

Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type:


	For the Years Ended December 31,
(In millions)		2025		2024		2023
Products (Pharmacy revenues) (ASC 606)
Network revenues		$	125,573	$	105,340	$	67,514
Home delivery and specialty revenues		80,492		72,476		65,732
Other revenues		13,329		11,545		9,047
Total Evernorth Health Services		219,394		189,361		142,293
Other Operations		54		60		—
Corporate and eliminations		(2,776)		(4,059)		(5,050)
Total Pharmacy revenues		216,672		185,362		137,243
Insurance premiums (ASC 944)
Cigna Healthcare
U.S. Healthcare
Employer insured		18,852		17,576		16,490
Medicare Advantage		2,363		8,679		8,771
Stop loss		7,599		6,744		6,143
Individual and Family Plans		3,371		3,951		5,088
Other		3,366		4,938		4,095
U.S. Healthcare		35,551		41,888		40,587
International Health		4,126		3,624		3,295
Total Cigna Healthcare		39,677		45,512		43,882
Other Operations		288		380		281
Corporate and eliminations		296		104		74
Total Premiums		40,261		45,996		44,237
Services (Fees) (ASC 606) and Other revenues (1)
Evernorth Health Services		15,417		12,591		10,965
Cigna Healthcare		7,154		6,988		6,669
Other Operations		34		79		10
Corporate and eliminations		(5,684)		(4,868)		(5,025)
Total Fees and other revenues (1)		16,921		14,790		12,619
Total revenues from external customers		$	273,854	$	246,148	$	194,099

(1)Other revenues for the years ended December 31, 2025, 2024 and 2023 were $696 million, $584 million and $210 million, respectively.

Schedule I - Condensed Financial Information of The Cigna Group (Tables)

12 Months Ended

Dec. 31, 2025

Condensed Financial Statements, Captions [Line Items]

Condensed Income Statement

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE I

CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP

(REGISTRANT)

STATEMENTS OF INCOME


	For the Years Ended December 31,

(In millions)	2025		2024		2023
Revenues
Net investment income and other revenue	$	21	$	26	$	22
Intercompany interest income	469		469		516
Total revenues	490		495		538
Operating expenses
Selling, general and administrative expenses	5		14		2
Total operating expenses	5		14		2
lncome from operations	485		481		536
Interest expense and other	(1,365)		(1,388)		(1,332)
Gain on sale of businesses	4,890		—		—
Intercompany interest expense	—		(2)		(118)


lncome (loss) before income taxes	4,010		(909)		(914)
Income tax benefits	(201)		(189)		(192)
lncome (loss) of parent company	4,211		(720)		(722)
Equity in income of subsidiaries	1,746		4,154		5,886
Shareholders' net income	5,957		3,434		5,164
Shareholders' other comprehensive (loss) income, net of tax
Net unrealized (depreciation) appreciation on securities and derivatives	(238)		661		503
Net long-duration insurance and contractholder liabilities measurement adjustments	(291)		(1,067)		(715)
Net translation gains (losses) of foreign currencies	71		(49)		5
Postretirement benefits liability adjustment	(7)		(22)		1
Shareholders' other comprehensive loss, net of tax	(465)		(477)		(206)
Shareholders' comprehensive income	$	5,492	$	2,957	$	4,958

See Notes to Financial Statements on the following pages.

Condensed Statement of Comprehensive Income

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE I

CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP

(REGISTRANT)

STATEMENTS OF INCOME


	For the Years Ended December 31,

(In millions)	2025		2024		2023
Revenues
Net investment income and other revenue	$	21	$	26	$	22
Intercompany interest income	469		469		516
Total revenues	490		495		538
Operating expenses
Selling, general and administrative expenses	5		14		2
Total operating expenses	5		14		2
lncome from operations	485		481		536
Interest expense and other	(1,365)		(1,388)		(1,332)
Gain on sale of businesses	4,890		—		—
Intercompany interest expense	—		(2)		(118)


lncome (loss) before income taxes	4,010		(909)		(914)
Income tax benefits	(201)		(189)		(192)
lncome (loss) of parent company	4,211		(720)		(722)
Equity in income of subsidiaries	1,746		4,154		5,886
Shareholders' net income	5,957		3,434		5,164
Shareholders' other comprehensive (loss) income, net of tax
Net unrealized (depreciation) appreciation on securities and derivatives	(238)		661		503
Net long-duration insurance and contractholder liabilities measurement adjustments	(291)		(1,067)		(715)
Net translation gains (losses) of foreign currencies	71		(49)		5
Postretirement benefits liability adjustment	(7)		(22)		1
Shareholders' other comprehensive loss, net of tax	(465)		(477)		(206)
Shareholders' comprehensive income	$	5,492	$	2,957	$	4,958

See Notes to Financial Statements on the following pages.

Condensed Balance Sheet

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE I

CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP

(REGISTRANT)

BALANCE SHEETS


	As of December 31,
(In millions)	2025		2024
Assets
Cash and cash equivalents	$	118	$	164

Other current assets	29		103
Total current assets	147		267
Investments in subsidiaries	61,382		62,887
Intercompany receivable	14,146		10,546
Other non-current assets	48		71
TOTAL ASSETS	$	75,723	$	73,771
Liabilities
Short-term debt	$	550	$	2,848
Other current liabilities	1,983		1,528
Total current liabilities	2,533		4,376
Long-term debt	30,268		28,134
Intercompany payable	1,134		195
Other non-current liabilities	75		33
TOTAL LIABILITIES	34,010		32,738
Shareholders' equity
Common stock (shares issued, 405 and 403; authorized, 600)	4		4
Additional paid-in capital	31,790		31,288
Accumulated other comprehensive loss	(2,806)		(2,341)
Retained earnings	47,865		43,519
Less treasury stock, at cost	(35,140)		(31,437)
TOTAL SHAREHOLDERS' EQUITY	41,713		41,033
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	75,723	$	73,771

See Notes to Financial Statements on the following pages.

Condensed Cash Flow Statement

THE CIGNA GROUP AND SUBSIDIARIES

SCHEDULE I

CONDENSED FINANCIAL INFORMATION OF THE CIGNA GROUP

(REGISTRANT)

STATEMENTS OF CASH FLOWS


	For the Years Ended December 31,

(In millions)	2025		2024		2023
Cash Flows from Operating Activities
Shareholders' net income	$	5,957	$	3,434	$	5,164
Adjustments to reconcile Shareholders' net income to net cash provided by operating activities
Equity in income from subsidiaries	(1,746)		(4,154)		(5,886)

Dividends received from subsidiaries	1,171		2,916		1,381
Gain on sale of businesses	(4,890)		—		—
Other liabilities	496		(306)		540
Other, net	592		243		640
NET CASH PROVIDED BY OPERATING ACTIVITIES	1,580		2,133		1,839
Cash Flows from Investing Activities
Net change in amounts due from affiliates	—		—		622
Proceeds from divestiture of businesses	4,891		—		—


NET CASH PROVIDED BY INVESTING ACTIVITIES	4,891		—		622
Cash Flows from Financing Activities
Net change in amounts due to/from affiliates	(1,101)		4,761		1,473
Net change in commercial paper	(880)		(357)		1,237

Repayment of term loan	(2,000)		—		—
Net proceeds on issuance of term loan	1,999		—		—
Repayment of long-term debt	(3,861)		(2,731)		(2,822)
Net proceeds on issuance of long-term debt	4,458		4,462		1,491
Issuance of common stock	203		305		187
Common stock dividend paid	(1,611)		(1,567)		(1,450)
Repurchase of common stock	(3,621)		(7,034)		(2,284)

Other, net	(108)		(117)		(110)
NET CASH USED IN FINANCING ACTIVITIES	(6,522)		(2,278)		(2,278)
Net (decrease) increase in cash, cash equivalents and restricted cash	(51)		(145)		183
Cash, cash equivalents and restricted cash, beginning of year	190		335		152
Cash, cash equivalents and restricted cash, end of year (1)	$	139	$	190	$	335
Noncash Investing and Financing Activities:
Net amounts due from affiliates settled through capital transactions	$	(1,617)	$	(7,565)	$	(5,221)

(1) Includes restricted cash reported in Other non-current assets.

See Notes to Financial Statements on the following pages.

Outstanding amounts of debt and finance leases

The outstanding amounts of debt (net of issuance costs, discounts or premiums) and finance leases were as follows:


(In millions)	December 31, 2025		December 31, 2024
Short-term debt
Commercial paper	$	—	$	880
$900 million, 3.250% Notes due April 2025	—		897
$1,216 million, 4.125% Notes due November 2025	—		1,215

$550 million, 1.250% Notes due March 2026	549		—
Other, including finance leases	43		43
Total short-term debt	$	592	$	3,035
Long-term debt
$1,284 million, 4.500% Notes due February 2026	$	—	$	1,285
$700 million, 5.685% Notes due March 2026	—		699
$550 million, 1.250% Notes due March 2026	—		549
$1,500 million, 3.400% Notes due March 2027	1,481		1,466
$259 million, 7.875% Debentures due May 2027	260		259
$600 million, 3.050% Notes due October 2027	599		598
$3,800 million, 4.375% Notes due October 2028	3,792		3,790
$1,000 million, 5.000% Notes due May 2029	996		995
$1,400 million, 2.400% Notes due March 2030 (1)	1,406		1,386
$1,000 million, 4.500% Notes due September 2030	993		—
$1,500 million, 2.375% Notes due March 2031 (1)	1,420		1,384
$750 million, 5.125% Notes due May 2031 (1)	750		745
$1,250 million, 4.875% Notes due September 2032	1,243		—
$45 million, 8.080% Step Down Notes due January 2033	45		45
$800 million, 5.400% Notes due March 2033 (1)	796		795
$1,250 million, 5.250% Notes due February 2034 (1)	1,250		1,226
$1,500 million, 5.250% Notes due January 2036	1,488		—
$190 million, 6.150% Notes due November 2036	190		190
$2,200 million, 4.800% Notes due August 2038 (1)	2,194		2,193
$750 million, 3.200% Notes due March 2040	748		744
$121 million, 5.875% Notes due March 2041	119		119
$448 million, 6.125% Notes due November 2041	484		485
$317 million, 5.375% Notes due February 2042	315		315
$1,500 million, 4.800% Notes due July 2046	1,469		1,469
$1,000 million, 3.875% Notes due October 2047	990		990
$3,000 million, 4.900% Notes due December 2048	2,972		2,971
$1,184 million, 3.400% Notes due March 2050	1,172		1,237
$1,429 million, 3.400% Notes due March 2051	1,410		1,479
$1,500 million, 5.600% Notes due February 2054	1,486		1,482
$750 million, 6.000% Notes due January 2056	735		—
Other, including finance leases	68		41
Total long-term debt	$	30,871	$	28,937

(1)The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments as of December 31, 2025. See Note 11 to the Consolidated Financial Statements for further information about the Company's interest rate risk management and these derivative instruments.

Debt Issuance. In September 2025, we issued $4.5 billion of new senior notes, as detailed in the table below. The proceeds from this debt issuance were used to repay the $2.0 billion of loans outstanding under the Term Loan Facility as described below. We used the remaining net proceeds for general corporate purposes, including investments and repayment of indebtedness. Interest on this debt is paid semiannually.

Principal

Maturity Date

Interest Rate

Net Proceeds

Redeemable Date(1)

"Make Whole" Premium (2)

$1,000 million

September 15, 2030

4.500%

$994 million

August 15, 2030

15

$1,250 million

September 15, 2032

4.875%

$1,245 million

July 15, 2032

15

$1,500 million

January 15, 2036

5.250%

$1,490 million

October 15, 2035

15

$750 million

January 15, 2056

6.000%

$736 million

July 15, 2055

20

(1) Redeemable at any time prior to this date at a "make whole" premium, defined below. Redeemable at par on or after this date.

(2) "Make whole" premium calculated using a comparable U.S. Treasury rate plus the amount of basis points set forth in this column.

Maturities of Outstanding Long-Term Debt

Maturities of outstanding long-term debt as of December 31, 2025 are as follows:


(In millions)	Scheduled Maturities (1)
2026	$	550
2027	$	2,359
2028	$	3,800
2029	$	1,000
2030	$	2,400
Maturities after 2030	$	21,485

(1) Long-term debt maturity amounts include current maturities of long-term debt. Finance leases are excluded from this table.

The Cigna Group

Condensed Financial Statements, Captions [Line Items]

Outstanding amounts of debt and finance leases

Debt Issuance. In September 2025, we issued $4.5 billion of new senior notes, as detailed in the table below. The proceeds from this debt issuance were used to repay the $2.0 billion of loans outstanding under the Term Loan Facility as described above. We used the remaining net proceeds for general corporate purposes, including investments and repayment of indebtedness. Interest on this debt is paid semiannually.

Principal

Maturity Date

Interest Rate

Net Proceeds

Redeemable Date(1)

"Make Whole" Premium (2)

$1,000 million

September 15, 2030

4.500%

$994 million

August 15, 2030

15

$1,250 million

September 15, 2032

4.875%

$1,245 million

July 15, 2032

15

$1,500 million

January 15, 2036

5.250%

$1,490 million

October 15, 2035

15

$750 million

January 15, 2056

6.000%

$736 million

July 15, 2055

20

(1) Redeemable at any time prior to this date at a "make whole" premium, defined below. Redeemable at par on or after this date.

(2) "Make whole" premium calculated using the most directly comparable U.S. Treasury rate plus the amount of basis points set forth in this column.

Maturities of Outstanding Long-Term Debt

Maturities of the Company's long-term debt as of December 31, 2025 are as follows:


(In millions)
2026	$	550
2027	$	2,055
2028	$	3,800
2029	$	1,000
2030	$	2,400
Maturities after 2030	$	21,255

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 04
-Paragraph a
-Publisher SEC

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 5
-Subsection 04
-Paragraph c
-Subparagraph Schedule I
-Publisher SEC

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 7
-Subsection 05
-Paragraph c
-Subparagraph Schedule II
-Publisher SEC

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 9
-Subsection 06
-Publisher SEC

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 8: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-11

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 7
-Subparagraph (SAB Topic 1.B.2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480922/205-10-S99-7

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481003/205-10-S50-2

Description of Business - Segment Information (Details)	12 Months Ended
Description of Business - Segment Information (Details)	Dec. 31, 2025 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of Reportable Segments	2

Summary of Significant Accounting Policies (Details) - USD ($) $ in Billions	Dec. 31, 2025	Dec. 31, 2024
Financial and performance guarantees \| Evernorth Health Services
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Guarantee liability	$ 1.8	$ 1.9

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476173/280-10-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476173/280-10-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-9

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-9

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-1

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479832/842-10-65-8

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479832/842-10-65-8

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 50
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477123/405-50-65-1

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482477/820-10-65-13

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482477/820-10-65-13

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-5

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 49: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 50: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 51: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 52: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 53: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 54: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 55: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 56: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479845/805-20-65-3

Reference 57: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479845/805-20-65-3

Reference 58: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479845/805-20-65-3

Reference 59: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 60: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 61: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 62: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 63: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6

Reference 64: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 65: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 66: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 67: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 68: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 69: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 70: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 71: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 72: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 73: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 74: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 75: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5

Reference 76: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8

Reference 77: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8

Reference 78: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 79: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 80: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 81: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 82: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 83: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 84: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 85: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483421/250-10-45-6

Reference 86: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 87: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 88: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 89: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 90: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 91: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 92: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 93: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 94: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 95: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 96: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 97: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480424/946-10-50-3

Reference 98: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476166/350-60-65-1

Reference 99: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 100: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 101: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476166/350-60-65-1

Reference 102: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476151/220-40-65-1

Reference 103: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 104: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 105: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476151/220-40-65-1

Reference 106: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476151/220-40-65-1

Accounts Receivable, Net - Amounts (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Receivables [Abstract]
Noninsurance customer receivables	$ 14,707
Pharmaceutical manufacturer receivables	12,437
Insurance customer receivables	1,385
Other receivables	239
Accounts receivable, net	$ 28,768	$ 24,227

Accounts Receivable, Net - Amounts, Including Disposal Groups (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Accounts, Notes, Loans and Financing Receivable [Line Items]
Noninsurance customer receivables, including held for sale assets		$ 11,879
Pharmaceutical manufacturers receivable, including held for sale assets		10,914
Insurance customer receivables, including held for sale assets		3,199
Other receivables, including held for sale assets		162
Total		26,154
Accounts receivable, net	$ 28,768	24,227
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, net classified as assets of businesses held for sale		$ (1,927)

Accounts Receivable, Net - Allowances (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Receivables [Abstract]
allowances	$ 6,800	$ 5,000
contractual allowances for certain pharmaceutical manufacturers rebate receivables	6,200	4,300
contractual allowances for third-party payor noninsurance customer receivables	270	388
allowances for current expected credit losses	$ 199	$ 84

Accounts Receivable, Net - Factoring Facility (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Receivables [Abstract]
Total capacity, uncommitted factoring facility	$ 1,500,000,000
Automatic renewal term, uncommitted factoring facility (in years)	1 year
Accounts receivable sold, uncommitted factoring facility	$ 4,400,000,000	$ 5,500,000,000
Factoring fees paid, uncommitted factoring facility
Accounts receivable sold that remain outstanding, uncommitted factoring facility	0	0
Accounts receivable received but not remitted, uncommitted factoring facility	$ 400,000,000	$ 1,000,000,000.0

Supplier Finance Program (Details) - USD ($) $ in Millions	12 Months Ended
Supplier Finance Program (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Payment term (in months)	1 month
Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]	Accounts payable	Accounts payable
Supplier Finance Program, Obligation, Current, Statement of Financial Position [Extensible Enumeration]	Accounts payable	Accounts payable
Outstanding payment obligations, current	$ 1,602	$ 1,637	$ 1,536
Supplier Finance Program, Obligation [Roll Forward]
Confirmed obligations outstanding at the beginning of the year	1,637	1,536
Invoices confirmed during the year	39,108	39,091
Supplier Finance Program, Obligation, Settlement	39,143	38,990
Confirmed obligations outstanding at the end of the year	$ 1,602	$ 1,637

Divestiture (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
Divestiture (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Mar. 19, 2025	Jan. 31, 2024
Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]
Integration and transaction-related costs		$ 327	$ 275	$ 45
Integration and transaction-related costs, after-tax		$ 247	211	35
Disposed of by Sale \| Medicare Advantage and related Cigna Healthcare businesses \| Health Care Services Corporation (HCSC)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale price					$ 4,900
Proceeds from divestiture of businesses	$ 4,900
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
Loss on sale of businesses, Consolidated Statements of Income location		Net gain (loss) on sale of businesses
Estimated loss on sale, pre-tax		$ 9	(472)	(1,500)
Estimated loss on sale, after-tax		$ 401	$ (363)	(1,400)
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
Goodwill impairment loss, Consolidated Statements of Income location			Net gain (loss) on sale of businesses
Goodwill impairments			$ 302	$ 1,200
Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]
Cash and cash equivalents			1,339
Investments			1,444
Accounts receivable, net			1,927
Other assets, including Goodwill			2,294
Goodwill classified as Assets of businesses held for sale			94
Total assets of businesses held for sale			7,004
Insurance and contractholder liabilities			1,579
All other liabilities			831
Total liabilities of businesses held for sale			$ 2,410
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses \| Health Care Services Corporation (HCSC)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale price						$ 3,300

Earnings Per Share - Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Earnings Per Share [Abstract]
SHAREHOLDERS' NET INCOME	$ 5,957	$ 3,434	$ 5,164
Shares:
Weighted average	266,744	280,294	293,892
Common stock equivalents	1,819	2,924	2,990
Total shares	268,563	283,218	296,882
Earnings per share, basic	$ 22.33	$ 12.25	$ 17.57
Earnings per share, effect of dilution	(0.15)	(0.13)	(0.18)
Earnings per share, diluted	$ 22.18	$ 12.12	$ 17.39

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Earnings Per Share - Anti-dilutive Options (Details) - shares shares in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Employee Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive options	2.0	1.1	0.9

Debt - Outstanding Amounts of Debt and Finance Leases (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Short-term debt
Commercial paper	$ 0	$ 880
Other, including finance leases	43	43
Total short-term debt	$ 592	$ 3,035
Balance sheet location of current finance lease liabilities	Total short-term debt	Total short-term debt
Long-term debt
Other, including finance leases	$ 68	$ 41
Total long-term debt	$ 30,871	$ 28,937
Balance sheet location of non-current finance lease liabilities	Total long-term debt	Total long-term debt
3.250% Notes due April 2025
Debt Instrument [Line Items]
Gross value	$ 900
Interest Rate	3.25%
Short-term debt
Current maturities	$ 0	$ 897
4.125% Notes due November 2025,
Debt Instrument [Line Items]
Gross value	$ 1,216
Interest Rate	4.125%
Short-term debt
Current maturities	$ 0	1,215
4.500% Notes due February 2026
Debt Instrument [Line Items]
Gross value	$ 1,284
Interest Rate	4.50%
Long-term debt
Long-term debt	$ 0	1,285
1.250% Notes due March 2026
Debt Instrument [Line Items]
Gross value	$ 550
Interest Rate	1.25%
Short-term debt
Current maturities	$ 549	0
Long-term debt
Long-term debt	0	549
5.685% Notes due March 2026
Debt Instrument [Line Items]
Gross value	$ 700
Interest Rate	5.685%
Long-term debt
Long-term debt	$ 0	699
3.400% Notes due March 2027
Debt Instrument [Line Items]
Gross value	$ 1,500
Interest Rate	3.40%
Long-term debt
Long-term debt	$ 1,481	1,466
7.875% Debentures due May 2027
Debt Instrument [Line Items]
Gross value	$ 259
Interest Rate	7.875%
Long-term debt
Long-term debt	$ 260	259
3.050% Notes due October 2027
Debt Instrument [Line Items]
Gross value	$ 600
Interest Rate	3.05%
Long-term debt
Long-term debt	$ 599	598
4.375% Notes due October 2028
Debt Instrument [Line Items]
Gross value	$ 3,800
Interest Rate	4.375%
Long-term debt
Long-term debt	$ 3,792	3,790
5.000% Notes due May 2029
Debt Instrument [Line Items]
Gross value	$ 1,000
Interest Rate	5.00%
Long-term debt
Long-term debt	$ 996	995
2.400% Notes due March 2030
Debt Instrument [Line Items]
Gross value	$ 1,400
Interest Rate	2.40%
Long-term debt
Long-term debt	$ 1,406	1,386
4.500% Notes due September 2030
Debt Instrument [Line Items]
Gross value	$ 1,000
Interest Rate	4.50%
Long-term debt
Long-term debt	$ 993	0
2.375% Notes due March 2031
Debt Instrument [Line Items]
Gross value	$ 1,500
Interest Rate	2.375%
Long-term debt
Long-term debt	$ 1,420	1,384
5.125% Notes due May 2031
Debt Instrument [Line Items]
Gross value	$ 750
Interest Rate	5.125%
Long-term debt
Long-term debt	$ 750	745
4.875% Notes due September 2032
Debt Instrument [Line Items]
Gross value	$ 1,250
Interest Rate	4.875%
Long-term debt
Long-term debt	$ 1,243	0
Step Down Notes due January 2033
Debt Instrument [Line Items]
Gross value	$ 45
Interest Rate	8.08%
Long-term debt
Long-term debt	$ 45	45
5.400% Notes due March 2033
Debt Instrument [Line Items]
Gross value	$ 800
Interest Rate	5.40%
Long-term debt
Long-term debt	$ 796	795
5.250% Notes due February 2034
Debt Instrument [Line Items]
Gross value	$ 1,250
Interest Rate	5.25%
Long-term debt
Long-term debt	$ 1,250	1,226
5.250% Notes due January 2036
Debt Instrument [Line Items]
Gross value	$ 1,500
Interest Rate	5.25%
Long-term debt
Long-term debt	$ 1,488	0
6.150% Notes due November 2036
Debt Instrument [Line Items]
Gross value	$ 190
Interest Rate	6.15%
Long-term debt
Long-term debt	$ 190	190
4.800% Notes due August 2038
Debt Instrument [Line Items]
Gross value	$ 2,200
Interest Rate	4.80%
Long-term debt
Long-term debt	$ 2,194	2,193
3.200% Notes due March 2040
Debt Instrument [Line Items]
Gross value	$ 750
Interest Rate	3.20%
Long-term debt
Long-term debt	$ 748	744
5.875% Notes due March 2041
Debt Instrument [Line Items]
Gross value	$ 121
Interest Rate	5.875%
Long-term debt
Long-term debt	$ 119	119
6.125% Notes due November 2041
Debt Instrument [Line Items]
Gross value	$ 448
Interest Rate	6.125%
Long-term debt
Long-term debt	$ 484	485
5.375% Notes due February 2042
Debt Instrument [Line Items]
Gross value	$ 317
Interest Rate	5.375%
Long-term debt
Long-term debt	$ 315	315
4.800% Notes due July 2046
Debt Instrument [Line Items]
Gross value	$ 1,500
Interest Rate	4.80%
Long-term debt
Long-term debt	$ 1,469	1,469
3.875% Notes due October 2047
Debt Instrument [Line Items]
Gross value	$ 1,000
Interest Rate	3.875%
Long-term debt
Long-term debt	$ 990	990
4.900% Notes due December 2048
Debt Instrument [Line Items]
Gross value	$ 3,000
Interest Rate	4.90%
Long-term debt
Long-term debt	$ 2,972	2,971
3.400% Notes due March 2050
Debt Instrument [Line Items]
Gross value	$ 1,184
Interest Rate	3.40%
Long-term debt
Long-term debt	$ 1,172	1,237
3.400% Notes due March 2051
Debt Instrument [Line Items]
Gross value	$ 1,429
Interest Rate	3.40%
Long-term debt
Long-term debt	$ 1,410	1,479
5.600% Notes due February 2054
Debt Instrument [Line Items]
Gross value	$ 1,500
Interest Rate	5.60%
Long-term debt
Long-term debt	$ 1,486	1,482
6.000% Notes due January 2056
Debt Instrument [Line Items]
Gross value	$ 750
Interest Rate	6.00%
Long-term debt
Long-term debt	$ 735	$ 0

Debt - Debt Redemption and Issuance (Details)	1 Months Ended
Debt - Debt Redemption and Issuance (Details)	Sep. 30, 2025 USD ($)	Dec. 31, 2025
Senior Notes Issued September 2025 \| Senior Notes
Debt Instrument [Line Items]
Principal	$ 4,500,000,000
4.500% Notes due September 2030
Debt Instrument [Line Items]
Interest rate		4.50%
4.500% Notes due September 2030 \| Senior Notes
Debt Instrument [Line Items]
Principal	$ 1,000,000,000
Interest rate	4.50%
Net proceeds	$ 994,000,000
Redemption price discount, spread on variable rate	0.0015
4.875% Notes due September 2032
Debt Instrument [Line Items]
Interest rate		4.875%
4.875% Notes due September 2032 \| Senior Notes
Debt Instrument [Line Items]
Principal	$ 1,250,000,000
Interest rate	4.875%
Net proceeds	$ 1,245,000,000
Redemption price discount, spread on variable rate	0.0015
5.250% Notes due January 2036
Debt Instrument [Line Items]
Interest rate		5.25%
5.250% Notes due January 2036 \| Senior Notes
Debt Instrument [Line Items]
Principal	$ 1,500,000,000
Interest rate	5.25%
Net proceeds	$ 1,490,000,000
Redemption price discount, spread on variable rate	0.0015
6.000% Notes due January 2056
Debt Instrument [Line Items]
Interest rate		6.00%
6.000% Notes due January 2056 \| Senior Notes
Debt Instrument [Line Items]
Principal	$ 750,000,000
Interest rate	6.00%
Net proceeds	$ 736,000,000
Redemption price discount, spread on variable rate	0.0020

Debt - Term Loan (Details) - Term Loan Facility - Line of Credit - USD ($) $ in Billions	1 Months Ended
	Sep. 30, 2025	Aug. 31, 2025
Short-Term Debt [Line Items]
Credit agreement term		364 days
Principal		$ 2.0
Extinguishment of debt amount	$ 2.0

Debt - Revolving Credit Agreement and Commercial Paper (Details) - USD ($)	1 Months Ended
	Apr. 30, 2025	Dec. 31, 2025	Dec. 31, 2024
Debt Instrument [Line Items]
Commercial paper		$ 0	$ 880,000,000
Commercial Paper
Debt Instrument [Line Items]
Maximum borrowing capacity		6,500,000,000
Commercial paper		0
Revolving Credit Agreements, April 2025
Debt Instrument [Line Items]
Outstanding balances		$ 0
Maximum borrowing capacity	$ 6,500,000,000
Credit agreement term	5 years
Credit agreement term extension	1 year
Aggregate amount of options to increase commitments	$ 1,500,000,000
Maximum total commitment	$ 8,000,000,000.0
Leverage ratio covenant	60.00%
Revolving Credit Agreements, April 2025 \| Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 500,000,000

Debt - Debt Maturities (Details) $ in Millions	Dec. 31, 2025 USD ($)
Long-term Debt
2026	$ 550
2027	2,359
2028	3,800
2029	1,000
2030	2,400
Maturities after 2030	$ 21,485

Debt - Interest Expense (Details) - USD ($) $ in Billions	12 Months Ended
Debt - Interest Expense (Details) - USD ($) $ in Billions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Interest expense on long-term and short-term debt	$ 1.4	$ 1.5	$ 1.4

Common and Preferred Stock - Share Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Equity [Abstract]
Preferred stock, shares authorized	25,000,000
Preferred stock, par value	$ 1
Preferred stock, shares outstanding	0	0	0
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Common stock, par value	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized	600,000,000	600,000,000	600,000,000
Changes in Total Equity
Outstanding- January 1,	273,789,000	292,504,000	298,676,000
Net issued for stock option exercises and other benefit plans	1,569,000	2,198,000	1,619,000
Repurchased common stock	(11,894,000)	(20,913,000)	(7,791,000)
December 31,	263,464,000	273,789,000	292,504,000
Treasury stock	141,136,000	128,723,000	107,390,000
December 31,	404,600,000	402,512,000	399,894,000

Common and Preferred Stock - Dividends (Details) - USD ($) $ / shares in Units, $ in Millions														12 Months Ended
	Feb. 05, 2026	Dec. 18, 2025	Sep. 18, 2025	Jun. 18, 2025	Mar. 20, 2025	Dec. 19, 2024	Sep. 19, 2024	Jun. 20, 2024	Mar. 21, 2024	Dec. 21, 2023	Sep. 21, 2023	Jun. 22, 2023	Mar. 23, 2023	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Equity [Abstract]
Amount per share (in dollars per share)		$ 1.51	$ 1.51	$ 1.51	$ 1.51	$ 1.40	$ 1.40	$ 1.40	$ 1.40	$ 1.23	$ 1.23	$ 1.23	$ 1.23
Total amount paid		$ 396	$ 402	$ 401	$ 412	$ 384	$ 390	$ 392	$ 401	$ 358	$ 362	$ 362	$ 368	$ 1,611	$ 1,567	$ 1,450
Dividends Payable [Line Items]
Common dividends declared (in dollars per share)														$ 6.04	$ 5.60	$ 4.92
R2026Q1 Dividends [Member] \| Subsequent Event
Dividends Payable [Line Items]
Dividends Payable, Date Declared	Feb. 05, 2026
Common dividends declared (in dollars per share)	$ 1.56
Dividends Payable, Date to be Paid	Mar. 19, 2026
Dividends Payable, Date of Record	Mar. 05, 2026

Insurance and Contractholder Liabilities - Account Balances (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Current
Market risk benefits, current	$ 25	$ 25
Unearned premiums, current	822
Current insurance and contractholder liabilities	5,710	5,388
Non-current
Market risk benefits, non-current	649	760
Unearned premiums, non-current	40
Non-current insurance and contractholder liabilities	9,938	10,254
Total
Market risk benefits	674	785
Unearned premiums	862
Total insurance and contractholder liabilities	15,648	15,642
Cigna Healthcare
Current
Unpaid claims and claim expenses, current	4,180
Future policy benefits, current	38
Contractholder deposit funds, current	0
Non-current
Unpaid claims and claim expenses, non-current	61
Future policy benefits, non-current	153
Contractholder deposit funds, non-current	0
Total
Unpaid claims and claim expenses	4,241			$ 4,176
Total liability for future policy benefits	191
Contractholder deposit funds	0
Other
Current
Unpaid claims and claim expenses, current	167	147
Non-current
Unpaid claims and claim expenses, non-current	176	144
Total
Unpaid claims and claim expenses	343	291
Other Operations
Current
Future policy benefits, current	142	157
Contractholder deposit funds, current	336	366
Non-current
Future policy benefits, non-current	3,081	3,140
Contractholder deposit funds, non-current	5,778	5,958
Total
Total liability for future policy benefits	3,223	3,297
Contractholder deposit funds	$ 6,114	$ 6,324	$ 6,500

Insurance and Contractholder Liabilities - Account Balances including Disposal Groups (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Current
Market risk benefits, current	$ 25	$ 25
Unearned premiums, current, including held for sale liabilities		753
Total, including held for sale liabilities, current		6,480
Current insurance and contractholder liabilities	5,710	5,388
Non-current
Market risk benefits, non-current	649	760
Unearned premiums, non-current, including held for sale liabilities		31
Total, including liabilities held for sale, non-current		10,741
Non-current insurance and contractholder liabilities	9,938	10,254
Total
Market risk benefits	674	785
Unearned premiums, including held for sale liabilities		784
Total, including held for sale liabilities		17,221
Total insurance and contractholder liabilities	$ 15,648	15,642
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Current
Insurance and contractholder liabilities current, classified as held for sale		(1,092)
Non-current
Insurance and contractholder liabilities, non-current, classified as held for sale		(487)
Total
Insurance and contractholder liabilities classified as held for sale		(1,579)
Unpaid claims classified as liabilities of business held for sale			$ 823
Cigna Healthcare
Current
Unpaid claims and claim expenses, current, including held for sale liabilities		4,932
Future policy benefits, current, including held for sale liabilities		91
Contractholder deposit funds, current, including held for sale liabilities		9
Non-current
Unpaid claims and claim expenses, non-current, including held for sale liabilities		86
Future policy benefits, non-current, including held for sale liabilities		507
Contractholder deposit funds, non-current, including liabilities held for sale		115
Total
Unpaid claims and claim expenses, including held for sale liabilities		5,018	$ 5,092
Future policy benefits, including held for sale liabilities		598
Contractholder deposit funds, including liabilities held for sale		124
Cigna Healthcare \| Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Total
Unpaid claims classified as liabilities of business held for sale		983
Future policy benefits classified as liabilities of business held for sale		408
Unearned premiums classified as liabilities of business held for sale		85
Contractholder deposit funds classified as liabilities held for sale		$ 103

Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Paid costs related to:
Unpaid claims classified as liabilities of business held for sale			$ 823
Cigna Healthcare
Liability for Claims and Claims Adjustment Expense [Line Items]
Total of incurred but not reported liabilities plus expected claim development on reported claims and reported claims in process	$ 4,000	$ 4,600
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Beginning balance			4,176
Less: Reinsurance and other amounts recoverable			221
Beginning balance, net			3,955
Beginning balance, including held for sale liabilities	5,018	5,092
Less: Reinsurance, including held for sale liabilities	159	236
Beginning balance, net, including held for sale liabilities	4,859	4,856
Incurred costs related to:
Current year	33,816	38,347	35,953
Prior years	(342)	(456)	(279)
Total incurred	33,474	37,891	35,674
Paid costs related to:
Current year	28,769	33,718	31,322
Prior years	4,147	4,170	3,451
Total paid	32,916	37,888	34,773
Less: Divestiture and other	1,323	0	0
Ending balance, net	4,094
Add: Reinsurance and other amounts recoverable	147
Ending balance	$ 4,241
Ending balance, net, including held for sale liabilities		4,859	4,856
Add: Reinsurance, including held for sale liabilities		159	236
Ending balance, including held for sale liabilities		5,018	$ 5,092
Cigna Healthcare \| Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Paid costs related to:
Unpaid claims classified as liabilities of business held for sale		$ 983

Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details) - Cigna Healthcare - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 342	$ 456	$ 279
Favorable (unfavorable) variance, percentage	0.90%	1.30%
Actual completion factors and other
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 200	$ 223
Favorable (unfavorable) variance, percentage	0.50%	0.60%
Medical cost trend
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 142	$ 233
Favorable (unfavorable) variance, percentage	0.40%	0.70%

Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Incurred and Paid Claims Development and Unpaid Claims Liability (Details) - Cigna Healthcare claim in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2025 USD ($) claim	Dec. 31, 2024 USD ($) claim	Dec. 31, 2022 USD ($)
Claims Development [Line Items]
Incurred Costs	$ 70,383
Cumulative Costs Paid	65,179
Outstanding liabilities for the periods presented, net of reinsurance	5,204
Net unpaid claims and claims expenses - Cigna Healthcare	4,094		$ 3,955
Reinsurance and other amounts recoverable	147		221
Unpaid claims and claim expenses	$ 4,241		$ 4,176
Percent of health claims paid within one year	95.00%
Claim frequency \| claim	4.9	5.3
Disposed of by Sale \| Medicare Advantage and related Cigna Healthcare businesses
Claims Development [Line Items]
Divestiture and other	$ (1,110)
Incurral Year - 2024
Claims Development [Line Items]
Incurred Costs	36,853	$ 37,179
Cumulative Costs Paid	36,544	$ 32,719
Net unpaid claims and claims expenses - Cigna Healthcare	88
Incurral Year 2025
Claims Development [Line Items]
Incurred Costs	33,530
Cumulative Costs Paid	28,635
Net unpaid claims and claims expenses - Cigna Healthcare	$ 4,006

Insurance and Contractholder Liabilities - Future Policy Benefits - Accounting Policy (Details)	12 Months Ended
	Dec. 31, 2025
Insurance [Abstract]
Observable inputs from published spot rate curve term (in years)	30 years
Percent of the liability for future policy benefits supported by assets held in trust	36.00%

Insurance and Contractholder Liabilities - Future Policy Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cigna Healthcare
Liability for Future Policy Benefit Activity [Line Items]
Liability for Future Policy Benefit, Expected Net Premium, Period Increase (Decrease)
Liability for Future Policy Benefit, Expected Future Policy Benefit, Period Increase (Decrease)
Total liability for future policy benefits	191
Other Operations
Liability for Future Policy Benefit Activity [Line Items]
Deferred profit liability included in future policy benefits	347	366
Future policy benefit, excluding deferred profit liability	2,900	2,900	$ 3,200
Total liability for future policy benefits	3,223	3,297
Undiscounted expected future policy benefits	4,200	4,300
Future policy benefits reserve, reinsurance recoverables	$ 800	$ 900
Other Operations \| Life and annuity insurance products
Liability for Future Policy Benefit Activity [Line Items]
Interest accretion rate	5.64%	5.64%
Current discount rate	5.18%	5.42%
Weighted average duration	10 years 7 months 6 days	10 years 9 months 18 days

Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details) - Other Operations - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Policyholder Account Balance [Line Items]
Contractholder deposit funds	$ 6,114	$ 6,324	$ 6,500
Contractholder deposit fund liabilities, approximate percent reinsured externally	37.00%	38.00%
Weighted average crediting rate	3.29%	3.33%
Net amount at risk	$ 2,500	$ 2,800
Cash surrender value	$ 2,800	$ 2,800
Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400
Policyholder Account Balance [Line Items]
Contractholder deposit funds not reinsured externally, percent with guaranteed interest rates of 0300 to 0400	99.00%	99.00%
Contractholder deposit funds not reinsured externally	$ 3,900	$ 4,000
Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 \| Policyholder Account Balance, at Guaranteed Minimum Crediting Rate
Policyholder Account Balance [Line Items]
Contractholder deposit funds not reinsured externally	1,200	1,200
Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 \| Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150
Policyholder Account Balance [Line Items]
Contractholder deposit funds not reinsured externally	1,100	1,200
Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400 \| Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value
Policyholder Account Balance [Line Items]
Contractholder deposit funds not reinsured externally	$ 1,600	$ 1,600
Percentage with cash values at more than 110% of guaranteed cash value	90.00%	90.00%
Minimum \| Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150
Policyholder Account Balance [Line Items]
Basis points above guaranteed minimum crediting rate	0.0050	0.0050
Minimum \| Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400
Policyholder Account Balance [Line Items]
Guaranteed minimum credit rating	3.00%	3.00%
Maximum \| Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150
Policyholder Account Balance [Line Items]
Basis points above guaranteed minimum crediting rate	0.0150	0.0150
Maximum \| Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400
Policyholder Account Balance [Line Items]
Guaranteed minimum credit rating	4.00%	4.00%

Insurance and Contractholder Liabilities - Market Risk Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Insurance Loss Reserves [Abstract]
Annuitization election period	30 days
Market Risk Benefit [Roll Forward]
Balance, beginning of year	$ 785	$ 1,003
Balance, beginning of year, before the effect of nonperformance risk (own credit risk)	838	1,085
Changes due to expected run-off	(20)	(12)
Changes due to capital markets versus expected	(63)	(233)
Changes due to policyholder behavior versus expected	(24)	(39)
Assumption changes	(17)	37
Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)	714	838
Nonperformance risk (own credit risk), end of period	(40)	(53)
Balance, end of period	674	785
Reinsured market risk benefit, end of period	$ 712	$ 836

Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details) - Variable Annuity contractholder in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2025 USD ($) contractholder	Dec. 31, 2024 USD ($) contractholder
Net Amount at Risk by Product and Guarantee [Line Items]
Account value	$ 7,281	$ 7,777
Net amount at risk	$ 1,115	$ 1,283
Average attained age of contractholders (weighted by exposure)	78 years 3 months 18 days	77 years 8 months 12 days
Guaranteed Minimum Death Benefits Total Contractholders \| contractholder	110	130

Reinsurance - Reinsurance Recoverables (Details) $ in Millions	12 Months Ended
	Dec. 31, 2025 USD ($) reinsurer	Dec. 31, 2024 USD ($)
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	$ 3,534
Allowance for uncollectible reinsurance	(23)
Market risk benefits	712	$ 836
Total reinsurance recoverables	4,223
Other Current Assets
Ceded Credit Risk [Line Items]
Total reinsurance recoverables	120
Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	373
Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	2,849
No Collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	312
BBB+ equivalent and higher current ratings \| Acquisition, disposition or run-off activities
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	$ 3,158
Number of reinsurers \| reinsurer	6
BBB+ equivalent and higher current ratings \| Acquisition, disposition or run-off activities \| The Lincoln National Life Insurance Company And Lincoln Life And Annuity Of New York
Ceded Credit Risk [Line Items]
Number of reinsurers \| reinsurer	2
BBB+ equivalent and higher current ratings \| Acquisition, disposition or run-off activities \| The Lincoln National Life Insurance Company And Lincoln Life And Annuity Of New York \| Reinsurer Concentration Risk \| Reinsurance Recoverables, Gross, Acquisition Disposition Runoff Activities, Nationally Recognized Statistical Rating Organizations, BBB+ Or Higher
Ceded Credit Risk [Line Items]
Concentration percentage	76.00%
BBB+ equivalent and higher current ratings \| Acquisition, disposition or run-off activities \| Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	$ 288
BBB+ equivalent and higher current ratings \| Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	2,838
BBB+ equivalent and higher current ratings \| Acquisition, disposition or run-off activities \| No Collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	32
A- equivalent and higher current ratings \| Ongoing operations
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	216
A- equivalent and higher current ratings \| Ongoing operations \| Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	0
A- equivalent and higher current ratings \| Ongoing operations \| Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	5
A- equivalent and higher current ratings \| Ongoing operations \| No Collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	211
BBB- to BBB+ equivalent current credit ratings \| Ongoing operations
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	64
BBB- to BBB+ equivalent current credit ratings \| Ongoing operations \| Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	0
BBB- to BBB+ equivalent current credit ratings \| Ongoing operations \| Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	0
BBB- to BBB+ equivalent current credit ratings \| Ongoing operations \| No Collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	64
Not rated \| Ongoing operations
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	90
Not rated \| Ongoing operations \| Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	85
Not rated \| Ongoing operations \| Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	1
Not rated \| Ongoing operations \| No Collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	4
Not rated \| Acquisition, disposition or run-off activities
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	6
Not rated \| Acquisition, disposition or run-off activities \| Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	0
Not rated \| Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	5
Not rated \| Acquisition, disposition or run-off activities \| No Collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables before market risk benefits	$ 1

Reinsurance - Variable Annuity Reinsurance Agreement (Details) - Variable Annuity - Berkshire Hathway Life Insurance Company Of Nebraska - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2013
Ceded Credit Risk [Line Items]
Reinsurance, Reinsured Risk, Percentage		100.00%
Remaining overall limit under reinsurance agreement	$ 3.0
Secured \| Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due \| Collateralization risk
Ceded Credit Risk [Line Items]
Concentration percentage	100.00%

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

Reinsurance - Effects of Reinsurance (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Effects of Reinsurance [Line Items]
Premiums	$ 40,261	$ 45,996	$ 44,237
Reinsurance recoveries	671	573	456
Short-duration
Effects of Reinsurance [Line Items]
Premiums	39,300	43,900	42,300
Assumed premiums earned
Ceded premiums earned
Long-duration
Effects of Reinsurance [Line Items]
Premiums	1,000	2,000	1,900
Assumed premiums earned
Ceded premiums earned

Amount of earned premiums ceded to other entities.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-15

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479838/944-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478832/944-605-45-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478832/944-605-45-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479032/944-605-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479032/944-605-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.12-17(Column C))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477965/944-235-S99-2

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479032/944-605-50-1

Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-15

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479838/944-20-50-1

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.12-17(Column E))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477965/944-235-S99-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479032/944-605-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13)(c))
-SubTopic 220
-Topic 942
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(1))
-SubTopic 220
-Topic 944
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Investments - Investments by Category (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Schedule of Investments [Line Items]
Current investments	$ 1,056	$ 665
Long-term investments	18,471	15,128
Total investments	19,527	$ 15,793
Debt securities
Schedule of Investments [Line Items]
Current investments	691
Long-term investments	7,671
Total investments	8,362
Equity securities
Schedule of Investments [Line Items]
Current investments	22
Long-term investments	3,534
Total investments	3,556
Commercial mortgage loans
Schedule of Investments [Line Items]
Current investments	86
Long-term investments	1,147
Total investments	1,233
Policy loans
Schedule of Investments [Line Items]
Current investments	0
Long-term investments	1,082
Total investments	1,082
Other long-term investments
Schedule of Investments [Line Items]
Current investments	0
Long-term investments	5,037
Total investments	5,037
Short-term investments
Schedule of Investments [Line Items]
Current investments	257
Long-term investments	0
Total investments	$ 257

Investments - Investments by Category, Including Disposal Groups (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Current
Investments including held for sale assets		$ 748
Current investments	$ 1,056	665
Long-term
Investments including held for sale assets		16,489
Investments per Consolidated Balance Sheets	18,471	15,128
Total
Investments including held for sale assets		17,237
Total investments	19,527	15,793
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Current
Investments classified as assets of business held for sale		(83)
Long-term
Investments classified as assets of business held for sale		(1,361)
Total
Investments classified as assets of business held for sale		(1,444)
Debt securities
Current
Investments including held for sale assets		463
Current investments	691
Long-term
Investments including held for sale assets		8,960
Investments per Consolidated Balance Sheets	7,671
Total
Investments including held for sale assets		9,423
Total investments	8,362
Equity securities
Current
Investments including held for sale assets		7
Current investments	22
Long-term
Investments including held for sale assets		554
Investments per Consolidated Balance Sheets	3,534
Total
Investments including held for sale assets		561
Total investments	3,556
Commercial mortgage loans
Current
Investments including held for sale assets		108
Current investments	86
Long-term
Investments including held for sale assets		1,243
Investments per Consolidated Balance Sheets	1,147
Total
Investments including held for sale assets		1,351
Total investments	1,233
Policy loans
Current
Investments including held for sale assets		0
Current investments	0
Long-term
Investments including held for sale assets		1,156
Investments per Consolidated Balance Sheets	1,082
Total
Investments including held for sale assets		1,156
Total investments	1,082
Other long-term investments
Current
Investments including held for sale assets		0
Current investments	0
Long-term
Investments including held for sale assets		4,576
Investments per Consolidated Balance Sheets	5,037
Total
Investments including held for sale assets		4,576
Total investments	5,037
Short-term investments
Current
Investments including held for sale assets		170
Current investments	257
Long-term
Investments including held for sale assets		0
Investments per Consolidated Balance Sheets	0
Total
Investments including held for sale assets		$ 170
Total investments	$ 257

Investments - Debt Securities by Contractual Maturity Periods (Details) $ in Millions	Dec. 31, 2025 USD ($)
Amortized Cost
Due in one year or less	$ 695
Due after one year through five years	3,700
Due after five years through ten years	2,030
Due after ten years	1,968
Mortgage and other asset-backed securities	267
Total	8,660
Fair Value
Due in one year or less	598
Due after one year through five years	3,703
Due after five years through ten years	1,995
Due after ten years	1,822
Mortgage and other asset-backed securities	244
Total	$ 8,362

Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities by Type of Issuer (Details) $ in Millions	Dec. 31, 2025 USD ($)
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 8,660
Allowance for Credit Loss	(137)
Unrealized Appreciation	206
Unrealized Depreciation	(367)
Fair Value	8,362
Federal government and agency
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	215
Allowance for Credit Loss	0
Unrealized Appreciation	15
Unrealized Depreciation	(3)
Fair Value	227
State and local government
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	24
Allowance for Credit Loss	0
Unrealized Appreciation	1
Unrealized Depreciation	0
Fair Value	25
Foreign government
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	450
Allowance for Credit Loss	0
Unrealized Appreciation	12
Unrealized Depreciation	(6)
Fair Value	456
Corporate
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	7,704
Allowance for Credit Loss	(137)
Unrealized Appreciation	175
Unrealized Depreciation	(332)
Fair Value	7,410
Mortgage and other asset-backed
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	267
Allowance for Credit Loss	0
Unrealized Appreciation	3
Unrealized Depreciation	(26)
Fair Value	$ 244

Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities by Type of Issuer, Including Disposal Groups (Details) $ in Millions	Dec. 31, 2024 USD ($)
Debt Securities, Available-for-sale [Line Items]
Amortized cost, including held for sale assets	$ 10,125
Allowance for Credit Loss, including held for sale assets	(111)
Unrealized Appreciation, including held for sale assets	123
Unrealized Depreciation, including held for sale assets	(714)
Fair Value, including held for sale assets	9,423
Federal government and agency
Debt Securities, Available-for-sale [Line Items]
Amortized cost, including held for sale assets	276
Allowance for Credit Loss, including held for sale assets	0
Unrealized Appreciation, including held for sale assets	14
Unrealized Depreciation, including held for sale assets	(9)
Fair Value, including held for sale assets	281
State and local government
Debt Securities, Available-for-sale [Line Items]
Amortized cost, including held for sale assets	37
Allowance for Credit Loss, including held for sale assets	0
Unrealized Appreciation, including held for sale assets	1
Unrealized Depreciation, including held for sale assets	(1)
Fair Value, including held for sale assets	37
Foreign government
Debt Securities, Available-for-sale [Line Items]
Amortized cost, including held for sale assets	350
Allowance for Credit Loss, including held for sale assets	0
Unrealized Appreciation, including held for sale assets	5
Unrealized Depreciation, including held for sale assets	(11)
Fair Value, including held for sale assets	344
Corporate
Debt Securities, Available-for-sale [Line Items]
Amortized cost, including held for sale assets	9,091
Allowance for Credit Loss, including held for sale assets	(111)
Unrealized Appreciation, including held for sale assets	102
Unrealized Depreciation, including held for sale assets	(659)
Fair Value, including held for sale assets	8,423
Mortgage and other asset-backed
Debt Securities, Available-for-sale [Line Items]
Amortized cost, including held for sale assets	371
Allowance for Credit Loss, including held for sale assets	0
Unrealized Appreciation, including held for sale assets	1
Unrealized Depreciation, including held for sale assets	(34)
Fair Value, including held for sale assets	$ 338

Investments - Summary of Debt Securities with a Decline in Fair Value (Details) $ in Millions	Dec. 31, 2025 USD ($) position
Total
Fair Value	$ 3,733
Total Amortized Cost	4,100
Unrealized Depreciation	$ (367)
Number of Issues \| position	1,273
Investment grade
One year or less
Fair Value	$ 384
Amortized Cost	386
Unrealized Depreciation	$ (2)
Number of Issues \| position	149
More than one year
Fair Value	$ 3,044
Amortized Cost	3,382
Unrealized Depreciation	$ (338)
Number of Issues \| position	799
Below investment grade
One year or less
Fair Value	$ 120
Amortized Cost	125
Unrealized Depreciation	$ (5)
Number of Issues \| position	239
More than one year
Fair Value	$ 185
Amortized Cost	207
Unrealized Depreciation	$ (22)
Number of Issues \| position	86

Investments - Debt Securities with a Decline in Fair Value, Including Disposal Groups (Details) $ in Millions	Dec. 31, 2024 USD ($) position
Total
Total Fair Value, including held for sale assets	$ 6,551
Total Amortized Cost, including held for sale assets	7,265
Total Unrealized Depreciation, including held for sale assets	$ (714)
Debt securities
Total
Total Number of Issues, including held for sale assets \| position	2,704
Investment grade \| Debt securities
One year or less
Fair Value, including held for sale assets	$ 1,203
Amortized Cost, including held for sale assets	1,227
Unrealized Depreciation, including held for sale assets	$ (24)
Number of Issues, including held for sale assets \| position	545
More than one year
Fair Value, including held for sale assets	$ 4,687
Amortized Cost, including held for sale assets	5,319
Unrealized Depreciation, including held for sale assets	$ (632)
Number of Issues, including held for sale assets \| position	1,297
Below investment grade \| Debt securities
One year or less
Fair Value, including held for sale assets	$ 245
Amortized Cost, including held for sale assets	250
Unrealized Depreciation, including held for sale assets	$ (5)
Number of Issues, including held for sale assets \| position	739
More than one year
Fair Value, including held for sale assets	$ 416
Amortized Cost, including held for sale assets	469
Unrealized Depreciation, including held for sale assets	$ (53)
Number of Issues, including held for sale assets \| position	123

Investments - Equity Securities (Details) - USD ($) $ in Millions	Dec. 31, 2025	Sep. 30, 2025	Dec. 31, 2024
Cost
Equity securities with readily determinable fair values	$ 78		$ 635
Equity securities with no readily determinable fair value	6,792		3,215
Total	6,870		3,850
Carrying Value
Equity securities with readily determinable fair values	92		37
Equity securities with no readily determinable fair value	3,464		524
Total	$ 3,556		$ 561
Shields Health Solutions \| Preferred Stock
Carrying Value
Equity securities with no readily determinable fair value		$ 3,500

Investments - Commercial Mortgage Loans (Details) - Real Estate Loan - Commercial Portfolio Segment $ in Millions	12 Months Ended
	Dec. 31, 2025 USD ($)
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss	$ 1,233
Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.72
Average Loan-to-Value Ratio	71.00%
Below 60%
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss	$ 355
Below 60% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	2.13
60% to 79%
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss	$ 694
60% to 79% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.81
80% to 100%
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss	$ 184
80% to 100% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	0.79

Investments - Commercial Mortgage Loans, Including Disposal Groups (Details) - Real Estate Loan - Commercial Portfolio Segment $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($)
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss, including assets held for sale	$ 1,351
Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio, including assets held for sale	1.70
Average Loan-to-Value Ratio, including assets held for sale	0.69
Below 60%
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss, including assets held for sale	$ 547
Below 60% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio, including assets held for sale	2.07
60% to 79%
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss, including assets held for sale	$ 595
60% to 79% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio, including assets held for sale	1.83
80% to 100%
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss, including assets held for sale	$ 209
80% to 100% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio, including assets held for sale	0.51

Investments - Other Long-Term Investments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Schedule of Investments [Line Items]
Unfunded commitments, percentage expected to fund in next fiscal year	30.00%
Income distributions	$ 314	$ 344	$ 253
Other long-term investments	5,037
Unfunded commitments	3,164
Real estate investments
Schedule of Investments [Line Items]
Other long-term investments	1,895	1,763
Unfunded commitments	1,106
Securities partnerships
Schedule of Investments [Line Items]
Other long-term investments	2,948	$ 2,587
Unfunded commitments	2,058
Other
Schedule of Investments [Line Items]
Other long-term investments	194
Unfunded commitments	$ 0

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column B)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column D))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column B)(Footnote 10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 12))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 13))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 49: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 50: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 51: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 52: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 53: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 54: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 55: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 56: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 57: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 58: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 59: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 60: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 61: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 62: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 63: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 64: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 19
-Subparagraph (1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19

Reference 65: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 19
-Subparagraph (3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19

Investments - Other Long-Term Investments, Including Disposal Groups (Details) $ in Millions	Dec. 31, 2024 USD ($)
Schedule of Investments [Line Items]
Other long term investments, including held for sale assets	$ 4,576
Other
Schedule of Investments [Line Items]
Other long term investments, including held for sale assets	$ 226

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column A)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column B)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12(Column C)(Footnote 10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column D))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column A)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column B)(Footnote 10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 12))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column C)(Footnote 13))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 49: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 50: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 51: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 52: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 53: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 54: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 55: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 56: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 57: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 58: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column A)(Footnote 3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 59: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 60: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 61: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 62: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 63: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14(Column F)(Footnote 9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6

Reference 64: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 19
-Subparagraph (1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19

Reference 65: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 320
-Name Accounting Standards Codification
-Section S99
-Paragraph 19
-Subparagraph (3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19

Investments - Derivative Financial Instruments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Derivative [Line Items]
Derivative gain (loss) reclassified from other comprehensive income into shareholders' net income
Derivative gain (loss) recognized in other comprehensive income
Derivative gain (loss) recognized in the income statement
Designated as Hedging Instrument \| Fair Value Hedging \| Currency Swap
Derivative [Line Items]
Notional Value	908	975
Designated as Hedging Instrument \| Fair Value Hedging \| Interest Rate Swap
Derivative [Line Items]
Notional Value	3,150	2,700
Designated as Hedging Instrument \| Net Investment Hedging \| Currency Swap
Derivative [Line Items]
Notional Value	$ 415	$ 415

Investments - Components of Net Investment Income/Losses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Net Investment Income [Line Items]
Investment income	$ 1,089	$ 1,017	$ 1,210
Less investment expenses	43	44	44
Net investment income	1,046	973	1,166
Impairment of dividend receivable		182
Debt securities
Net Investment Income [Line Items]
Investment income	454	492	500
Equity securities
Net Investment Income [Line Items]
Investment income	6	(114)	123
Commercial mortgage loans
Net Investment Income [Line Items]
Investment income	52	61	65
Policy loans
Net Investment Income [Line Items]
Investment income	51	56	60
Other long-term investments
Net Investment Income [Line Items]
Investment income	232	75	123
Short-term investments and cash
Net Investment Income [Line Items]
Investment income	$ 294	$ 447	$ 339

Investments - Investment Gains and Losses (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Investments [Abstract]
Net investment losses	$ (24)	$ (2,737)	$ (78)

Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Financial assets at fair value:
Equity securities	$ 92	$ 37
Liabilities, Fair Value Disclosure [Abstract]
Percent of debt securities classified in Level 3	4.00%
Recurring
Financial assets at fair value:
Debt Securities	$ 8,362
Equity securities	92	37
Short-term investments	257	170
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	105
Equity securities	54	1
Short-term investments	0	0
Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	7,932
Equity securities	36	36
Short-term investments	257	170
Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	325
Equity securities	2	0
Short-term investments	0	0
Federal government and agency \| Recurring
Financial assets at fair value:
Debt Securities	227
Federal government and agency \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	105
Federal government and agency \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	122
Federal government and agency \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	0
State and local government \| Recurring
Financial assets at fair value:
Debt Securities	25
State and local government \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	0
State and local government \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	25
State and local government \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	0
Foreign government \| Recurring
Financial assets at fair value:
Debt Securities	456
Foreign government \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	0
Foreign government \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	446
Foreign government \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	10
Corporate \| Recurring
Financial assets at fair value:
Debt Securities	7,410
Corporate \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	0
Corporate \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	7,133
Corporate \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	277
Mortgage and other asset-backed \| Recurring
Financial assets at fair value:
Debt Securities	244
Mortgage and other asset-backed \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	0
Mortgage and other asset-backed \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	206
Mortgage and other asset-backed \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	38
Derivatives \| Recurring
Financial assets at fair value:
Derivative assets	991	168
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	376	1
Derivatives \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Derivative assets	0	0
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	0	0
Derivatives \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Derivative assets	68	168
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	22	1
Derivatives \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Derivative assets	923	0
Liabilities, Fair Value Disclosure [Abstract]
Derivative liabilities	$ 354	$ 0

Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value, Including Disposal Groups (Details) - Recurring $ in Millions	Dec. 31, 2024 USD ($)
Financial assets at fair value:
Debt Securities, including held for sale assets	$ 9,423
Quoted Prices in Active Markets for Identical Assets (Level 1)
Financial assets at fair value:
Debt Securities, including held for sale assets	165
Significant Other Observable Inputs (Level 2)
Financial assets at fair value:
Debt Securities, including held for sale assets	8,841
Significant Unobservable Inputs (Level 3)
Financial assets at fair value:
Debt Securities, including held for sale assets	417
Federal government and agency
Financial assets at fair value:
Debt Securities, including held for sale assets	281
Federal government and agency \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Financial assets at fair value:
Debt Securities, including held for sale assets	165
Federal government and agency \| Significant Other Observable Inputs (Level 2)
Financial assets at fair value:
Debt Securities, including held for sale assets	116
Federal government and agency \| Significant Unobservable Inputs (Level 3)
Financial assets at fair value:
Debt Securities, including held for sale assets	0
State and local government
Financial assets at fair value:
Debt Securities, including held for sale assets	37
State and local government \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Financial assets at fair value:
Debt Securities, including held for sale assets	0
State and local government \| Significant Other Observable Inputs (Level 2)
Financial assets at fair value:
Debt Securities, including held for sale assets	37
State and local government \| Significant Unobservable Inputs (Level 3)
Financial assets at fair value:
Debt Securities, including held for sale assets	0
Foreign government
Financial assets at fair value:
Debt Securities, including held for sale assets	344
Foreign government \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Financial assets at fair value:
Debt Securities, including held for sale assets	0
Foreign government \| Significant Other Observable Inputs (Level 2)
Financial assets at fair value:
Debt Securities, including held for sale assets	344
Foreign government \| Significant Unobservable Inputs (Level 3)
Financial assets at fair value:
Debt Securities, including held for sale assets	0
Corporate
Financial assets at fair value:
Debt Securities, including held for sale assets	8,423
Corporate \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Financial assets at fair value:
Debt Securities, including held for sale assets	0
Corporate \| Significant Other Observable Inputs (Level 2)
Financial assets at fair value:
Debt Securities, including held for sale assets	8,049
Corporate \| Significant Unobservable Inputs (Level 3)
Financial assets at fair value:
Debt Securities, including held for sale assets	374
Mortgage and other asset-backed
Financial assets at fair value:
Debt Securities, including held for sale assets	338
Mortgage and other asset-backed \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Financial assets at fair value:
Debt Securities, including held for sale assets	0
Mortgage and other asset-backed \| Significant Other Observable Inputs (Level 2)
Financial assets at fair value:
Debt Securities, including held for sale assets	295
Mortgage and other asset-backed \| Significant Unobservable Inputs (Level 3)
Financial assets at fair value:
Debt Securities, including held for sale assets	$ 43

Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details) - Recurring - Significant Unobservable Inputs (Level 3) $ in Millions	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Debt securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 325
Corporate \| Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 286
Corporate \| Securities Priced by the Company \| Minimum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0060
Corporate \| Securities Priced by the Company \| Maximum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0920
Corporate \| Securities Priced by the Company \| Weighted Average \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0175
Mortgage and other asset-backed securities \| Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 38
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Minimum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0105
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Maximum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0350
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Weighted Average \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0160
Other debt securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 1	$ 1

Fair Value Measurements - Quantitative Information About Unobservable Inputs, Including Disposal Groups (Details) - Recurring - Significant Unobservable Inputs (Level 3) $ in Millions	Dec. 31, 2024 USD ($)
Debt securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value, including held for sale assets	$ 417
Corporate \| Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value, including held for sale assets	$ 373
Corporate \| Securities Priced by the Company \| Minimum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment, including held for sale assets	0.0060
Corporate \| Securities Priced by the Company \| Maximum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment, including held for sale assets	0.1520
Corporate \| Securities Priced by the Company \| Weighted Average \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment, including held for sale assets	0.0370
Mortgage and other asset-backed securities \| Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value, including held for sale assets	$ 43
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Minimum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment, including held for sale assets	0.0100
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Maximum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment, including held for sale assets	0.0550
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Weighted Average \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment, including held for sale assets	0.0280

Fair Value Measurements - Information about Derivative Instruments (Details) - Discounted Cash Flow - Significant Unobservable Inputs (Level 3)	Dec. 31, 2025
Adjusted EBITDA Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Measurement Input	0.55
Equity Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Measurement Input	0.85
Correlation
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Measurement Input	0.35
Purchaser credit spread
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Measurement Input	0.007
Weighted Average Cost of Capital
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Measurement Input	0.135

Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance, including held for sale assets	$ 417	$ 447
Losses included in Shareholders' net income	(90)	(69)
Gains (losses) included in Other comprehensive loss	33	(9)
Purchases, sales and settlements
Purchases	655	17
Sales	(8)	(2)
Settlements	(105)	(21)
Total purchases, sales and settlements	542	(6)
Transfers into / (out of) Level 3
Transfers into Level 3	59	72
Transfers out of Level 3	(65)	(18)
Total transfers into / (out of) Level 3	(6)	54
Ending balance	896
Ending balance, including held for sale assets		417
Total losses included in Shareholders' net income attributable to instruments held at the reporting date	(94)	(69)
Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period	$ 19	$ (9)
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Net investment income, Net investment losses
Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Asset, Gain (Loss), Statement of Other Comprehensive Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Available-For-Sale Securities And Derivatives Adjustment, Net Of Tax

Fair Value Measurements - Separate Accounts (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	$ 7,487	$ 7,278
Separate Account Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate accounts assets classified in Level 3, period increase (decrease), including transfers in and out of Level 3
Pension Plans \| Separate Account, Non-Guaranteed Separate Accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	3,800	3,800
Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	6,826	6,646
Total \| Separate Account, Guaranteed Separate Accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	577	576
Total \| Separate Account, Non-Guaranteed Separate Accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	6,249	6,070
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	518	498
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Separate Account, Guaranteed Separate Accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	247	231
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Separate Account, Non-Guaranteed Separate Accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	271	267
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	6,099	5,920
Significant Other Observable Inputs (Level 2) \| Separate Account, Guaranteed Separate Accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	330	345
Significant Other Observable Inputs (Level 2) \| Separate Account, Non-Guaranteed Separate Accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	5,769	5,575
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	209	228
Significant Unobservable Inputs (Level 3) \| Separate Account, Guaranteed Separate Accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	0	0
Significant Unobservable Inputs (Level 3) \| Separate Account, Non-Guaranteed Separate Accounts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	209	228
Significant Unobservable Inputs (Level 3) \| Pension Plans
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	200	200
NAV
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Separate account assets	$ 661	$ 632

Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Impairments requiring certain assets and liabilities to be measured at fair value
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount
VillageMD
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount		$ 2.7

Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Fair Value \| Significant Other Observable Inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities, excluding finance leases	$ 29,907	$ 28,392
Fair Value \| Significant Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial mortgage loans	1,195	1,256
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial mortgage loans	1,233	1,351
Long-term debt, including current maturities, excluding finance leases	$ 31,352	$ 31,008

The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-SubTopic 10
-Topic 825
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482881/825-10-55-10

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-11

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-10

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482881/825-10-55-12

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Variable Interest Entities (Details)	Dec. 31, 2025 USD ($) entity limitedPartnership	Dec. 31, 2024 entity
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Number of VIEs \| entity	0	0
Variable Interest Entity, Not Primary Beneficiary \| Securities limited partnerships and real estate limited partnerships
Variable Interest Entity [Line Items]
Number of VIEs \| limitedPartnership	215
VIEs, Carrying value	$ 3,700,000,000
Maximum exposure to loss, variable interest entities	6,500,000,000
Variable Interest Entity, Not Primary Beneficiary \| Real estate limited partnerships
Variable Interest Entity [Line Items]
Guaranty liability	0
Maximum guarantee exposure	380,000,000
Variable Interest Entity, Not Primary Beneficiary \| Asset-backed and corporate securities
Variable Interest Entity [Line Items]
Maximum exposure to loss, variable interest entities	400,000,000
Variable Interest Entity, Not Primary Beneficiary \| Real estate joint ventures
Variable Interest Entity [Line Items]
Maximum exposure to loss, variable interest entities	1,000,000,000.0
Variable Interest Entity, Not Primary Beneficiary \| Other Variable Interest Entities
Variable Interest Entity [Line Items]
VIEs, Carrying value
Maximum exposure to loss, variable interest entities
Variable Interest Entity, Not Primary Beneficiary \| Securities limited partnerships and real estate limited partnerships \| Maximum
Variable Interest Entity [Line Items]
Ownership percentage, less than	9.00%
Variable Interest Entity, Not Primary Beneficiary \| Commitment to fund partnership \| Securities limited partnerships and real estate limited partnerships
Variable Interest Entity [Line Items]
Additional commitments	$ 2,800,000,000

Collectively Significant Operating Unconsolidated Subsidiaries (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Equity Method Investment, Summarized Financial Information [Abstract]
Loss related to unconsolidated entities reported on the equity method	$ (2,341)	$ (2,806)	$ (2,341)
Income Statement [Abstract]
Revenues		274,900	247,121	$ 195,265
Net income		6,288	3,778	5,372
Balance Sheet [Abstract]
Total assets	155,881	157,919	155,881
Total liabilities	114,638	116,045	114,638
Portion Of Operating Joint Venture \| Disposed of by Sale
Balance Sheet [Abstract]
Gain (loss) on sale of business, pre-tax	$ 496
Loss on sale of businesses, Consolidated Statements of Income location	Net gain (loss) on sale of businesses
Operating joint ventures
Equity Method Investment, Summarized Financial Information [Abstract]
Equity method investments, carrying value	$ 656	(211)	656
Joint venture in China
Equity Method Investment, Summarized Financial Information [Abstract]
Equity method investments, carrying value	43	(296)	43
Loss related to unconsolidated entities reported on the equity method	(979)	(1,672)	(979)
Operating joint ventures
Income Statement [Abstract]
Revenues		7,747	7,309	5,962
Net income		755	607	$ 98
Balance Sheet [Abstract]
Total assets	34,395	39,547	34,395
Total liabilities	$ 33,892	$ 40,009	$ 33,892

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance	$ 41,243	$ 46,244	$ 44,688
Other comprehensive income (loss)	(465)	(477)	(206)
Balance	41,874	41,243	46,244
AOCI Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance	(2,341)	(1,864)	(1,658)
Other comprehensive income (loss)	(465)	(477)	(206)
Balance	(2,806)	(2,341)	(1,864)
Other Comprehensive Income (Loss), Tax [Abstract]
Other Comprehensive Income (Loss), Tax	180	149	79
Securities and derivatives
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance	832	171	(332)
Other comprehensive income (loss) before reclassifications, after-tax	(309)	601	474
Net amounts reclassified from AOCI to net income	71	60	29
Other comprehensive income (loss)	(238)	661	503
Balance	594	832	171
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss), before reclassifications, tax	118	(207)	(146)
Reclassification adjustment, tax	(20)	(16)	(8)
Net long-duration insurance and contractholder liabilities measurement adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance	(2,038)	(971)	(256)
Other comprehensive income (loss)	(291)	(1,067)	(715)
Balance	(2,329)	(2,038)	(971)
Change in discount rate for certain long-duration liabilities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Other comprehensive income (loss) before reclassifications, after-tax	(225)	(1,044)	(691)
Net amounts reclassified from AOCI to net income	(56)	0	0
Other comprehensive income (loss)	(281)	(1,044)	(691)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss), before reclassifications, tax	71	357	222
Reclassification adjustment, tax	16	0	0
Other Comprehensive Income (Loss), Tax	87	357	222
Change in instrument-specific credit risk for market risk benefits
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Other comprehensive income (loss) before reclassifications, after-tax	(10)	(23)	(24)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss), before reclassifications, tax	3	6	5
Translation of foreign currencies
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance	(198)	(149)	(154)
Other comprehensive income (loss) before reclassifications, after-tax	71	(60)	5
Net amounts reclassified from AOCI to net income	0	11	0
Other comprehensive income (loss)	71	(49)	5
Balance	(127)	(198)	(149)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss), before reclassifications, tax	(9)	2	5
Reclassification adjustment, tax	0	0	0
Postretirement benefits liability
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance	(937)	(915)	(916)
Other comprehensive income (loss) before reclassifications, after-tax	(32)	(44)	(34)
Net amounts reclassified from AOCI to net income	25	22	35
Other comprehensive income (loss)	(7)	(22)	1
Balance	(944)	(937)	(915)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss), before reclassifications, tax	9	14	12
Reclassification adjustment, tax	$ (8)	$ (7)	$ (11)

Strategic Optimization Program (Details) - Strategic Optimization Program - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Restructuring Reserve [Roll Forward]
Strategic optimization program costs	$ 749	$ 0	$ 0
Strategic optimization program costs, after-tax	565	0	$ 0
Employee severance, asset impairments and other
Restructuring Reserve [Roll Forward]
Strategic optimization program costs	616
Employee severance
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Strategic optimization program costs	378
Payments	(238)
Restructuring Reserve, Ending Balance	140	$ 0
Asset impairments
Restructuring Reserve [Roll Forward]
Strategic optimization program costs	101
Operating results of certain non-strategic businesses
Restructuring Reserve [Roll Forward]
Strategic optimization program costs	$ 133

Pension - Narrative (Details) - USD ($)	12 Months Ended
Pension - Narrative (Details) - USD ($)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Non-Qualified Plan
Defined Benefit Plan Disclosure [Line Items]
Plan assets	$ 0
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Plan assets	3,848,000,000	$ 3,854,000,000	$ 4,138,000,000
Contributions to qualifed pension plans	1,000,000	$ 4,000,000
Plan assets invested in separate accounts of subsidiaries	3,800,000,000
Plan assets invested in funds offered by an unaffiliated insurance company	100,000,000
Pension Plans \| Qualified Plan
Defined Benefit Plan Disclosure [Line Items]
Contributions to qualifed pension plans
Expected contributions to qualified pension plans in next fiscal year

Amount of contribution received by defined benefit plan from employer which increases plan assets.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-18

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (k)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (m)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480482/715-20-55-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-1

Pension - Projected Benefit Obligations and Assets (Details) - Pension Plans - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Change in benefit obligation
Benefit obligation, January 1	$ 3,643	$ 3,934
Service cost	0	1	$ 1
Interest cost	196	194	204
Actuarial (gains), net	109	(146)
Benefits paid from plan assets	(309)	(328)
Other	(9)	(12)
Benefit obligation, December 31	3,630	3,643	3,934
Change in plan assets
Fair value of plan assets, January 1	3,854	4,138
Actual return on plan assets	302	40
Benefits paid	(309)	(328)
Contributions	1	4
Fair value of plan assets, December 31	3,848	3,854	$ 4,138
Funded status	218	211
Amounts presented in Consolidated Balance Sheets
Other assets	$ 218	$ 211

Pension - Benefit Payments (Details) - Pension Plans $ in Millions	Dec. 31, 2025 USD ($)
Benefit payments including expected future services [Abstract]
2026	$ 316
2027	312
2028	310
2029	307
2030	304
2031 - 2035	$ 1,409

Pension - Amounts Included in Accumulated Other Comprehensive Income (Details) - Pension Plans - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Defined Benefit Plan Disclosure [Line Items]
Unrecognized net losses	$ (1,230)	$ (1,228)
Unrecognized prior service cost	(4)	(4)
Postretirement benefits liability adjustment	$ (1,234)	$ (1,232)

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (k)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (j)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (c)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (m)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480506/715-20-50-5

Pension - Net Pension Cost (Details) - Pension Plans - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost	$ 0	$ 1	$ 1
Interest cost	196	194	204
Expected long-term return on plan assets	(232)	(247)	(204)
Amortization of:
Prior actuarial losses, net	38	39	52
Curtailment loss	0	1	0
Net cost (benefit)	$ 2	$ (12)	$ 53

Pension - Assumptions Used for Pension (Details) - Pension Plans	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Discount rate:
Pension benefit obligation	5.27%	5.57%
Pension benefit cost	5.57%	5.10%
Expected long-term return on plan assets:
Pension benefit cost	6.50%	6.50%

Pension - Pension Plan Assets (Details) - Pension Plans - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	$ 3,848	$ 3,854	$ 4,138
Debt securities
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	$ 2,978	2,986
Target allocation percentages	90.00%
Federal government and agency
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	$ 100	99
Corporate
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	2,674	2,673
Mortgage and other asset-backed
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	138	138
Fund investments
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	$ 66	76
Other investments
Defined Benefit Plan Disclosure [Line Items]
Target allocation percentages	10.00%
Equity securities
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	$ 23	27
Domestic
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	23	21
International, including funds and pooled separate accounts
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	0	6
Securities partnerships
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	447	402
Real estate funds, including pooled separate accounts
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	212	228
Commercial mortgage loans
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	21	27
Guaranteed deposit account contract
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	48	47
Cash equivalents and other current assets, net
Defined Benefit Plan Disclosure [Line Items]
Pension assets at fair value	$ 119	$ 137

Pension - Annual Expense for 401(k) Plans (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Retirement Benefits [Abstract]
401(k) plan expense	$ 280	$ 301	$ 296

Employee Incentive Plans - Shares of Common Stock Available for Award (Details) - shares shares in Millions	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Common shares available for award (in shares)	10.4	12.4	14.4

Employee Incentive Plans - Narrative (Details) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2025 USD ($) employee $ / shares shares	Dec. 31, 2024 $ / shares shares	Dec. 31, 2023 $ / shares shares	Dec. 31, 2022 shares
Employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining maturity of traded options	1 year
Compensation expense to be recognized	$ 62
Period over which compensation expense will be recognized	2 years
Restricted Stock Grants and Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense to be recognized	$ 187
Period over which compensation expense will be recognized	2 years
Number of employees holding share-based payment awards \| employee	8,400
Awards outstanding (in shares) \| shares	1,138	1,250	1,404	1,535
SPSs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense to be recognized	$ 43
Period over which compensation expense will be recognized	2 years
Weighted average fair value per share for expense purposes, including the Monte Carlo Factor \| $ / shares	$ 323.60	$ 377.23	$ 329.11
Number of employees holding share-based payment awards \| employee	600
Awards outstanding (in shares) \| shares	505	601	686	780
Performance period	3 years
Minimum \| Employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
Minimum \| Restricted Stock Grants and Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year
Minimum \| SPSs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of original shares granted that may be awarded at end of performance period	0.00%
Maximum \| Employee Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Award expiration period	10 years
Maximum \| Restricted Stock Grants and Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Maximum \| SPSs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of original shares granted that may be awarded at end of performance period	200.00%

Employee Incentive Plans - Black-Scholes Option-Pricing Model Assumptions (Details) - Employee Stock Options - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	2.04%	1.74%	1.58%
Expected volatility	31.00%	30.00%	30.00%
Risk-free interest rate	4.40%	4.00%	3.60%
Expected option life	4 years 10 months 24 days	4 years 9 months 18 days	4 years 8 months 12 days
Weighted average fair value of options (in dollars per share)	$ 86.13	$ 92.36	$ 79.66

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Employee Incentive Plans - Status of and Changes in Common Stock Options (Details) - Employee Stock Options - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Options
Outstanding - January 1 (in shares)	5,655	6,696	6,992
Granted (in shares)	857	781	915
Exercised (in shares)	(1,088)	(1,727)	(1,080)
Expired or canceled (in shares)	(222)	(95)	(131)
Options outstanding - December 31 (in shares)	5,202	5,655	6,696
Options exercisable at year-end (in shares)	3,806	3,941	4,616
Weighted Average Exercise Price
Outstanding - January 1 (in dollars per share)	$ 226.38	$ 202.02	$ 186.54
Granted (in dollars per share)	305.86	336.48	294.37
Exercised (in dollars per share)	192.40	178.82	174.66
Expired or canceled (in dollars per share)	314.78	278.78	246.95
Outstanding - December 31 (in dollars per share)	242.81	226.38	202.02
Options exercisable at year-end (in dollars per share)	$ 216.90	$ 196.01	$ 179.28

Employee Incentive Plans - Summary of Information for Stock Options Exercised (Details) - Employee Stock Options - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value of options exercised	$ 128	$ 275	$ 126
Cash received for options exercised	203	305	187
Tax benefit from options exercised	$ 16	$ 34	$ 17

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Employee Incentive Plans - Summary of Information for Stock Options Outstanding (Details) - Employee Stock Options - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Options Outstanding
Number (in shares)	5,202	5,655	6,696	6,992
Total intrinsic value	$ 246
Weighted average exercise price (in dollars per share)	$ 242.81	$ 226.38	$ 202.02	$ 186.54
Weighted average remaining contractual life	5 years 8 months 12 days
Options Exercisable
Number (in shares)	3,806	3,941	4,616
Total intrinsic value	$ 246
Weighted average exercise price (in dollars per share)	$ 216.90	$ 196.01	$ 179.28
Weighted average remaining contractual life	4 years 7 months 6 days

Employee Incentive Plans - Status of and Changes in Restricted Stock Awards and SPSs (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Restricted Stock Grants and Units
Grants/Units
Outstanding - January 1 (in shares)	1,250	1,404	1,535
Awarded (in shares)	701	624	700
Vested (in shares)	(664)	(713)	(759)
Forfeited (in shares)	(149)	(65)	(72)
Outstanding - December 31 (in shares)	1,138	1,250	1,404
Weighted Average Fair Value at Award Date
Outstanding - January 1 (in dollars per share)	$ 302.42	$ 257.38	$ 219.25
Awarded (in dollars per share)	305.67	319.39	294.60
Vested (in dollars per share)	284.20	245.35	214.70
Forfeited (in dollars per share)	316.12	283.62	256.24
Outstanding - December 31 (in dollars per share)	$ 313.25	$ 302.42	$ 257.38
SPSs
Grants/Units
Outstanding - January 1 (in shares)	601	686	780
Awarded (in shares)	217	195	219
Vested (in shares)	(233)	(242)	(250)
Forfeited (in shares)	(80)	(38)	(63)
Outstanding - December 31 (in shares)	505	601	686
Weighted Average Fair Value at Award Date
Outstanding - January 1 (in dollars per share)	$ 282.83	$ 243.90	$ 212.68
Awarded (in dollars per share)	305.28	336.81	293.85
Vested (in dollars per share)	231.75	214.93	191.78
Forfeited (in dollars per share)	317.01	289.35	237.50
Outstanding - December 31 (in dollars per share)	$ 310.78	$ 282.83	$ 243.90

Employee Incentive Plans - Fair Value of Vested Restricted Stock and SPSs (Details) - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Restricted Stock Grants and Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of vested shares	$ 203	$ 238	$ 220
SPSs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of The Cigna Group common stock distributed upon SPS vesting (in shares)	301	257	257
Fair value of vested shares	$ 92	$ 86	$ 76

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Employee Incentive Plans - Compensation Cost and Tax Effects of Share-based Compensation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]
Total compensation cost for shared-based awards	$ 291	$ 308	$ 286
Tax benefits recognized	$ 69	$ 94	$ 92

Goodwill, Other Intangibles and Property and Equipment - Narrative (Details) - USD ($) $ in Billions	Dec. 31, 2025	Dec. 31, 2024
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Indefinite-lived intangible assets	$ 8.4	$ 8.5
Minimum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Amortization period, other intangible assets	1 year
Maximum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Amortization period, other intangible assets	30 years
Buildings and Improvements \| Minimum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Estimated useful life, property, plant and equipment	10 years
Buildings and Improvements \| Maximum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Estimated useful life, property, plant and equipment	40 years
Purchased and internally developed software \| Minimum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Estimated useful life, property, plant and equipment	3 years
Purchased and internally developed software \| Maximum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Estimated useful life, property, plant and equipment	5 years
Furniture and Equipment (including Computer Equipment) \| Minimum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Estimated useful life, property, plant and equipment	3 years
Furniture and Equipment (including Computer Equipment) \| Maximum
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Estimated useful life, property, plant and equipment	10 years
Leasehold Improvements
Schedule Of Goodwill, Other Intangible Assets And Property, Plant And Equipment [Line Items]
Estimated useful life, leasehold improvements	Useful Life, Shorter of Lease Term or Asset Utility [Member]

Goodwill, Other Intangibles, and Property and Equipment - Goodwill Activity (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Goodwill [Roll Forward]
Balance at January 1	$ 44,370	$ 44,259
Goodwill acquired	548	114
Impact of foreign currency translation and other adjustments	6	(3)
Balance at December 31	44,924	44,370
Evernorth Health Services
Goodwill [Roll Forward]
Balance at January 1	35,434	35,130
Goodwill acquired	548	114
Impact of foreign currency translation and other adjustments	0	190
Balance at December 31	35,982	35,434
Cigna Healthcare
Goodwill [Roll Forward]
Balance at January 1	8,936	9,129
Goodwill acquired	0	0
Impact of foreign currency translation and other adjustments	6	(193)
Balance at December 31	$ 8,942	$ 8,936

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-41

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 740
-Name Accounting Standards Codification
-Section 55
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478064/805-740-55-13

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 39
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-39

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482598/350-20-45-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

Goodwill, Other Intangibles, and Property and Equipment - Other Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Customer relationships
Accumulated Amortization	$ 10,810
Accumulated Amortization, including held for sale assets		$ 9,250
Trade name - Express Scripts
Cost	8,400	8,500
Net Carrying Value	8,400	8,500
Total
Cost	39,370
Net Carrying Value	28,560	29,417
Cost, including held for sale assets		38,687
Net Carrying Value, including held for sale assets		29,437
Value of business acquired
Cost, including held for sale assets		211
Accumulated Amortization, including held for sale assets		142
Net Carrying Value, including held for sale assets		69
Total
Cost, including held for sale assets		38,898
Accumulated Amortization, including held for sale assets		9,392
Net Carrying Value, including held for sale assets		29,506
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Total
VOBA, held for sale		69
Other intangible assets, held for sale		20
Customer relationships
Customer relationships
Cost	30,624
Accumulated Amortization	10,655
Net Carrying Value	19,969
Cost, including held for sale assets		29,971
Accumulated Amortization, including held for sale assets		9,119
Net Carrying Value, including held for sale assets		20,852
Trade name - Express Scripts
Trade name - Express Scripts
Cost	8,400
Net Carrying Value	8,400
Cost, including held for sale assets		8,400
Net Carrying Value, including held for sale assets		8,400
Other
Customer relationships
Accumulated Amortization	155
Accumulated Amortization, including held for sale assets		131
Total
Cost	346
Net Carrying Value	$ 191
Cost, including held for sale assets		316
Net Carrying Value, including held for sale assets		$ 185

Goodwill, Other Intangibles, and Property and Equipment - Property and Equipment (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Property and equipment, including held for sale assets
Cost		$ 13,410
Accumulated Amortization		9,454
Net Carrying Value		3,956
Total property and equipment (1)
Cost	$ 13,753
Accumulated amortization	10,102
Net carrying value	3,651
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Property and equipment classified as Assets of businesses held for sale
Property and equipment, net carrying value classified as assets of business held for sale		302
Internal-use software
Property and equipment, including held for sale assets
Cost		11,295
Accumulated Amortization		8,167
Net Carrying Value		3,128
Total property and equipment (1)
Cost	11,678
Accumulated amortization	8,904
Net carrying value	2,774
Other property and equipment
Property and equipment, including held for sale assets
Cost		2,115
Accumulated Amortization		1,287
Net Carrying Value		$ 828
Total property and equipment (1)
Cost	2,075
Accumulated amortization	1,198
Net carrying value	$ 877

Goodwill, Other Intangibles, and Property and Equipment - Components of Depreciation and Amortization Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Depreciation And Amortization By Type [Line Items]
Depreciation and amortization	$ 2,775	$ 2,775	$ 3,035
Internal-use software
Depreciation And Amortization By Type [Line Items]
Depreciation and amortization	987	1,021	1,216
Other property and equipment
Depreciation And Amortization By Type [Line Items]
Depreciation and amortization	239	248	260
Value of business acquired (reported in Other assets)
Depreciation And Amortization By Type [Line Items]
Depreciation and amortization	0	0	7
Other intangibles
Depreciation And Amortization By Type [Line Items]
Depreciation and amortization	$ 1,549	$ 1,506	$ 1,552

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

Goodwill, Other Intangibles, and Property and Equipment - Estimated Annual Pre-Tax Amortization for Intangible Assets (Details) $ in Millions	Dec. 31, 2025 USD ($)
Goodwill Other Intangibles And Property And Equipment [Abstract]
2026	$ 2,360
2027	2,237
2028	2,062
2029	1,821
2030	$ 1,592

Shareholders Equity and Dividend Restrictions (Details) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Equity [Abstract]
Net income	$ 3.7	$ 3.9	$ 5.3
Surplus	13.0	$ 16.0	$ 14.9
Minimum statutory surplus required by regulators	4.5
Investments on deposit with regulatory bodies	0.3
Maximum dividend distributions permitted in 2026 without regulatory approval	2.0
Maximum loans to the parent company permitted without regulatory approval	1.2
Restricted GAAP net assets of subsidiaries of The Cigna Group	11.3
Undistributed earnings from equity method subidiaries	1.6
Statutory Accounting Practices, Statutory to NAIC, Permitted, Difference, Amount

Income Taxes - Components of Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Current taxes
U.S. income taxes	$ 807	$ 1,167	$ 1,459
Foreign income taxes	191	248	161
State income taxes	169	171	180
Total current taxes	1,167	1,586	1,800
Deferred taxes (tax benefits)
U.S. income tax benefits	(69)	(142)	(533)
Foreign income taxes (tax benefits)	447	64	(1,046)
State income tax benefits	(52)	(17)	(80)
Total deferred taxes (tax benefits)	326	(95)	(1,659)
Total income taxes	$ 1,493	$ 1,491	$ 141

Income Taxes - Nominal Tax Rate Reconciliation - 2025 Presentation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
$
Tax expense at statutory rate	$ 1,634	$ 1,107	$ 1,158
State income tax effect, net of federal income tax effect		62	(39)
Nontaxable or nondeductible items	13
Global intangible low-taxed income ("GILTI")	127
Other cross-border tax laws	11
Tax credits	(83)
Change in valuation allowance		767	1,290
Change in unrecognized tax benefits	37
Impact of sale of businesses	(173)
Investment tax credits	(102)	(111)	(48)
Other reconciling items	3	47	(7)
Total income taxes	$ 1,493	$ 1,491	$ 141
%
Tax expense at statutory rate	21.00%	21.00%	21.00%
State income tax effect, net of federal income tax effect		1.20%	(0.70%)
Nontaxable or nondeductible items	0.20%
Global intangible low-taxed income ("GILTI")	1.60%
Other cross-border tax laws	0.10%
Tax credits	(1.10%)
Change in valuation allowance		14.60%	23.40%
Change in unrecognized tax benefits	0.50%
Impact of sale of businesses	(2.20%)
Investment tax credits	(1.30%)	(2.10%)	(0.80%)
Other reconciling items	0.20%	0.90%	(0.10%)
Total income taxes	19.20%	28.30%	2.60%
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
$
Impact of sale of businesses		$ (129)	$ (213)
%
Impact of sale of businesses		(2.40%)	(3.90%)
United States
$
State income tax effect, net of federal income tax effect	$ 93
Change in valuation allowance	$ (74)
%
State income tax effect, net of federal income tax effect	1.20%
Change in valuation allowance	(1.00%)
Switzerland
$
State income tax effect, net of federal income tax effect	$ 206
Change in valuation allowance	384
Effect of rates different than U.S. statutory	$ (360)
%
State income tax effect, net of federal income tax effect	2.60%
Change in valuation allowance	4.90%
Effect of rates different than U.S. statutory	(4.60%)
Other countries
$
Effect of rates different than U.S. statutory	$ (223)
%
Effect of rates different than U.S. statutory	(2.90%)

Income Taxes - Nominal Tax Rate Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
$
Tax expense at statutory rate	$ 1,634	$ 1,107	$ 1,158
Change in valuation allowance		767	1,290
State income tax effect, net of federal income tax effect		62	(39)
Investment tax credits	(102)	(111)	(48)
Impact of sale of businesses	(173)
Effect of foreign earnings		(252)	(173)
Other reconciling items	3	47	(7)
Total income taxes	$ 1,493	$ 1,491	$ 141
%
Tax expense at statutory rate	21.00%	21.00%	21.00%
Change in valuation allowance		14.60%	23.40%
State income tax effect, net of federal income tax effect		1.20%	(0.70%)
Investment tax credits	(1.30%)	(2.10%)	(0.80%)
Impact of sale of businesses	(2.20%)
Effect of foreign earnings		(4.90%)	(3.10%)
Other reconciling items	0.20%	0.90%	(0.10%)
Total income taxes	19.20%	28.30%	2.60%
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
$
Impact of sale of businesses		$ (129)	$ (213)
%
Impact of sale of businesses		(2.40%)	(3.90%)
United States
$
Change in valuation allowance	$ (74)
State income tax effect, net of federal income tax effect	$ 93
%
Change in valuation allowance	(1.00%)
State income tax effect, net of federal income tax effect	1.20%
Switzerland
$
Change in valuation allowance	$ 384
State income tax effect, net of federal income tax effect	$ 206
Foreign tax attributes		$ 0	$ (1,674)
%
Change in valuation allowance	4.90%
State income tax effect, net of federal income tax effect	2.60%
Foreign tax attributes, percent		0.00%	(30.40%)
Other countries
$
Foreign tax attributes		$ 0	$ (153)
%
Foreign tax attributes, percent		0.00%	(2.80%)

Income Taxes - Investment Tax Credits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Renewable energy tax credits	$ 968	$ 1,057	$ 453

Income Taxes - Foreign Operations (Details)	12 Months Ended
Income Taxes - Foreign Operations (Details)	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Pre-Tax Income \| Geographic Concentration Risk \| Foreign
Concentration Risk [Line Items]
Concentration percentage	53.00%	62.00%	48.00%

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482836/275-10-55-18

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 954
-SubTopic 310
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478785/954-310-50-2

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

Income Taxes - Deferred Income Taxes (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Deferred tax assets
Foreign tax attributes	$ 1,615	$ 1,800
Deferred loss - sale of business	0	773
Investments	587	561
Other insurance and contractholder liabilities	241
Loss carryforwards	492
Other accrued liabilities	321
Employee and retiree benefit plans	190
Unrealized depreciation on investments and foreign currency translation	10
Policy acquisition expenses	53
Other	339
Deferred tax assets before valuation allowance	3,848
Valuation allowance for deferred tax assets	(2,374)
Deferred tax assets, net of valuation allowance	1,474
Deferred tax liabilities
Acquisition-related basis differences	7,558
Depreciation and amortization	602
Policy acquisition expenses	0
Total deferred tax liabilities	8,160
Deferred tax assets, including held for sale assets
Foreign tax attributes		1,752
Deferred loss - sale of business	0	773
Investments	587	561
Other insurance and contractholder liabilities		300
Loss carryforwards		270
Other accrued liabilities		207
Employee and retiree benefit plans		177
Unrealized depreciation on investments and foreign currency translation		93
Policy acquisition expenses		0
Other		256
Deferred tax assets before valuation allowance		4,389
Valuation allowance for deferred tax assets		(2,332)
Deferred tax assets, net of valuation allowance		2,057
Deferred tax liabilities, including held for sale liabilities
Acquisition-related basis differences		7,822
Depreciation and amortization		243
Policy acquisition expenses		74
Total deferred tax liabilities		8,139
Net deferred income tax liabilities(1)	(6,686)
Net deferred tax liabilities, including amounts reported in Liabilities of businesses held for sale		(6,082)
Deferred tax assets reported in Other Assets	$ 459	954
Held-for-Sale \| Medicare Advantage and related Cigna Healthcare businesses
Deferred tax liabilities, including held for sale liabilities
Net deferred income tax liabilities classified as liabilities of businesses held for sale		$ 61

Income Taxes - Valuation Allowances (Details) - USD ($) $ in Millions	Dec. 31, 2025	Dec. 31, 2024
Valuation Allowance [Line Items]
Deferred tax assets, impairment of equity securities and other unrealized investment losses.	$ 819	$ 880
Deferred tax assets associated with foreign tax attributes	1,615	1,800
Deferred tax assets in connection with HCSC transaction	237
Deferred tax assets in connection with HCSC transaction, before sale completion	0	773
Deferred tax assets, valuation allowance	2,374
Sale of Medicare Advantage and related businesses
Valuation Allowance [Line Items]
Deferred tax assets, valuation allowance	1,025	1,351
Foreign jurisdiction tax attributes
Valuation Allowance [Line Items]
Deferred tax assets, valuation allowance	$ 1,200	$ 800

Income Taxes - Uncertain Tax Positions (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Balance at January 1,	$ 1,477	$ 1,399	$ 1,343
(Decrease) due to prior year tax positions	(50)	(7)	(26)
Increase due to current year positions	187	165	107
Reduction related to settlements with taxing authorities	(62)	(22)	(13)
Reduction related to lapse of applicable statute of limitations	(14)	(58)	(12)
Balance at December 31,	1,538	1,477	1,399
Liability for net interest expense on uncertain tax positions	$ 223	$ 228	$ 220

Income Taxes - Income Taxes Paid (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Taxes Paid, Net [Abstract]
Income taxes paid	$ 399	$ 898	$ 1,471
Federal income taxes paid	(4)
State income taxes paid	140
Foreign income taxes paid	263
Renewable energy tax credits	$ 968	$ 1,057	$ 453

Contingencies and Other Matters (Details)	12 Months Ended
Contingencies and Other Matters (Details)	Dec. 31, 2025 USD ($)
Guaranty Fund Assessments
Commitments And Contingencies [Line Items]
Loss contingency accrual, period increase (decrease)
Indemnification obligations
Commitments And Contingencies [Line Items]
Liability for guarantees	0
Retiree and Life Insurance Benefits \| Financial Guarantees
Commitments And Contingencies [Line Items]
Maximum guarantee exposure	400,000,000
Assets maintained by employers (minimum)	400,000,000
Liability for guarantees	$ 0

Segment Information - Special Item Charges (Benefits) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Pre-tax
Deferred tax expenses (benefits)	$ 0	$ 0	$ 0
Integration and transaction-related costs	327	275	45
Charges (benefits) associated with litigation matters	(17)	0	201
Net (gain) loss on sale of businesses	(13)	(24)	1,499
Impairment of dividend receivable	0	182	0
Total impact from special items, pre-tax	1,046	433	1,997
After-tax
Deferred tax expenses (benefits), after-tax	427	84	(1,071)
Integration and transaction-related costs, after-tax	247	211	35
Charges (benefits) associated with litigation matters, after-tax	(13)	0	171
Net (gain) loss on sale of businesses, after-tax	(404)	(2)	1,429
Impairment of dividend receivable, after-tax	0	138	0
Total impact from special items, after-tax	822	431	757
Strategic Optimization Program
Pre-tax
Strategic optimization program	749	0	0
After-tax
Strategic optimization program, after-tax	565	0	0
Organizational Efficiency Plan
Pre-tax
Strategic optimization program	0	0	252
After-tax
Strategic optimization program, after-tax	$ 0	$ 0	$ 193

Segment Information - Summarized Segment Financial Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Revenues from customers	$ 273,854	$ 246,148	$ 194,099
Net investment income (loss)	1,046	973	1,166
TOTAL REVENUES	274,900	247,121	195,265
Net investment results from certain equity method investments	(249)	(204)	57
Special item related to impairment of dividend receivable	0	182	0
Adjusted revenues	274,651	247,099	195,322
Pharmacy and other service costs	214,991	182,509	133,801
Medical costs and other benefit expenses	34,349	38,648	36,287
Interest expense and other	(1,408)	(1,435)	(1,446)
Pre-tax adjusted income (loss) from operations	9,870	9,533	9,318
Income before income taxes	7,781	5,269	5,513
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	(475)	(405)	(146)
Net realized investment (gains) losses	(225)	2,533	135
Amortization of acquired intangible assets	1,743	1,703	1,819
Special items
Integration and transaction-related costs	327	275	45
Net (gain) loss on sale of businesses	(13)	(24)	1,499
(Benefits) charges associated with litigation matters	(17)	0	201
Deferred tax expenses	0	0	0
Impairment of dividend receivable	0	182	0
Pre-tax adjusted income (loss) from operations	9,870	9,533	9,318
Depreciation and amortization	2,775	2,775	3,035
Strategic Optimization Program
Special items
Strategic optimization program costs	749	0	0
Organizational Efficiency Plan
Special items
Strategic optimization program costs	0	0	252
Evernorth Health Services
Segment Reporting Information [Line Items]
Revenues from customers	232,098	198,177	147,588
Cigna Healthcare
Segment Reporting Information [Line Items]
Revenues from customers	41,426	47,528	46,219
Other Operations
Segment Reporting Information [Line Items]
Revenues from customers	325	440	291
Operating Segments \| Evernorth Health Services
Segment Reporting Information [Line Items]
Net investment income (loss)	142	21	241
TOTAL REVENUES	234,953	201,973	153,499
Net investment results from certain equity method investments	0	0	0
Special item related to impairment of dividend receivable		182
Adjusted revenues	234,953	202,155	153,499
Pharmacy and other service costs	223,086	190,968	143,571
Medical costs and other benefit expenses	0	0	0
Selling, general and administrative expenses	4,170	3,779	3,340
Interest expense and other	(1)	(2)	(2)
Less: Income attributable to noncontrolling interests	475	405	144
Pre-tax adjusted income (loss) from operations	7,221	7,001	6,442
Income before income taxes	5,826	3,929	4,768
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	(475)	(405)	(144)
Net realized investment (gains) losses	(20)	2,129	0
Amortization of acquired intangible assets	1,720	1,662	1,774
Special items
Integration and transaction-related costs	0	0	0
Net (gain) loss on sale of businesses	(4)	(496)	0
(Benefits) charges associated with litigation matters	0		44
Impairment of dividend receivable		182
Pre-tax adjusted income (loss) from operations	7,221	7,001	6,442
Depreciation and amortization	2,400	2,319	2,438
Operating Segments \| Evernorth Health Services \| Strategic Optimization Program
Special items
Strategic optimization program costs	174
Operating Segments \| Evernorth Health Services \| Organizational Efficiency Plan
Special items
Strategic optimization program costs			0
Operating Segments \| Cigna Healthcare
Segment Reporting Information [Line Items]
Net investment income (loss)	581	618	597
TOTAL REVENUES	47,412	53,118	51,148
Net investment results from certain equity method investments	(249)	(204)	57
Special item related to impairment of dividend receivable		0
Adjusted revenues	47,163	52,914	51,205
Pharmacy and other service costs	0	0	0
Medical costs and other benefit expenses	33,474	37,887	35,678
Selling, general and administrative expenses	9,545	10,805	11,055
Interest expense and other	9	7	8
Less: Income attributable to noncontrolling interests	0	0	2
Pre-tax adjusted income (loss) from operations	4,153	4,229	4,478
Income before income taxes	4,344	3,315	2,664
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	0	0	(2)
Net realized investment (gains) losses	(210)	401	133
Amortization of acquired intangible assets	23	41	45
Special items
Integration and transaction-related costs	0	0	0
Net (gain) loss on sale of businesses	(9)	472	1,481
(Benefits) charges associated with litigation matters	(17)		157
Impairment of dividend receivable		0
Pre-tax adjusted income (loss) from operations	4,153	4,229	4,478
Depreciation and amortization	339	417	569
Operating Segments \| Cigna Healthcare \| Strategic Optimization Program
Special items
Strategic optimization program costs	22
Operating Segments \| Cigna Healthcare \| Organizational Efficiency Plan
Special items
Strategic optimization program costs			0
Operating Segments \| Other Operations
Segment Reporting Information [Line Items]
Net investment income (loss)	298	309	305
TOTAL REVENUES	674	828	596
Net investment results from certain equity method investments	0	0	0
Special item related to impairment of dividend receivable		0
Adjusted revenues	674	828	596
Pre-tax adjusted income (loss) from operations	89	(9)	96
Income before income taxes	(46)	(12)	76
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	0	0	0
Net realized investment (gains) losses	2	3	2
Amortization of acquired intangible assets	0	0	0
Special items
Integration and transaction-related costs	0	0	0
Net (gain) loss on sale of businesses	0	0	18
(Benefits) charges associated with litigation matters	0		0
Impairment of dividend receivable		0
Pre-tax adjusted income (loss) from operations	89	(9)	96
Depreciation and amortization	16	9	3
Operating Segments \| Other Operations \| Strategic Optimization Program
Special items
Strategic optimization program costs	133
Operating Segments \| Other Operations \| Organizational Efficiency Plan
Special items
Strategic optimization program costs			0
Corporate and Eliminations
Segment Reporting Information [Line Items]
TOTAL REVENUES	(8,139)	(8,798)	(9,978)
Special item related to impairment of dividend receivable		0
Adjusted revenues	(8,139)	(8,798)	(9,978)
Special items
Impairment of dividend receivable		0
Depreciation and amortization	20	30	25
Corporate
Segment Reporting Information [Line Items]
Revenues from customers	5	3	1
Net investment income (loss)	25	25	23
Net investment results from certain equity method investments	0	0	0
Special item related to impairment of dividend receivable		0
Pre-tax adjusted income (loss) from operations	(1,593)	(1,688)	(1,698)
Income before income taxes	(2,343)	(1,963)	(1,995)
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	0	0	0
Net realized investment (gains) losses	3	0	0
Amortization of acquired intangible assets	0	0	0
Special items
Integration and transaction-related costs	327	275	45
Net (gain) loss on sale of businesses	0	0	0
(Benefits) charges associated with litigation matters	0		0
Impairment of dividend receivable		0
Pre-tax adjusted income (loss) from operations	(1,593)	(1,688)	(1,698)
Corporate \| Strategic Optimization Program
Special items
Strategic optimization program costs	420
Corporate \| Organizational Efficiency Plan
Special items
Strategic optimization program costs			252
Intersegment Eliminations
Segment Reporting Information [Line Items]
Revenues from customers	(8,169)	(8,826)	(10,002)
Intersegment Eliminations \| Evernorth Health Services
Segment Reporting Information [Line Items]
Revenues from customers	(2,713)	(3,775)	(5,670)
Intersegment Eliminations \| Cigna Healthcare
Segment Reporting Information [Line Items]
Revenues from customers	(5,405)	(4,972)	(4,332)
Intersegment Eliminations \| Other Operations
Segment Reporting Information [Line Items]
Revenues from customers	$ (51)	$ (79)	$ 0

Segment Information - Revenue from External Customers (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenue from External Customer [Line Items]
Premiums	$ 40,261	$ 45,996	$ 44,237
Total revenues from external customers	273,854	246,148	194,099
Pharmacy revenues
Revenue from External Customer [Line Items]
Revenue from contract with customer	216,672	185,362	137,243
Service
Revenue from External Customer [Line Items]
Revenue from contract with customer	16,921	14,790	12,619
Service, Fees And Other Revenues [Member]
Revenue from External Customer [Line Items]
Revenue from contract with customer	16,921	14,790	12,619
Other revenue
Revenue from External Customer [Line Items]
Revenue from contract with customer	696	584	210
Evernorth Health Services
Revenue from External Customer [Line Items]
Total revenues from external customers	232,098	198,177	147,588
Cigna Healthcare
Revenue from External Customer [Line Items]
Total revenues from external customers	41,426	47,528	46,219
Other Operations
Revenue from External Customer [Line Items]
Total revenues from external customers	325	440	291
Operating Segments \| Evernorth Health Services \| Pharmacy revenues
Revenue from External Customer [Line Items]
Revenue from contract with customer	219,394	189,361	142,293
Operating Segments \| Evernorth Health Services \| Network revenues
Revenue from External Customer [Line Items]
Revenue from contract with customer	125,573	105,340	67,514
Operating Segments \| Evernorth Health Services \| Home delivery and specialty revenues
Revenue from External Customer [Line Items]
Revenue from contract with customer	80,492	72,476	65,732
Operating Segments \| Evernorth Health Services \| Other revenues
Revenue from External Customer [Line Items]
Revenue from contract with customer	13,329	11,545	9,047
Operating Segments \| Evernorth Health Services \| Service, Fees And Other Revenues [Member]
Revenue from External Customer [Line Items]
Revenue from contract with customer	15,417	12,591	10,965
Operating Segments \| Cigna Healthcare
Revenue from External Customer [Line Items]
Premiums	39,677	45,512	43,882
Operating Segments \| Cigna Healthcare \| Service, Fees And Other Revenues [Member]
Revenue from External Customer [Line Items]
Revenue from contract with customer	7,154	6,988	6,669
Operating Segments \| Cigna Healthcare \| U.S. Healthcare
Revenue from External Customer [Line Items]
Premiums	35,551	41,888	40,587
Operating Segments \| Cigna Healthcare \| U.S. Healthcare \| Employer insured
Revenue from External Customer [Line Items]
Premiums	18,852	17,576	16,490
Operating Segments \| Cigna Healthcare \| U.S. Healthcare \| Medicare Advantage
Revenue from External Customer [Line Items]
Premiums	2,363	8,679	8,771
Operating Segments \| Cigna Healthcare \| U.S. Healthcare \| Stop loss
Revenue from External Customer [Line Items]
Premiums	7,599	6,744	6,143
Operating Segments \| Cigna Healthcare \| U.S. Healthcare \| Individual and Family Plans
Revenue from External Customer [Line Items]
Premiums	3,371	3,951	5,088
Operating Segments \| Cigna Healthcare \| U.S. Healthcare \| Other
Revenue from External Customer [Line Items]
Premiums	3,366	4,938	4,095
Operating Segments \| Cigna Healthcare \| International Health
Revenue from External Customer [Line Items]
Premiums	4,126	3,624	3,295
Operating Segments \| Other Operations
Revenue from External Customer [Line Items]
Premiums	288	380	281
Operating Segments \| Other Operations \| Pharmacy revenues
Revenue from External Customer [Line Items]
Revenue from contract with customer	54	60	0
Operating Segments \| Other Operations \| Service, Fees And Other Revenues [Member]
Revenue from External Customer [Line Items]
Revenue from contract with customer	34	79	10
Corporate and Eliminations
Revenue from External Customer [Line Items]
Premiums	296	104	74
Corporate and Eliminations \| Pharmacy revenues
Revenue from External Customer [Line Items]
Revenue from contract with customer	(2,776)	(4,059)	(5,050)
Corporate and Eliminations \| Service, Fees And Other Revenues [Member]
Revenue from External Customer [Line Items]
Revenue from contract with customer	(5,684)	(4,868)	(5,025)
Corporate
Revenue from External Customer [Line Items]
Total revenues from external customers	5	3	1
Intersegment Eliminations
Revenue from External Customer [Line Items]
Total revenues from external customers	(8,169)	(8,826)	(10,002)
Intersegment Eliminations \| Evernorth Health Services
Revenue from External Customer [Line Items]
Total revenues from external customers	(2,713)	(3,775)	(5,670)
Intersegment Eliminations \| Cigna Healthcare
Revenue from External Customer [Line Items]
Total revenues from external customers	(5,405)	(4,972)	(4,332)
Intersegment Eliminations \| Other Operations
Revenue from External Customer [Line Items]
Total revenues from external customers	$ (51)	$ (79)	$ 0

Segment Information - Major Customers (Details) - Revenue - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Single Pharmacy Benefit Client
Concentration Risk [Line Items]
Concentration percentage	19.00%	16.00%
U.S. Federal Government Agencies
Concentration Risk [Line Items]
Concentration percentage		11.00%	15.00%

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-18

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482836/275-10-55-18

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-20

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 954
-SubTopic 310
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478785/954-310-50-2

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

Segment Information - U.S. and Foreign Revenues (Details)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenues from external customers \| Geographic Concentration Risk \| United States
Loss Contingencies [Line Items]
Concentration percentage	98.00%	98.00%	98.00%

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 275
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 720
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483359/720-20-50-1

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 27
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482395/460-10-55-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 460
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482425/460-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

Cash and cash equivalents

Schedule I - Condensed Financial Information of The Cigna Group - Statements of Income (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Revenues
Net investment income (loss)	$ 1,046	$ 973	$ 1,166
TOTAL REVENUES	274,900	247,121	195,265
Operating expenses
Selling, general and administrative expenses	14,617	14,844	14,822
TOTAL BENEFITS AND EXPENSES	265,700	237,704	186,729
Income from operations	9,200	9,417	8,536
Interest expense and other	(1,408)	(1,435)	(1,446)
Gain on sale of businesses	13	24	(1,499)
Net investment losses	(24)	(2,737)	(78)
Income before income taxes	7,781	5,269	5,513
Income tax benefits	1,493	1,491	141
SHAREHOLDERS' NET INCOME	5,957	3,434	5,164
Other comprehensive income (loss), net of tax
Net long-duration insurance and contractholder liabilities measurement adjustments	(291)	(1,067)	(715)
SHAREHOLDERS' COMPREHENSIVE INCOME	5,492	2,957	4,958
The Cigna Group
Revenues
Net investment income (loss)	21	26	22
Intercompany interest income	469	469	516
TOTAL REVENUES	490	495	538
Operating expenses
Selling, general and administrative expenses	5	14	2
TOTAL BENEFITS AND EXPENSES	5	14	2
Income from operations	485	481	536
Interest expense and other	(1,365)	(1,388)	(1,332)
Gain on sale of businesses	4,890	0	0
Intercompany interest expense	0	(2)	(118)
Income before income taxes	4,010	(909)	(914)
Income tax benefits	(201)	(189)	(192)
lncome (loss) of parent company	4,211	(720)	(722)
Equity in income of subsidiaries	1,746	4,154	5,886
SHAREHOLDERS' NET INCOME	5,957	3,434	5,164
Other comprehensive income (loss), net of tax
Net unrealized (depreciation) appreciation on securities and derivatives	(238)	661	503
Net long-duration insurance and contractholder liabilities measurement adjustments	(291)	(1,067)	(715)
Net translation gains (losses) of foreign currencies	71	(49)	5
Postretirement benefits liability adjustment	(7)	(22)	1
Shareholders' other comprehensive loss, net of tax	(465)	(477)	(206)
SHAREHOLDERS' COMPREHENSIVE INCOME	$ 5,492	$ 2,957	$ 4,958

Schedule I - Condensed Financial Information of The Cigna Group - Balance Sheets (Details) - USD ($)
$ in Millions

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

Assets

$ 7,676

$ 7,550

Other current assets

2,976

2,732

Total current assets

47,814

48,870

Other non-current assets

2,885

2,786

TOTAL ASSETS

157,919

155,881

Total current liabilities

Short-term debt

592

3,035

56,342

57,979

Long-term debt

30,871

28,937

Additional paid-in capital

4,238

3,215

TOTAL LIABILITIES

116,045

114,638

Shareholders' equity

Common stock

^[1]

4

31,790

31,288

Accumulated other comprehensive loss

(2,806)

(2,341)

Retained earnings

47,865

43,519

Less: Treasury stock, at cost

(35,140)

(31,437)

TOTAL SHAREHOLDERS' EQUITY

41,713

41,033

Total liabilities and equity

$ 157,919

$ 155,881

Common stock, shares issued (in shares)

404,600,000

402,512,000

399,894,000

Common stock, shares authorized

600,000,000

The Cigna Group

Assets

Cash and cash equivalents

$ 118

$ 164

Other current assets

29

103

Total current assets

147

267

TOTAL ASSETS

75,723

73,771

Other current liabilities

Short-term debt

550

2,848

1,983

1,528

Total current liabilities

2,533

4,376

Long-term debt

30,268

28,134

TOTAL LIABILITIES

34,010

32,738

Shareholders' equity

Common stock

4

Additional paid-in capital

31,790

31,288

Accumulated other comprehensive loss

(2,806)

(2,341)

Retained earnings

47,865

43,519

Less: Treasury stock, at cost

(35,140)

(31,437)

TOTAL SHAREHOLDERS' EQUITY

41,713

41,033

Total liabilities and equity

$ 75,723

$ 73,771

Common stock, shares issued (in shares)

405,000,000

403,000,000

Common stock, shares authorized

600,000,000

The Cigna Group | Nonrelated Party

Assets

Other non-current assets

$ 48

$ 71

The Cigna Group | Subsidiaries

75

33

Assets

Investments in subsidiaries

61,382

62,887

Other non-current assets

14,146

10,546

Cash Flows from Operating Activities

$ 1,134

$ 195

[1]	Par value per share, $0.01; shares issued, 405 million as of December 31, 2025 and 403 million as of December 31, 2024; authorized shares, 600 million.

Schedule I - Condensed Financial Information of The Cigna Group - Statements of Cash Flows (Details) - USD ($)
$ in Millions

12 Months Ended

Dec. 18, 2025

Sep. 18, 2025

Jun. 18, 2025

Mar. 20, 2025

Dec. 19, 2024

Sep. 19, 2024

Jun. 20, 2024

Mar. 21, 2024

Dec. 21, 2023

Sep. 21, 2023

Jun. 22, 2023

Mar. 23, 2023

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

Shareholders' net income

$ 5,957

$ 3,434

$ 5,164

Adjustments to reconcile shareholders' net income to net cash provided by (used in) operating activities:

Net (gain) loss on sale of businesses

(13)

(24)

1,499

Other liabilities

2,797

1,138

3,481

NET CASH PROVIDED BY OPERATING ACTIVITIES

462

774

463

9,601

10,363

11,813

Cash Flows from Investing Activities

Net proceeds from short-term investments (purchased) sold

(1,416)

(1,309)

(1,205)

NET CASH USED IN INVESTING ACTIVITIES

(4,407)

(2,102)

(5,174)

Net proceeds on issuance of term loan

Repayment of term loan

2,000

0

1,999

0

Repayment of long-term debt

(4,197)

(3,000)

(2,967)

Net proceeds on issuance of long-term debt

4,458

4,462

1,491

Issuance of common stock

203

305

187

Common stock dividend paid

$ (396)

$ (402)

$ (401)

$ (412)

$ (384)

$ (390)

$ (392)

$ (401)

$ (358)

$ (362)

$ (368)

(1,611)

(1,567)

(1,450)

Repurchase of common stock

(3,621)

(7,034)

(2,284)

NET CASH USED IN FINANCING ACTIVITIES

(624)

(349)

(413)

(6,421)

(7,647)

(4,294)

Net (decrease) increase in cash, cash equivalents and restricted cash

(1,195)

594

2,361

Cash, cash equivalents and restricted cash and cash equivalents January 1,

^[1]

7,592

7,870

Cash, cash equivalents and restricted cash, end of year (1)

^[1]

7,736

7,592

7,870

The Cigna Group

Cash Flows from Operating Activities

Shareholders' net income

5,957

3,434

5,164

Adjustments to reconcile shareholders' net income to net cash provided by (used in) operating activities:

Equity in income from subsidiaries

(1,746)

(4,154)

(5,886)

Dividends received from subsidiaries

1,171

2,916

1,381

Net (gain) loss on sale of businesses

(4,890)

0

Other liabilities

496

(306)

540

NET CASH PROVIDED BY OPERATING ACTIVITIES

592

243

640

1,580

2,133

1,839

Cash Flows from Investing Activities

Proceeds from divestiture of businesses

4,891

0

NET CASH USED IN INVESTING ACTIVITIES

4,891

0

622

Net change in commercial paper

(880)

(357)

1,237

Repayment of term loan

(2,000)

0

Net proceeds on issuance of term loan

1,999

0

Repayment of long-term debt

(3,861)

(2,731)

(2,822)

Net proceeds on issuance of long-term debt

4,458

4,462

1,491

Issuance of common stock

203

305

187

Common stock dividend paid

(1,611)

(1,567)

(1,450)

Repurchase of common stock

(3,621)

(7,034)

(2,284)

NET CASH USED IN FINANCING ACTIVITIES

(108)

(117)

(110)

(6,522)

(2,278)

Net (decrease) increase in cash, cash equivalents and restricted cash

(51)

(145)

183

Cash, cash equivalents and restricted cash and cash equivalents January 1,

190

335

152

Cash, cash equivalents and restricted cash, end of year (1)

139

190

335

The Cigna Group | Subsidiaries

Cash Flows from Investing Activities

Net change in amounts due from affiliates

0

622

Net change in amounts due to/from affiliates

(1,101)

4,761

1,473

Net amounts due from affiliates settled through capital transactions

$ (1,617)

$ (7,565)

$ (5,221)

[1]	Restricted cash and cash equivalents were reported in other long-term investments and Other assets.

Schedule I - Condensed Financial Information of The Cigna Group - Short-term and Credit Facilities Debt (Details) - USD ($)	1 Months Ended
	Sep. 30, 2025	Aug. 31, 2025	Apr. 30, 2025	Dec. 31, 2025	Dec. 31, 2024
Line of Credit Facility [Line Items]
Commercial paper				$ 0	$ 880,000,000
Commercial Paper
Line of Credit Facility [Line Items]
Maximum borrowing capacity				6,500,000,000
Commercial paper				0
Term Loan Facility \| Line of Credit
Line of Credit Facility [Line Items]
Principal		$ 2,000,000,000.0
Extinguishment of debt amount	$ 2,000,000,000.0
Credit agreement term		364 days
Revolving Credit Agreements, April 2025
Line of Credit Facility [Line Items]
Outstanding balances				0
Maximum borrowing capacity			$ 6,500,000,000
Credit agreement term			5 years
Credit agreement term extension			1 year
Aggregate amount of options to increase commitments			$ 1,500,000,000
Maximum total commitment			$ 8,000,000,000.0
Leverage ratio covenant			60.00%
Revolving Credit Agreements, April 2025 \| Letter of Credit
Line of Credit Facility [Line Items]
Maximum borrowing capacity			$ 500,000,000
The Cigna Group \| Commercial Paper
Line of Credit Facility [Line Items]
Maximum borrowing capacity				6,500,000,000
Commercial paper				0
The Cigna Group \| Term Loan Facility \| Line of Credit
Line of Credit Facility [Line Items]
Principal		$ 2,000,000,000.0
Extinguishment of debt amount	$ 2,000,000,000.0
Credit agreement term		364 days
The Cigna Group \| Revolving Credit Agreements, April 2025
Line of Credit Facility [Line Items]
Outstanding balances				$ 0
Maximum borrowing capacity			$ 6,500,000,000
Credit agreement term			5 years
Credit agreement term extension			1 year
Aggregate amount of options to increase commitments			$ 1,500,000,000
Maximum total commitment			$ 8,000,000,000.0
Leverage ratio covenant			60.00%
The Cigna Group \| Revolving Credit Agreements, April 2025 \| Letter of Credit
Line of Credit Facility [Line Items]
Maximum borrowing capacity			$ 500,000,000

Schedule I - Condensed Financial Information of The Cigna Group - Long-term Debt (Details)	1 Months Ended
	Sep. 30, 2025 USD ($)	Dec. 31, 2025	Aug. 31, 2025 USD ($)
Line of Credit \| Term Loan Facility
Debt Instrument [Line Items]
Principal			$ 2,000,000,000.0
Extinguishment of debt amount	$ 2,000,000,000.0
4.500% Notes due September 2030
Debt Instrument [Line Items]
Interest Rate		4.50%
4.875% Notes due September 2032
Debt Instrument [Line Items]
Interest Rate		4.875%
5.250% Notes due January 2036
Debt Instrument [Line Items]
Interest Rate		5.25%
6.000% Notes due January 2056
Debt Instrument [Line Items]
Interest Rate		6.00%
Senior Notes \| Senior Notes Issued September 2025
Debt Instrument [Line Items]
Principal	4,500,000,000
Senior Notes \| 4.500% Notes due September 2030
Debt Instrument [Line Items]
Principal	1,000,000,000
Net proceeds	$ 994,000,000
Interest Rate	4.50%
Redemption price discount, spread on variable rate	0.0015
Senior Notes \| 4.875% Notes due September 2032
Debt Instrument [Line Items]
Principal	$ 1,250,000,000
Net proceeds	$ 1,245,000,000
Interest Rate	4.875%
Redemption price discount, spread on variable rate	0.0015
Senior Notes \| 5.250% Notes due January 2036
Debt Instrument [Line Items]
Principal	$ 1,500,000,000
Net proceeds	$ 1,490,000,000
Interest Rate	5.25%
Redemption price discount, spread on variable rate	0.0015
Senior Notes \| 6.000% Notes due January 2056
Debt Instrument [Line Items]
Principal	$ 750,000,000
Net proceeds	$ 736,000,000
Interest Rate	6.00%
Redemption price discount, spread on variable rate	0.0020
The Cigna Group \| Line of Credit \| Term Loan Facility
Debt Instrument [Line Items]
Principal			$ 2,000,000,000.0
Extinguishment of debt amount	$ 2,000,000,000.0
The Cigna Group \| Senior Notes \| Senior Notes Issued September 2025
Debt Instrument [Line Items]
Principal	4,500,000,000
The Cigna Group \| Senior Notes \| 4.500% Notes due September 2030
Debt Instrument [Line Items]
Principal	1,000,000,000
Net proceeds	$ 994,000,000
Interest Rate	4.50%
Redemption price discount, spread on variable rate	0.0015
The Cigna Group \| Senior Notes \| 4.875% Notes due September 2032
Debt Instrument [Line Items]
Principal	$ 1,250,000,000
Net proceeds	$ 1,245,000,000
Interest Rate	4.875%
Redemption price discount, spread on variable rate	0.0015
The Cigna Group \| Senior Notes \| 5.250% Notes due January 2036
Debt Instrument [Line Items]
Principal	$ 1,500,000,000
Net proceeds	$ 1,490,000,000
Interest Rate	5.25%
Redemption price discount, spread on variable rate	0.0015
The Cigna Group \| Senior Notes \| 6.000% Notes due January 2056
Debt Instrument [Line Items]
Principal	$ 750,000,000
Net proceeds	$ 736,000,000
Interest Rate	6.00%
Redemption price discount, spread on variable rate	0.0020

Schedule I - Condensed Financial Information of The Cigna Group - Debt Maturities (Details) $ in Millions	Dec. 31, 2025 USD ($)
Debt Instrument [Line Items]
2026	$ 550
2027	2,359
2028	3,800
2029	1,000
2030	2,400
Maturities after 2030	21,485
The Cigna Group
Debt Instrument [Line Items]
2026	550
2027	2,055
2028	3,800
2029	1,000
2030	2,400
Maturities after 2030	$ 21,255

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(f))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69F
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

Schedule I - Condensed Financial Information of The Cigna Group - Intercompany Balances (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Condensed Financial Statements, Captions [Line Items]
Other current assets	$ 2,976	$ 2,732
The Cigna Group
Condensed Financial Statements, Captions [Line Items]
Other current assets	29	103
The Cigna Group \| Evernorth Health, Inc.
Condensed Financial Statements, Captions [Line Items]
Other current assets	$ 8,500	$ 8,500
Interest rate, intercompany receivables	5.50%

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 12
-Subsection 04
-Paragraph a
-Publisher SEC

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 5
-Subsection 04
-Paragraph c
-Subparagraph Schedule I
-Publisher SEC

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 7
-Subsection 05
-Paragraph c
-Subparagraph Schedule II
-Publisher SEC

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-X (SX)
-Number 210
-Section 9
-Subsection 06
-Publisher SEC

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 8: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-11

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 7
-Subparagraph (SAB Topic 1.B.2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480922/205-10-S99-7

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481003/205-10-S50-2